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Abstract 
ABSTRACT 
In advancement to the conventional drug delivery, controlled and targeted delivery 
systems offer an effective choice in facilitating nearly constant drug levels at the site 
of action, minimizing peak valley fluctuations, eventually leading to reduction in drug 
doses and dosage frequency as well as specific targeting at otherwise difficult sites. 
Natural and biodegradable/biocompatible polymers have additional advantages over 
synthetic/non-biodegradable ones and have wide applications as drug delivery 
systems. The fibrinogen-fibrin system forms one such natural and biocompatible 
system, which is involved in the last stages of the blood coagulation cascade. The 
fibrin-based systems have shown promising results in delivery of drugs, growth 
factors, cells and genes as well as in the delivery of DNA vaccines. However, these 
systems do not overrule the risk of transmission of infectious diseases and 
immunological complications. Work presented in the thesis describes a novel strategy 
of preparing fibrin crosslinked pla&ma beads and plasma microparticles as potential 
carriers of drugs and antigens. 
Plasma clots in beaded form were prepared from blood plasma obtained from 
rabbits/mice in presence of EDTA. The plasma was enriched with CaCl2 and the 
molecule of interest (drug/enzyme or the same loaded in liposomes/ erythrocytes), 
immediately transferred in the form of tiny droplets on a slide covered with Parafilm, 
with the help of a micropipette. Clot formation was accomplished by incubating the 
slides under moist conditions at 37 °C. The beads formed were porous and released 
both the entrapped proteins and drugs gradually under simulated physiological 
c;onditions. The dual entrapment was aimed at achieving improved sustained release 
of the drug or antigen which is evident from comparison of the observed release of 
directly entrapped blue dextran and horse radish peroxidase from plasma beads or 
that after their preentrapment in the liposomes. The release of Amphotericin B from 
jDlasma beads however did not show significant differences when entrapped 
additionally in the liposomes both in vitro and in vivo. Treatment of the plasma beads 
with glutaraldehyde, that resulted in crosslinking of the bead proteins, also decreased 
the drug release in a highly concentration dependent manner. Beads prepared by 
concentrating plasma on a Sephadex G-10 matrix as well as composite beads of 
plasma-alginate however failed to register noteworthy reduction in the release of 
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entrapped therapeutics. A n in vivo study with Amphotericin B suggested that the 
antibiotic was released gradually in the circulation and vital organs when administered 
in mice after entrapment in the plasma beads alone or after entrapment in liposomes. 
Administration of the free drug lead to its rapid entry as well as elimination from the 
circulation and vital organs investigated. 
Remarkable reduction in the in vitro release of invertase entrapped erythrocyte was 
evident when it was entrapped further in plasma beads. This encouraged their in vivo 
investigation in controlled antigen delivery. Experiments in rabbit were performed 
with three groups comprising invertase emulsified with complete Freund's adjuvant 
(C'FA) (CFA-Inv), invertase encapsulated in erythrocyte (EE-Inv) and erythrocyte 
encapsulated invertase further entrapped in plasma beads (EE-Inv-PB). High titers 
were obtained in all the groups after primary immunization which remained in 
circulation till 35 days, the order being CFA-Inv > EE-Inv-PB >EE-Inv. The order of 
titers remained the same when a booster dose was administered except that the 
animals in adjuvant group witnessed remarkably higher antibody titers. The study was 
further extended in the mice model by including additional formulations and groups 
receiving the formulations via different routes. The various formulations studied 
include CFA-Inv, EE-Inv (administered via s.c, i.p. and i.v. routes), EE-Inv 
crosslinked fiirther with 0.05% glutaraldehyde (EE-Inv-CL) (administered via i.p and 
i.v routes), EE-Inv-PB (administered via s.c. and i.p. routes) and EE-Inv-PB 
crosslinked with 0.05% glutaraldehyde (EE-Inv-PB-CL) (administered s.c. and i.p). 
Plasma beads could not be administered i.v. owing to their particulate nature. In case 
of the EE-Inv and EE-Inv-CL groups, the route of administration of antigen 
Ibrmulation made no difference in the induced humoral responses as evident from the 
specific antibody titers obtained after primary immunization as well as after a booster 
dose. Crosslinking however moderately increased the titers. In case of the EE-Inv-PB 
and EE-Inv-PB-CL groups, however, marked differences were observed in the titers 
when the route of administration was varied (especially after a priming dose), with 
very high titers obtained by their i.p. administration as compared to the s.c. 
administration. Also, the antibody response generated in the EE-Inv-PB-CL group 
receiving the formulation i.p. was comparable with that obtained by the CFA-Inv 
group both after primary and booster doses. Considering the well-known toxicity of 
the adjuvant, comparable antibody titers induced by the erythrocyte-plasma bead 
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system was encouraging. Also, there was a moderate shift toward the Th-2 biased 
immune response in the animals receiving erythrocyte- entrapped antigen especially 
after plasma bead entrapment and crosslinking. This suggests their role in the 
induction of humoral immunity. 
In an attempt to further enhance the humoral as well as cell-mediated immune 
responses, a novel microparticle system was prepared from blood plasma. Plasma 
enriched with CaCb and entrapped pharmaceutical was stirred at high speed in a 
mineral oil bath to obtain microparticles of 1 -5 [i diameter. The additional advantage 
of the microparticle system is their easy injectbility, possibly near the target site. The 
plasma microparticles were subjected to varying times and temperatures of incubation 
and it was observed that stable particles were formed at a stirred incubation of 60 min 
and 40 "C in the presence of 40 mM CaC^. This was evident from the SDS-PAGE in 
which no increase in the high molecular weight polypeptide was observed after 60 
min and 40 °C, also from the entrapment studies with invertase. 
In vitro studies performed with plasma microparticles containing entrapped invertase 
and Amphotericin B suggested the release to be slow was with only 26-28% of the 
entrapped enzyme and 14-16% of the entrapped drug being released in the buffer in 
72 hr; crosslinking further reduced the leakage to 12% and 7%) respectively. Plasma 
microparticles prepared at high temperatures however failed to register any lowering 
in the release of the enzyme/drug. 
In vivo studies on the immunogenicity of the plasma microparticles entrapped antigen 
were carried out in rabbit and mice models and the groups investigated include CFA-
Inv, plasma microparticles containing entrapped invertase (PMP-Inv) and those 
crosslinked with 0.05% glutaraldehyde (PMP-Inv-CL). In case of the mice immune 
response of invertase dissolved in PBS (Sal-Inv) vras also investigated. High antibody 
titers were obtained in both rabbit and mice in the PMP-Inv group, which were 
comparable to those of the CFA-Inv. Encouragingly, superior titers were obtained in 
animals administered the PMP-hiv-CL formulations both after primary and booster 
doses. Isotype studies suggest a higher Thl/Th2a immune response in both PMP-Inv 
and PMP-Inv-CL group, more in the later, suggesting a Thl biasing, thereby 
promotion of the cell-mediated immunity. Flow cytometric analysis was undertaken 
to further ascertain the CMI responses. Study of CD4^ positive T-cells in the 
ui 
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splenocytes isolated from the animals immunized with PMP-hiv-CL and PMP-Inv 
fonnulations also revealed marked upregulation of both CD4'*' (21 % and 16.5%, 
respectively) when compared with those of the CFA-Inv (13.5%) and Sal-Inv (3.2%)) 
groups. The difference was more marked in case of CD8^ positive T-cells with only 
7%) of CD8^ cells being present on the surface of APCs in case of CFA-Inv group 
against 16%) and 12%o of the PMP-Inv-CL and PMP-lnv groups, respectively. The 
levels remained lower in animals of Sal-Inv group (3.4 %). FACS analysis was also 
conducted to evaluate the expression of CD80 and CD86 on the surface of APCs 
isolated from groups of animals immunized with PMP-Inv-CL and PMP-Inv showed 
significantly higher level of their expression (CD80, 12% and 10.5%; CD86, 12.4% 
and 11.5%o) respectively as compared to CFA-Inv and Sal-Inv (CD80, 6.7% and 3.4%; 
CD86, 3.5%) and 3.4%o) respectively. Our overall results with the plasma 
microparticles, especially after crosslinking indicate good humoral/ CMI response, 
especially after booster. 
li; is proposed that plasma beads and plasma microparticles prepared and investigated 
in this study have remarkable potential as drug/antigen delivery systems. The risk of 
immunological complications is minimized since the preparations can be obtained 
using autologous plasma without the need for any foreign protein/enzyme. Total 
biodegradability and biocompatibility as well as ease of preparation using simple 
laboratory set up are the other advantages. The highly sustained in vitro and in vivo 
release of entrapped pharmaceuticals makes them very attractive in the delivery of 
drugs. Also, they appear promising as vaccine delivery candidates. The plasma 
preparations have the potential to regulate the nature of immune response in addition 
to the induction of high titers; the erythrocyte-bead system gave a humoral shift while 
the plasma microparticles resulted in a CMI switch. 
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Abstract 
ABSTRACT 
In advancement to the conventional drug delivery, controlled and targeted delivery 
systems offer an effective choice in facilitating nearly constant drug levels at the site 
of action, minimizing peak valley fluctuations, eventually leading to reduction in drug 
doses and dosage frequency as well as specific targeting at otherwise difficult sites. 
Natural and biodegradable/biocompatible polymers have additional advantages over 
synthetic/non-biodegradable ones and have wide applications as drug delivery 
systems. The fibrinogen-fibrin system forms one such natural and biocompatible 
system, which is involved in the last stages of the blood coagulation cascade. The 
fibrin-based systems have shown promising results in delivery of drugs, growth 
factors, cells and genes as well as in the delivery of DNA vaccines. However, these 
systems do not overrule the risk of transmission of infectious diseases and 
immunological complications. Work presented in the thesis describes a novel strategy 
of preparing fibrin crosslinked plasma beads and plasma microparticles as potential 
carriers of drugs and antigens. 
Plasma clots in beaded form were prepared from blood plasma obtained from 
r£ibbits/mice in presence of EDTA. The plasma was enriched with CaCb and the 
molecule of interest (drug/enzyme or the same loaded in liposomes/ erythrocytes), 
immediately transferred in the form of tiny droplets on a slide covered with Parafilm, 
with the help of a micropipette. Clot formation was accomplished by incubating the 
slides under moist conditions at 37 °C. The beads formed were porous and released 
both the entrapped proteins and drugs gradually under simulated physiological 
conditions. The dual entrapment was aimed at achieving improved sustained release 
of the drug or antigen which is evident from comparison of the observed release of 
directly entrapped blue dextran and horse radish peroxidase from plasma beads or 
that after their preentrapment in the liposomes. The release of Amphotericin B from 
plasma beads however did not show significant differences when entrapped 
additionally in the liposomes both in vitro and in vivo. Treatment of the plasma beads 
v/ith glutaraldehyde, that resulted in crosslinking of the bead proteins, also decreased 
tlie drug release in a highly concentration dependent manner Beads prepared by 
concentrating plasma on a Sephadex G-10 matrix as well as composite beads of 
ptlasma-alginate however failed to register noteworthy reduction in the release of 
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entrapped therapeutics. A n in vivo study with Amphotericin B suggested that the 
antibiotic was released gradually in the circulation and vital organs M'hen administered 
in mice after entrapment in the plasma beads alone or after entrapment in liposomes. 
Administration of the free drug lead to its rapid entry as well as elimination from the 
circulation and vital organs investigated. 
Remarkable reduction in the in vitro release of invertase entrapped erythrocyte was 
evident when it was entrapped further in plasma beads. This encouraged their in vivo 
investigation in controlled antigen delivery. Experiments in rabbit were performed 
with three groups comprising invertase emulsified with complete Freund's adjuvant 
(("FA) (CFA-Inv), invertase encapsulated in erythrocyte (EE-Inv) and erythrocyte 
encapsulated invertase further entrapped in plasma beads (EE-Inv-PB). High titers 
were obtained in all the groups after primary immunization which remained in 
circulation till 35 days, the order being CFA-Inv > EE-Inv-PB >EE-Inv. The order of 
titers remained the same when a booster dose was administered except that the 
animals in adjuvant group witnessed remarkably higher antibody titers. The study was 
farther extended in the mice model by including additional formulations and groups 
receiving the formulations via different routes. The various formulations studied 
include CFA-Inv, EE-Inv (administered via s.c, i.p. and i.v. routes), EE-Inv 
crosslinked further with 0.05% glutaraldehyde (EE-Inv-CL) (administered via i.p and 
i.v routes), EE-Inv-PB (administered via s.c. and i.p. routes) and EE-Inv-PB 
crosslinked with 0.05% glutaraldehyde (EE-Inv-PB-CL) (administered s.c. and i.p). 
Plasma beads could not be administered i.v. owing to their particulate nature. In case 
of the EE-Inv and EE-Inv-CL groups, the route of administration of antigen 
formulation made no difference in the induced humoral responses as evident from the 
specific antibody titers obtained after primary immunization as well as after a booster 
close. Crosslinking however moderately increased the titers. In case of the EE-Inv-PB 
and EE-Inv-PB-CL groups, however, marked differences were observed in the fiters 
when the route of administration was varied (especially after a priming dose), with 
\'ery high titers obtained by their i.p. administration as compared to the s.c. 
administration. Also, the antibody response generated in the EE-Inv-PB-CL group 
receiving the formulation i.p. was comparable with that obtained by the CFA-Inv 
group both after primary and booster doses. Considering the well-known toxicity of 
the adjuvant, comparable antibody titers induced by the erythrocyte-plasma bead 
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system was encouraging. Also, there was a moderate shift toward the Th-2 biased 
immune response in the animals receiving erythrocyte- entrapped antigen especially 
after plasma bead entrapment and crosslinking. This suggests their role in the 
induction of humoral immunity. 
In an attempt to further enhance the humoral as well as cell-mediated immune 
responses, a novel microparticle system was prepared from blood plasma. Plasma 
enriched with CaCh and entrapped pharmaceutical was stirred at high speed in a 
mineral oil bath to obtain microparticles of 1-5 |.i diameter. The additional advantage 
of the microparticle system is their easy injectbility, possibly near the target site. The 
plasma microparticles were subjected to varying times and temperatures of incubation 
and it was observed that stable particles were formed at a stirred incubation of 60 min 
and 40 °C in the presence of 40 mM CaCh. This was evident from the SDS-PAGE in 
which no increase in the high molecular weight polypeptide was observed after 60 
min and 40 ''C, also from the entrapment studies with invertase. 
In vitro studies performed with plasma microparticles containing entrapped invertase 
and Amphotericin B suggested the release to be slow was with only 26-28% of the 
entrapped enzyme and 14-16% of the entrapped drug being released in the buffer in 
72 hr; crosslinking further reduced the leakage to 12% and 7% respectively. Plasma 
microparticles prepared at high temperatures however failed to register any lowering 
in the release of the enzyme/drug. 
In vivo studies on the immunogenicity of the plasma microparticles entrapped antigen 
were carried out in rabbit and mice models and the groups investigated include CFA-
Inv, plasma microparticles containing entrapped invertase (PMP-Inv) and those 
crosslinked with 0.05% glutaraldehyde (PMP-Inv-CL). In case of the mice immune 
response of invertase dissolved in PBS (Sal-Inv) was also investigated. High antibody 
titers were obtained in both rabbit and mice in the PMP-Inv g;roup, which were 
comparable to those of the CFA-Inv. Encouragingly, superior titers were obtained in 
animals administered the PMP-Inv-CL formulations both after primary and booster 
doses. Isotype studies suggest a higher Thl/Th2a immune response in both PMP-Inv 
and PMP-Inv-CL group, more in the later, suggesting a Thl biasing, thereby 
promotion of the cell-mediated immunity. Flow cytometric analysis was undertaken 
to further ascertain the CMI responses. Study of CD4" positive T-cells in the 
ni 
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splenocytes isolated from the animals immunized with PMP-Inv-CL and PMP-Inv 
formulations also revealed marked upregulation of both 004"*^  (21 % and 16.5%, 
respectively) when compared with those of the CFA-Inv (13.5%) and Sal-Inv (3.2%)) 
groups. The difference was miore marked in case of CD8^ positive T-cells with only 
7% of CD8^ cells being present on the surface of APCs in case of CFA-Inv group 
against 16% and 12% of the PMP-Inv-CL and PMP-Inv groups, respectively. The 
levels remained lower in animals of Sal-Inv group (3.4 %). FACS analysis was also 
conducted to evaluate the expression of CD80 and CD86 on the surface of APCs 
isolated from groups of animals immunized with PMP-Inv-CL and PMP-Inv showed 
significantly higher level of their expression (CD80, 12% and 10.5%; CD86, 12.4% 
and 11.5%) respectively as compared to CFA-Inv and Sal-Inv (CD80, 6.7%) and 3.4%; 
CD86, 3.5% and 3.4%) respectively. Our overall results with the plasma 
microparticles, especially after crosslinking indicate good humoral/ CMI response, 
especially after booster. 
][t is proposed that plasma beads and plasma microparticles prepared and investigated 
in this study have remarkable potential as drug/antigen delivery systems. The risk of 
immunological complications is minimized since the preparations can be obtained 
using autologous plasma without the need for any foreign protein/enzyme. Total 
iDiodegradability and biocompatibility as well as ease of preparation using simple 
laboratory set up are the other advantages. The highly sustained in vitro and in vivo 
release of entrapped pharmaceuticals makes them very attractive in the delivery of 
(irugs. Also, they appear promising as vaccine delivery candidates. The plasma 
]3reparations have the potential to regulate the nature of immune response in addition 
i;o the induction of high titers; the erythrocyte-bead system gave a humoral shift while 
the plasma microparticles resulted in a CMI switch. 
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Introduction 
1.0. INTRODUCTION 
The efficacy of a therapeutic agent depends on its action on the target molecule 
located either within or outside the cell. Drugs administered orally, parentally or 
through other modes enter blood circulation and gain access both to target and non-
taiget sites, necessitating larger doses that in turn exacerbate their toxic side effects. 
Thierapeutic efficacy of the drug can however be markedly improved and harmful 
efiiects reduced by augmenting the amount and persistence of the drag in the vicinity 
of the target cells, while ensuring lowered exposure of the non-target cells. Delivery 
systems that regulate in vivo drug release have therefore acquired seminal significance 
in pharmaceutical research. An ideal drag delivery system should have the ability to 
release therapeutics at predetermined anatomical site and maintain circulating 
concentration of the released substance within a therapeutic band for the desired 
duration. Good drag delivery system tend to contribute towards minimizing peak-
valley fluctuations, reduction in drag dosage, lowering of dosage frequency, decrease 
in side effects and improved patient compliance. They should also integrate elements 
of responsive behavior to the in vivo surroundings and be amenable to feed-back 
controls. 
According to BCC research reports the global market for advanced drag delivery 
systems was more than $131.6 billion in the year 2010 and is expected to reach $176 
in 2016. The drag delivery systems being investigated currently include micelles, 
liposomes, dendrimers, liquid crystals, nanoparticles hydrogels, biological and 
synthetic polymers and in situ implants (Kaparissides et al, 2006). Biodegradability 
of the delivery systems offers remarkable advantage and those that are enzymatically 
or non-enzymatically degraded in vivo continue to receive remarkable attention. 
Among those being investigated currently, the in situ implantations are most 
prominent. These are attractive in parenteral applications in view of their low costs 
and being less painful. Localized or systemic drag delivery can be realized for 
sustained periods ranging from one to several months (Hatefi and Amsden, 2002; 
Ruszczak and Friess, 2003; Kaparissides et al, 2006). Nanoparticulate drag delivery 
systems appear to have remarkable potential for diverse applications, including anti-
tumour therapy, gene therapy, and delivery of proteins, antibiotics and vaccines. 
Current focus is on the constraction of biocompatible and biodegradable delivery 
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systems that can deliver adequate quantities of drugs to target areas in a controlled 
manner (Ghosh et a/., 2011; Kaparissides et al, 2006; Gupta et al, 2009). 
1.1. Biodegradable delivery systems 
Polymers are highly favored candidates for construction of three-dimensional entities 
su(;h as scaffolds for tissue engineering, controlled/sustained drug delivery, as gene 
delivery vehicles as well as in bionanotechnology (Nair and Laurencin, 2007). 
Biodegradable polymers constitiite a favoured class of starting materials for building 
controlled drug delivery vehicles. While the term biodegradation is used 
interchangeably with bioerosion, both can occur as surface or bulk processes. The two 
however differ in the mechanism of drug release; while the former involves covalent 
bond cleavage, enzymatic or otherwise, erosion results from dissolution of chain 
fragments with no chemical alterations (Liechty et al, 2010). The drug deliverers 
degrade into biologically acceptable compounds usually via enzymatic/non-enzymatic 
hydrolysis; subsequently release the incorporated medications (Vogelson, 2001). An 
ideal biodegradable polymer would be cleaved to metabolic compounds small enough 
fo]' elimination through natural clearance mechanisms. Biodegradable polymers 
usually contain bonds susceptible to hydrolytic (proteolytic, estrolytic, etc) cleavage, 
either in the backbone or crosslinks. Their in vivo degradation can therefore be 
controlled by varying the nature and extent of crosslinks and/or chemical modification 
of the backbone (Nair and Laurencin, 2007). 
Therapeutics for regulated in vivo delivery is usually associated with polymers by 
physical entrapment but conjugation of a therapeutic molecule to the polymer may 
further improve its pharmacokinetic and pharmacodynamic properties. These include 
increase in plasma half-life and a consequent reduction in dosage frequency, 
protection of the therapeutic from enzymatic degradation, enhanced stability, 
increased solubility and potential for targeted delivery (Roberts et a!., 2002; Duncan, 
2003; 2006). 
Biodegradable drug delivery systems employ molecules of diverse origin including 
both natural and synthetic polymers. Among the natural polymers polysaccharides, 
aljginate, dextran, hyaluronic acid, chitosan and cellulose have been studied 
extensively for their drug delivery potential. Gelatin, collagen, albumin, elastin, 
elastin-like peptides, silk fibroin and fibrin are the principal proteins that continue to 
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receive remarkable attention in this regard. Synthetic polymers that have been 
investigated in remarkable detail as drug carriers include polyphosphazene, 
polyurethane, polycaprolactone and polyorthoester (Gunatillake and Adhikari, 2003). 
Most of the synthetic biodegradable drug carriers undergo fragmentation due to 
cleavage of the ester bond, ester derivatives like poly (lactic/glycolic acid) and poly 
(s-caprolactone) or peptide bond. Other hydrolysable bonds that exist in the polymers 
include those of poly (anhydrides), poly (orthoesters), poly (phophoesters) (Park et 
ai, 1993). 
1.1.1. Polysaccharide based delivery systems 
Polysaccharides comprise large number of monosaccharide units linked together by 
glycosidic bonds and exhibit a spectrum of biological properties ranging from cell 
signaling to immune recognition. New procedures available for the tailored synthesis 
ol" oligosaccharide, modification of polysaccharides, and their proficiency to be 
fabricated into desirable structures, place the saccharide-based delivery systems 
among the most extensively investigated and potential natural biomaterials (Nair and 
Laurencin, 2007). 
1.1.1.1. Alginate 
Alginate is a linear polymer of glycosidically linked p (l->4)-D-mannuronic acid and 
a-L-guIuronic acid (Fig. 1.1a), but its exact composition varies with the source (Haug 
et ai, 1967). Alginic acid is a constituent of the cell walls and intercellular spaces of 
brown algae. Its high acid content facilitates spontaneous and mild gelling in the 
presence of divalent/trivalent cations, and facilitates the entrapment of numerous 
molecules or even cells (Klock ei ai, 1997). Also, the highly reactive carboxylic acid 
groups of alginates can be aptly modified for a number of applications such as in drug 
delivery. For example, the rate of drug release from alginate matrices can be varied by 
altering drug-polymer interaction or chemically coupling the drug to the polymer back 
bone via carboxyl groups. 
Alginate microparticles show sustained release of the anti-tubercular drugs isoniazid, 
rifampicin and pyrazinamide both in vitro and in vivo (in guinea pigs). A nine-fold 
increase in the bioavailability of the drug upon entrapment into alginate was observed 
as compared with that administered in the free form (Qurrat-ul-Ain et al, 2003). 
Ghosh et al (2011) prepared low molecular weight alginic acid (LMWA) 
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n8.noparticles by cation-induced gelification of depolymerized alginic acid. 
Tetracyclin was effectively loaded in the LMWA nanoparticles with an entrapment of 
67 %. Release of the drug in vitro was gradual and 62 % of the entrapped drug leaked 
into the medium in 100 hr, while in vivo studies provided evidence for effective drug 
deilivery against tetracyclin resistant Escherichia coli XL-1. Tugcu-Demiroz et al 
(2007) developed alginate-based mesalazine tablets which could efficiently deliver 
the drug to the small and large intestine, with potential in the treatment of Crohn's 
disease. Other studies suggest that the entrapment of proteins and other therapeutics 
within crosslinked alginate gels greatly augment their efficiency, targetability and 
efforts continue to develop novel drug delivery systems based on these gels (Kuo and 
Ma,2001;Augste?a/.,2006). 
1.1.1.2. Starch 
Starch-based systems like gels and microparticles have long been in focus for a 
variety of medicinal applications like scaffolds for bone and tissue engineering 
(Gomes et al, 2001; 2003), and drug delivery (Silva et al., 2005; 2007). Malafaya et 
al (2006) incorporated the model drug meclofenamic sodium salt which is a non-
st(;roidal anti-inflammatory dmg (NSAID) in starch microspheres and used in the 
tn;atment of arthritic inflammations. Release profile of the entrapped drug suggested 
the possibility of its regulation by pH and ionic strength. 
Silva et al (2004) synthesized starch-based microparticles by combining starch with 
the bioactive and bone-bonding bioactive glass (BG). Novel and bioactive composite 
starch-BG microparticles were synthesized by blending starch and polylactic acid 
(50%/50% wt) with BG 45S5 powder using a simple emulsion method. The particles 
formed were spherical and about 350 i^ m in size. These particles were bioactive and 
non-toxic as evident from various in vitro experiments. The starch-based 
microparticles were investigated for entrapment and release of the corticosteroids 
dexamethasone (DEX), 16a-methylprednisonole (MP), and 16a-methylprednisolone 
acetate (MPA) (Silva et al. 2005). The entrapment efficiencies were 82, 84 and 51% 
for DEX, MPA and MP respectively. The carriers were able to sustain a controlled in 
vitro release of the entrapped corticosteroids for over four weeks after an initial burst 
release supporting their potential in sustained delivery. 
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St£irch-based systems have also been used for nasal delivery of insulin. Freeze-dried 
powder of insulin with drum-dried waxy maize starch or maltodextrins and 
Carbopol®974P was administered to rabbits. The bioavailability of insulin achieved 
on applying Starch-Carbopol® 974P powder nasally was significantl)^ higher than that 
of the maltodextrin-Carbopol® 974P mixtures (Callens and Remon, 2000). 
The vasoactive drug angiotensin II combined with degradable starch microspheres 
showed improvement in the delivery of various anti-cancer drugs to hepatic tumours, 
reducing exposure of normal hepatic parenchyma to the potentially hepatotoxic drug 
as compared to their independent use (Carter et al, 1992). Phenylephrine and 
angiotensin II have also been used to favourably affect the hepatic and tumour blood 
flow in an animal model. A 4-fold increase in the retention of a low molecular weight 
radio-labelled marker, ^^"Tc methylene diphosphonate (MDP) in the tumour tissue 
was observed relative to normal hepatic parenchyma at one min after injection, but the 
duration of vasoconstriction was small and significant amount of marker was washed 
out by 90 min (Hemingway et al, 1990). Combining degradable starch microspheres 
to manipulate drug delivery showed a similar 4-fold retention in tumour at one min, 
bvit with decreased washout at 90 min (Cooke and Chand., 1990). 
Com starch aerogel microspheres were prepared successfully by combining emulsion-
gelation and supercritical drying, without the use of any chemical crosslinkers or toxic 
organic solvent. The starch aerogel microspheres showed high internal surface area 
and loading capacity with the NSAID Ketoprofen (Garcia-Gonzalez et al., 2012). 
1.1.1.3. Hyaluronic acid 
Hyaluronic acid (HA) is a member of the glycosaminoglycans family present in 
almost all vertebrate tissues. It is a ubiquitous linear polysaccharide polymer of 
repeating disaccharide units of N-acetyl-D-glucosamine, 3 (l->4), and D-glucuronic 
acid, P (l->3) (Fig. 1.1c) (Napier and Hadler, 1978). The aqueous solubility of HA 
allows it to be fabricated into different types of porous, three-dimensional structures 
making it an ideal biomaterial for tissue engineering and drug delivery applications 
(Price et al, 2007). HA has received remarkable attention as a drug delivery system 
also because of its mucoadhesive and immunoneutral property (Jin et al, 2010). 
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H/^  based systems have been probed for drug delivery via various routes of 
adiministration, including ocular, ophthalmic (Jarvinen et al, 1995; Bucolo et al, 
1998), nasal (Morimoto et al, 1991; Lim et al, 2002), pulmonary, parenteral 
(Drobnik, 1991; Peer et al, 2003) and topical (Brown and Jones, 2005). Pilocarpine 
association with sodium hyaluronate increased two-fold the absorption of Pilocarpine 
as compared to the drug administered topically to the eye (Camber et al, 1987), 
improving the bioavailability and miotic response while extending the duration of 
action (Bucolo and Mangiafico, 1999). In another study, aqueous solution of sodium 
hyaluronate prolonged the residence time of Pilocarpine on the precorneal surface 
suggesting its use as an additive in various drug-release systems for the eye (Gumy et 
al, 1990). Gentamicin bioavailability was increased at the ocular surface when 
formulated with a 0.25 % HA solution in humans (Bematchez et al 1993). 
Microparticles prepared by the spray-dry method using HA-based microspheres 
containing PEG 6000 and/or sodium taurocholate for the nasal delivery of 
Fexofenadine hydrochloride (an anti-histamine drug) increased its bioavailability 
remarkably in rabbits (Huh et al, 2010). 
Regulatory approvals in Europe, Canada and USA have been granted for the use of 
3% Diclofenac in 2.5% HA gel, Solaraze®, for the topical treatment of actinic 
keratosis. The gel is well tolerated, safe and provides an attractive and cost-effective 
alternative to Cryoablation, Dermabrasion, or 5-Fluorouracil (Brown and Jones, 
2005). 
Yadav et al (2008) prepared nanoparticles of Doxorubicin (DOX) using hyaluronic 
acid-polyethyleneglycol-polycaprolactone (HA-PEG-PCL) copolymer and 
compared its tumour targeting efficiency with non-HA-containing nanoparticles 
(raethoxy poly ethylene glycol (MPEG)-PCL). The HA-PEG-PCL nanoparticles 
facilitated sustained release of DOX over a period of 17 days, whereas the release 
from MPEG-PCL nanoparticles was completed within 14 days. Tissue distribution 
study and tumor growth inhibition were performed after i.v. injection of nanoparticles 
in Ehriich ascites tumor (EAT)-bearing mice. Use of HA-PEG-PCL nanoparticles 
resulted in more efficient delivery of DOX in EAT as compared to the MPEG-PCL 
microparticles. The affinity of HA for the CD44 receptor that is overexpressed in 
various tumor cells makes HA an important tool for targeted drug delivery to cancer 
cell (Jin e/fl/., 2010). 
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1.1.1.4. Chitosan 
Chitosan is a cationic linear co-polymer derived from chitin. It comprises repeating p 
(1-^4)-glucosamine and N-acetyl-D-glucosamine units (Fig. l.ld). Owing to its high 
water solubility, chitosan like HA can be formulated into gels, microspheres, 
nanospheres and nanofibers. In addition, the pH sensitivity, excellent biocompatibility 
and biodegradability, 
• ^ . 
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COOH 
OH 
(a) (c) 
OH 
5--A.-0 
i pH Hbi 
HO^.^.4^0 OH 
H O V . - - ^ / 
HO^,^i^.O 
HO 
Fig. 1.1. Partial structure of alginate (a), starch (b), hyalouronic acid (c) and chitosan 
(d). 
makes chitosan a promising candidate for drug delivery devices as well as scaffolds 
for tissue engineering (Nair and Laurencin, 2007). Due to the mild gelling properties, 
the hydrogel is a potential delivery candidate tbr labile therapeutics such as growth 
factors and living cells in addition to small molecular weight dnigs especially for 
localized therapy (Nair et al, 2007). Chitosans binds DNA to form complexes and a 
chitosan-based non-viral gene delivery strategy has also been envisaged (Mao et al, 
2001). 
Martinac et al (2005) were successful in the preparation of bioadhesive chitosan 
microspheres using a spray-drying method for nasal delivery of lipophilic model drug 
Loratadine. Ilium et al (2001) also worked with chitosan-based systems for nasal 
delivery of influenza, pertussis and diphtheria vaccines in mice. While the serum IgG 
levels were comparable, those of IgA were superior in animals that received the 
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chitosan formulation in comparison to those releasing the vaccine parenterally. Also 
the animals receiving the chitosan-based vaccine were remarkably protected against 
appropriate challenges by the causative microbes. A nasal chitosan-based vaccine 
delivery system has also been tested against influenza in human subjects and the 
results were encouraging (Ilium et al, 2001). 
Cliitosan-based injectable in situ gelling hydrogels were developed first by Ruel-
Garie'py et al (2004). The thermosensitive hydrogel, liquid at room temperature gels 
widen exposed to body temperature and showed sustained release of the anti-cancer 
drug Paclitaxel over four weeks in vitro. A single injection of the Paclitaxel 
formulation given intratumorally in EMT-6 tumors implanted subcutaneously in 
Balb/c mice was as efficacious as four i.v. injections of Taxol® in inhibiting the 
growth of the tumour. Animals receiving the chitosan formulation also exhibited 
fewer toxic effects associated with the drug. 
1.1.2. Protein-based delivery systems 
Being a major constituent of various tissues, proteins and other amino acid-derived 
polymers continue to be considered ideal materials for sutures, haemostatic agents, 
scaffolds for tissue engineering and drug delivery vehicles (Nair and Laurencin, 
2007). Protein-based polymers also offer the advantage of mimicking many features 
of extracellular matrix and facilitating the migration, growth and organization of cells 
during tissue regeneration, wound healing as well as for stabilization of encapsulated 
pharmaceuticals and cells (Malafaya et al, 2007). Proteins used currently in tissue 
engineering and drug deliver}/ include silk fibroin (SF), albumin, collagen, zein, 
keratin, casein and fibrin (Wang et al, 2009). 
1.1.2.1. Silk fibroin 
SF comprises of repetitive protein sequences with structural roles in egg protection, 
cocoon and web formafion as well as nest building (Wang et al, 2009). Silks are 
attracfive biomaterials for tissue engineering owing to their excellent mechanical 
properties, slow degradability (Sofia et al, 2001; Horan et al, 2005) and remarkable 
biocompatibility (Altman et al, 2003; Dal Pra et al, 2005). Silk is also mechanically 
robust and hence best suited for many medicinal applicafions including drug delivery 
(Sofia et al, 2001; Hofmann et al, 2006). Owing to the mild processing conditions 
required, SF-based delivery system find application as carriers of labile and bioactive 
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therapeutics (Wang et ai, 2009). The amino acid side chains of fibroin have also been 
modified for the immobiHzation of growth factors (Unger et ai, 2004; Fuchs et al, 
2006; Vepari and Kalpan 2007). Wenk et al (2008) fabricated saHcylic acid and 
Prcipranol hydrochloride-loaded and the insuHn-like growth factor I-loaded SF 
spheres with encapsulation efficiencies close to 100%. Release of insulin-like growth 
factor I in vivo occurred over seven weeks in bioactive form. 
Examples of other bioactive substrates laden in SF films and scaffolds include 
horseradish peroxidase (HRP), lysozyme and nerve growth factor (Hofmann et ai, 
2006; Uebersax et al, 2007), BMP-2, IGF-I, alkaline phosphatase and staphylococcal 
protein A (Demura et al, 1992; Kikuchi et al, 1999; Li. et al, 2006; Uebersax et al, 
2007). These entrapped proteins exhibited good bioactivity after processing 
presumably due to the induction of crystallity in the SF films which restricts the inifial 
burst and subsequent release (Hofmann et al, 2006). SF-based formulations also 
support the adherence and metabolic activity of PC 12 cells (cell line derived from a 
pheochromocytoma of the rat adrenal medulla) and, in combination with nerve growth 
factor (NGF), support neurite outgrowth during PCI2 cell differentiation (Uebersax et 
al, 2007). 
SF microparticles were used as carriers for the delivery of bone morphogenetic 
proteins (BMPs) BMP-2, BMP-9 or BMP-14. Encapsulation efficiencies of the BMP-
containing fibroin microparticles varied between 70 % and 98% depending on the 
type and the amount of BMP load. Release kinetics showed that BMP-2, BMP-9 and 
BMP-14 were released with a burst in the first two days followed by a slower release 
lasting over 14 days (Bessa et ai, 2010). 
Nanoparticles were also fabricated by noncovalent blending of SF and chitosan (CS) 
in various proportions (SF: CS, 75:25, 50:50, and 25:75) or pure SF for sustained 
local delivery of curcumin to cancer cells. The entrapment yields were remarkably 
higher and the release was gradual lasting over 8 days for SF-derived nanoparticles as 
compared to other SFCS blends. Also, pure SF-based curcumin nanoparticles showed 
potent tumouricidal activity against some breast cancer cell lines (Gupta et al, 2009). 
1.1.2.2. Serum albumins 
Albumin is the most abundant protein in blood of higher animals constituting almost 
50% of the total plasma proteins (Quinlan et al, 2005). Human serum albumin (HSA) 
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can be readily processed into a variety of forms including microspheres, nanospheres, 
nanofibres and membranes (Nair and Laurencin, 2007). Its excellent blood 
compatibility together with its ready digestibility allows the extensive application of 
HSA as a carrier vehicle for drug/gene delivery (Chuang et al, 2002; Prinsen and de 
Sain-van der Velden, 2004; Kratz, 2008). Almost all tissues in the body have the 
ability to degrade albumin (Prinsen and de Sain-van der Velden, 2004). Several 
studies suggest that HSA microspheres have potential as a slow drug release delivery 
system (Kramer, 1974; Kandzia et al, 1984), as a carrier system for a variety of 
proteins and enzymes (Ovadia et al, 1982; Kandzia et al, 1981) as well as antitumour 
agents like Cytarabine (Noorwali et al, 1986; Kim et al, 1986) and Epirubicin 
(Leucuta et al, 1988). Most of the entrapped Cytarabine was retained in the bovine 
albumin microspheres in vitro, save the initial ten minute burst release. Drug release 
in the initial burst was affected by heating temperature during preparation, 
drug/albumin concentration ratio and size distribution of the microspheres (Noorwali 
et al, 1986). Another study reported the release of Cytarabine from albumin 
microspheres to be dependent upon the drug/albumin ratio as well as the degree of 
cross-linking (with formaldehyde) and cross-linking time (Kim et al., 1986). Heat 
denaturation also caused significant but reciprocal effects on the in vitro release rates 
of Prednisolone from albumin microspheres (Burgess etal, 1987). 
Leucuta et al (1988) evaluated the efficacy of intratumoral administration of 
epirubicin-loaded albumin microspheres in mice with Ehrlich ascites carcinoma and 
experimental metastases in rats with Walker carcinoma. The difference in the mean 
survival time in animals treated with the drug loaded microspheres when compared to 
the free-epirubicin group/controls was statistically significant in both the cases. These 
findings suggest the potential of albumin microspheres organ reducing side-effects, 
especially the cardiotoxicity of the drug. Sebak et al (2010) reported the use of the 
tumoricidal drug, Noscapine loaded in HSA nanoparticles as promising strategy for 
targeted delivery of the drug to tumor cells. 
The accretion of albumin in solid tumors facilitates albumin-based drug delivery 
systems for tumor targeting (Kratz, 2008). An albumin-binding prodrug of 
Doxorubicin, (6-maleimido) caproylhydrazone, and albumin Paclitaxel nanoparticles 
(Abraxane) have been evaluated clinically (Kratz et al, 2002; Kratz et al, 2007; 
Unger et al, 2007; Lebrecht et al, 2007). The latter has also been approved for 
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treating metastatic breast cancer (Ibrahim et al, 2002; Goble and Bear, 2003; 
Gradishar et al, 2005; Ibrahim et al, 2005). 
Levemir, a myristic acid derivative of insulin that binds to the fatty acid binding sites 
of circulating albumin, has also been approved for the treatment of diabetes (Home 
and Kurtzhals, 2006). Also, Albuferon, a fusion protein of albumin and interferon, is 
cuirrently undergoing phase III clinical trials for the treatment of hepatitis C and could 
bei^ ome an alternative to PEGylated interferon (Chemmanur and Wu, 2006; Kratz, 
2008). 
1.1.2.3. Collagens 
CoUagens are a group of proteins, especially abundant in the muscle and connective 
tissues of higher animals (Muller, 2003), constituting 25-35 percent of the whole-
body protein content (Di Lullo et al, 2002). Collagens are the primary initiators of the 
coagulation cascade and their high thrombogenicity makes them useful as hemostats 
(Kair and Laurencin, 2007). Many collagen-based hemostats are now commercially 
available which include Sulzer-Spine® Tech, CoStasis®, Floseal®. Collagen-based 
Gentamicin delivery vehicles, Sulmycins-® Implant, Collatamps-® G and Septocoll® 
that facilitate prolong local drug delivery with very low systemic exposure are also 
available (Gruessner et al, 2001). Collagen-based release systems have also been 
useful in sustained local deHvery of tobramycin (Lindsey et al, 1993; Gonzalez Delia 
Valle et al, 2001; Nelson et al, 2002), Minocycline (Galandiuk et al, 1997), 
Tetracycline (Singh et al, 1996), Teicoplanin (Venice et al, 2002) and Sulbactam-
cefoperazone (Yagmurlu et al, 1999). Composites of collagen and other synthetic 
polymers (such as poly (lactic-co-glycolic acid, PLGA) as drug carriers have also 
been developed (Ruszczak et al, 2000) and used effectively in the local controlled 
delivery of gentamicin (Schlapp and Friess, 2003). 
Cross-linked but absorbable collagen sponges (ACS) are undergoing clinical trials as 
protein carrier vehicles. Collagen sponges were investigated for local delivery of an 
osteoinductive differentiation factor, BMP. A combination of the recombinant human 
BMP-2 and an ACS was effective and safe in both animal and human trials, and 
resulted in controlled release of the differentiation factor (Geiger et al, 2003). Apart 
from protein delivery, collagen matrices have also been examined for gene and 
plasmid DNA delivery (Sano et al, 2003). 
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1.1.2.4. Gelatins 
Mild hydrolysis of collagen facilitates strand separation and induces the formation of 
globular, random coils of gelatin (Wang et al., 2009). Owing to their excellent 
bicicompatibility, gelatins are considered safe as components in drug formulations and 
scEilants for vascular prostheses (Djagny et al., 2001), and find several applications in 
tissue engineering, drug delivery and gene therapy (Tabata and Ikada, 1998; Malafaya 
et al, 2007). Gelatins retain some of the information signals (such as Arg-Gly-Asp, 
RCJD sequence) that promote cell adhesion, proliferation and differentiation but also 
have the advantage of low antigenicity as compared to collagen (Wang et al., 2009). 
Commercially available gelatin based formulations for drug deliveiy that are being 
applied in tissue engineering applications include Gelfoam®, Surgifoam®, 
CiiltiSpher-G®, etc (Malda et al, 2003; Awad et al, 2004; Ponticiello et al, 2000 ). 
Cisplatin-containing gelatin gels markedly suppressed in vivo tumor growth when 
administered intratumorally to Meth-AR-1 tumor-bearing mice as compared to those 
receiving the free drug (Konishi et al., 2003). Gelatin- based systems have also been 
investigated as in situ tissue adhesives to facilitate sustained release of drug 
incorporated in the gels directly in the vicinity of diseased tissues, especially the 
tumor cells (Okino et al., 2002). 
1.1.3. Fibrinogen and fibrin 
Fibrinogen is a soluble plasma protein synthesized in the liver and present copiously 
in the blood of higher animals. It plays the key role in blood clotting and several 
pathological processes, including heraostasis, thrombosis, adhesion and aggregation 
of platelets. Fibrinogen is a 360 kDa heterodimeric glycoprotein made up of three 
pairs of identical polypeptide chains, namely Aa, B(3, and y which are joined together 
by six disulfide bridges (Jackson and Nemerson, 1980). Fibrinogen is converted into 
soluble fibrin monomers via proteolytic cleavage by thrombin (Fig. 1.2). In vivo, 
formation of fibrin clots is initiated by vascular injury, which converts the zymogen 
prothrombin into active serine protease thrombin that in turn activates many 
constituents of the coagulation cascade leading to clot formation and prevents blood 
loss. Calcium ions serve as key cofactors in the enzymatic conversion of fibrinogen 
into fibrin. Many other factors including plasma proteins exert a significant influence 
on clot structure, imparting tensile strength and stability (Doolittle et al, 1998; Rowe 
era/., 2007). 
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During the clotting process, thrombin cleaves fibrinopeptides A from Aa, and 
fibrinopeptides B from Bp chains of fibrinogen (from the amino terminal ends) to 
form linear fibrin monomers (Laki, 1951; Lorand and Middlebrook, 1952). The 
monomers readily aggregate into fibrils to form loosely assembled three-dimensional 
biopolymer clot 
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Fig. 1.2. Mechanism of crosslinking in fibrin leading to clot formation (Lorand, 
2007). 
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Fig. 1.3. Structure illustrating the cleavage of fibrinopeptides from fibrinogen, 
formation of fibrin monomer, protofibril and fibrin clot (Geer et al, 2007). 
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(Fig. 1.3) (Mosesson et al., 2001). The clot contains entrapped platelets and other 
blood-borne components and is further stabilized by the activated Factor XIII 
(Schmoekel et al., 2004; Wolberg, 2007). Thrombin in association with Ca^ "^  
stimulates Factor XIII converting it into the catalytically active form (Factor Xllla). 
Factor Xllla contributes to the formation of lysyl-glutamine bonds, covalently linking 
the Y-Y dimer (Ehrbar et al, 2007; Ju et al., 2007). 
1.1.3.1. Fibrin based delivery systems 
Fibrin-based systems continue to receive remarkable attention for sustained and 
targeted delivery of pharmaceuticals for several reasons. These include (1) fibrin 
constitutes a natural and hence biodegradable, biocompatible and a readily resorbable 
native matrix (2) fibrin matrices can be formed under extremely mild experimental 
conditions in vitro by an enzymatic process and hence suitable as a carrier of heat-
labile drugs such as proteins (Ho and Chen, 1993) (3) the microstructaire of the fibrin 
polymers formed in vitro is dependent on reaction conditions such as pH and ionic 
stn^ngth, suggesting that formulation parameters may be manipulated to control 
relative availability of the entrapped pharmaceutical (4) fibrin based drug delivery 
systems exhibit bioadhesive properties capable of binding several biomolecules and 
cells. Table 1.1 Hsts many other important fibrin characteristics. 
Table 1.1. Desirable features of ideal scaffolds compared to various fibrin gel 
scaffolds. 
Ideal characteristic Fibrin characteristics Referecices 
Biocompatible Fibrin-based biomaterials Bensaid et al., 2003 
Non-toxic have high affinity to various 
Non-allergic biological surfaces and are 
Non- inflammatory already in clinical use 
Biodegradable Biodegradation can be Mol e/a/., 2005; 
Controlled and easily controlled with the Wozniak et al, 2003 
adjustable ^gg of cross-linking of fibres 
biodegradation • • , •, •. r-
,, . ^ or using inhibitors or 
allowing ^, . , . 
or • ..• c fibrinolysis 
sufficient time for ^ 
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new vessel formation 
Autologous nature 
Non-immunogenic 
No foreign body 
reaction 
Biological structure 
Three-dimensional 
supportive 
Assisting cellular 
growth 
Permitting easy 
diffusion 
cif nutrition and oxygen 
Easily processable 
Manufactured in less 
time 
Reproducible own 
blood 
Economical 
Affordable to all 
Considerable mechanical 
sti'ength 
Fibrin gels are autologously Ye et al, 2000; 
harvested from the patient's Aper et al, 2007; 
own blood, thus limiting Jockenhoevel e/a/., 
immune or foreign body ^"Ola 
reactions 
Fibrin is a provisional Rowe et ah, 2007 
matrix in the normal wound 
healing; 
its structural and 
biochemical properties 
make it a promising 
candidate as a scaffold in 
tissue engineering. 
Fibrin gels offer excellent Ye et al, 2000; 
cellular growth and tissue Aper et al, 2004 
development in a three-
dimensional matrix 
structure; 
however, there have been 
concerns regarding the 
diffusion limits in the gels. 
Fibrin gels are autologously Aper et al, 2007 
harvested from the patient's 
own blood, and are 
completely reproducible 
Being natural and Shaikh e/a/., 2008 
autologous scaffolds, the 
economical cost 
would be acceptable to all 
Structurally too weak to Jockenhoevel et al, 
withstand physiological 2001b 
dynamic environment 
Variable in shape and size Possible to constract fibrin Jockenlioevel et al, 
scaffolds to fill any, 2001a 
desired size shape or 
geometry and can be used as 
an injectable scaffold. 
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Tuneable chemical, The compliance and Rowe e?a/., 2007; 
physical and polymerisation rate of fibrin Eyrich et ah, 2007 
mechanical properties can be tightly controlled by Kjaergard e/a/., 1994 
varying ionic strength and 
the concentration of 
fibrinogen and thrombin. 
(Shaikh et al, 2008) 
1.1.3.1.1. Haemostatic glue and wound repair 
Fibrin sealants were first used as early as in eighteeth century as a hemostats (Bergel, 
1909) and continue to remain the most effective tissue adhesives even today. To 
ensure quick and efficient clotting, fibrin glues are prepared using ver/ high amounts 
of fibrinogen and thrombin (up to 60 mg/ ml fibrinogen and 300 lU/ ml thrombin) 
(Buchta et al., 2004, 2005). In order to restrict the risk of any kind of contaminafion 
or ti-ansmission of disease, fibrin isolated from autologous plasma has also been used 
(Redl et al, 1983; Zilch and lambiris, 1986). 
Fibrin-based preparations have also been used as an adjunct therapy to stem bleeding 
and to replace sutures in certain cases (Weisel and Cederholm-Williams 1997; Albala 
and Lawson 2006). The preparations enhance healing and minimize scarring 
compared to sutures and staples. Fibrin sealants are useful alternatives to sutures also 
be(;ause they facilitate wound healing and provide optimal wound integrity in 
situations where sutures cannot control and may even aggravate bleeding (Spotnitz et 
al, 1997). 
Fibrin sealants have been successfully used in a number of surgical procedures 
including thoracic surgery, cardiovascular surgery, plastic and reconstructive surgery, 
neurosurgery as well as dental surgery (Jackson, 2001). In case of neurosurgery, fibrin 
has been used for intracranial and spinal surgeries, including tumor resecfion, 
duraplasty, aneurysm repair, and nerve anastomosis (Shaffrey et al, 1990; Bento and 
Miniti, 1993; Povlsen, 1994). Fibrin glue is thus a popular tool in many aspects of 
modem day surgery (Petersen, 1985; Nomori et al, 2000; Czemy et al, 2000; Canby-
flagino et al, 2004). The use of fibrin sealants provides additional advantages of 
improved hemostasis together with reducfion in blood loss, bacterial infecdon and 
other complications (Mankad and Codispoti, 2001). Applications of fibrin sealants to 
other surgical areas, such as orthopedics ( Schlag and Redl, 1988; Thorns and 
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Marwin, 2009) and urology (Shekarriz and StoUer, 2002; Evans and Morey, 2006) 
have also been reported. 
1.1.3.1.2. Fibrin as a delivery vehicle 
Fibrin formulations are finding increasing applications in delivery of therapeutics, cell 
delivery and tissue engineering ( Cox et ai, 2004; Ho et ai, 2006; Liu et al., 2006; 
Mogford et al, 2009 Mooney et al, 2010). The extensive clinical usage and 
acceptance has also lead to investigate fibrin formulation as a potential alternative to 
conventional drug delivery in the areas of analgesia, chemotherapy, infection, gene 
delivery and regenerative medicine. All these disciplines benefit from the local 
deli\'ery of drugs/therapeutics, and easy usage and handling of fibrin coupled to its 
biomimetic proficiencies suggest its possible candidature as a promising delivery 
system (Spicer and Mikos, 2010). Fibrin formulations are also being investigated and 
used as tissue-adherent carriers for the local delivery and slow release of drugs, 
including antibiotics, growth factors, and for agents used in chemotherapy (Sierra, 
1993; Jackson e/a/., 1996). 
1.1.3.1.2.1. Drug delivery 
Fibrin formulations are among the earliest in situ delivery vehicles used for infection 
control in situ (Redl et al, 1983). Fibrin gels are highly porous facilitate the ready 
dif&sion of small and high molecular weight drugs. The diffusion rates are however 
slow in case of drugs that bind to the matrix constituents by ionic or hydrophobic 
interactions or by affinity (Block et al, 1974; Bekersky et al, 2002; Hartsel et al, 
2001). Furthermore, the porosity of the fibrin matrices is amenable to alterations by 
gelling strategies, chemical modification or crosslinking (Ho et al, 1995; Chung et 
al, 2006). 
Antibiotics were among the first therapeutics to be investigated for sustained delivery 
via fibrin matrices. A study suggested over 85% release of the entrapped antibiotics 
Gentamycin, Neomycin and Polymyxin E from fibrin matrix by progressive 
degradation of the clot within 72 hr (Redl et al, 1983). Another study investigated 
the release of Ampicillin, Carbenicillin, Ceftazydime, Clindamycin, Gentamycin, 
Cefotaxim, Mezlocillin, and Tobramycin from fibrin clots (Greco et al, 1991). The 
antibiotics investigated were released nearly completely by 96 hr. The release 
occurred faster in cases of Ampicillin and Clindamycin with most of the entrapped 
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drug being released in 48 hr and 72 hr respectively. Electron microscopic observation 
of th(j antibiotic-containing clots revealed no remarkable difference with respect to 
control clots constituted without antibiotics. Also, the clotting times for the antibiotic-
containing mixtures were comparable with those seen in case of the control fibrin 
clots (Greco et ai, 1991). This suggested that the biological properties of the fibrin 
clots are not altered by the association of the antibiotic and the latter maintains its 
antibacterial activity. 
Studies with Erythromycins, Tetracyclins and Penicillins show that water insolubility 
of the drug is the determining factor in the release from fibrin gels with highly 
insoluble drugs being released more slowly irrespective of the molecular dimensions 
(Woolverton et al., 1995, 1999). Tetracyciin entrapped fibrin sealant discs were used 
for local treatment of peritoneal sepsis in rats and mice infected with S. aureus. 
Tetracyciin was effectively released from the fibrin sealants for extended periods of 
time, providing flill protection against the infection. A dose of 500mg/kg of 
tetracyciin in fibrin sealant discs implanted in mice two days before infection resulted 
in complete protection while the same dose given seven days before infection resulted 
in complete survival. A Tetracyciin dose of 1750 mg/kg administered 35 days before 
infection also lead to complete survival in mice suggesting the potential of fibrin 
sealants in chemotherapy against S. aureus (Woolverton et al., 2001). 
Release of Lidocaine from fibrin glue for pain reduction was investigated in humans 
after breast augmentation. Patients who received fibrin glue with entrapped Lidocaine 
in ihe subpectoral pocket suffered less pain compared to those who received the same 
amount of free drug (Zhibo and Miaobo, 2009). 
Vancomycin (VCM) was mixed with fibrin glue and applied to Dacron grafts in 
Sprauge-Dawley rats (Fujimoto et al., 1997). The maximum VCM level in the tissues 
after implantation of the grafts was over seven times higher than the maximum 
concentration attained after the i.v. injection of the free antibiotic. The target index in 
case of the VCM-FG graft implantation was 12.11, suggesting availability of far more 
drug in the area of interest with fibrin glue used as a carrier. Also, the VCM-FG 
Dacron grafts remained uninfected even after inoculation with S. aureus ATCC 25923 
(Fujimoto e/fl/., 1997). 
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In a parallel study Sisomicin (SISO) was incorporated into fibrin glue around Dacron 
grafts in rats (Osada et al, 2000). The SISO-fibrin glue Dacron grafts were implanted 
subcutaneously in the anterior abdominal region and a comparison of serum and tissue 
level of the drug was made with rats that were given i.v. injection of the antibiotic at 
the same site. The serum SISO concentrations were significantly lower in the SISO-
FG Dacron graft group compared to that injected SISO intravenously. SISO levels in 
the tissues of animals around the graft implantation site were however 5.8 times 
greater than those of the i.v. injected groups after 4 hr (Osada et al, 2000). 
Several lipophilic anticancer drugs including Enocitabine, Etoposide and Doxorubicin 
were also entrapped in the fibrin glue and their release pattern investigated. The drug 
released correlated well with the hydrophobicity of the drug (Yoshida et al., 2000). 
Enocitabine, a nucleoside analog when entrapped along with a fibrinolytic inhibitor in 
fibi'in glue was released gradually against its rapid leakage in the absence of aprotinin. 
Etciposide derives its chemical make-up from podophyllotoxin, a toxin found in the 
American Mayapple. Doxorubicin is an anthracyclin antibiotic v/hich works by 
intercalating DNA. The levels of Etoposide and Doxorubicin in the supernatant 
increased rapidly reached a maximum and then decreased rapidly in the absence of 
apj-otinin. When aprotinin was co-entrapped however, the drug release was more 
sustained and gradual althrough (Yoshida et al., 2000). Drugs such as Mitomycin C, 
Fluorouracil and Tegafur were quickly released with or without aprotinin; these 
hydrophilic drugs apparently do not appear to interact with fibrin. Proteolysis thus 
seems to play an important role in the release of lipophilic drugs from fibrin matrices 
(Yoshida et al., 2000; Woolverton et al, 1999). 
Another study investigated the release kinetics of Doxorubicin (DOX) from fibrin 
glue in the presence and absence of sodium alginate in vitro. Burst release of DOX 
observed from the fibrin glue was restricted in the presence of sodium alginate 
(Kitazawa et al, 1997). Also local application of DOX using composite containing 
fibrin-alginate matrix resulted in its very high concentration in the tumour 
extracellular milieu as compared to that of plasma. 
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Table 1.2. Antibiotics entrapped in tlie fibrin matrices and used for in vitro or in 
vivo studies. 
Antibiotic References Nature of study 
Ampicillin Thompson and Davis, 1997; Park 
and Kim, 1997; Greco et al, 1991 
In vitro 
Oflaxacin 
Abiekacin sulfate 
Teicoplani 
Debakacin 
Sisomicin 
Gentamicin 
Park and Kim, 1997 
Itokazu er a/., 1997 
Kram et al, 1991; Marone et al, 
1999 
Thompson and Davis, 1997 
Osada et al, 2000 
Thompson and Davis, 1997; Park 
In vitro 
In vivo 
In vitro 
In vitro 
In vivo 
In vitro 
and Kim, 1997; Red! et al, 1983; 
Marone et al, 1999; Kram et al, 
1991; Greco e/a/., 1991 
Neomycin 
Ceirbenicillin 
Ceftazidin 
Clindamycin 
Vancomycin 
Cephalothin 
Metranidazole 
Bacitracine 
Redle/fl/., 1983 
Watanabe e^  o/., 1994 
Thompson and Davis, 
Thompson and Davis, 
1997 
1997 
VanderHam et al, 1992 
Thompson and Davis, 
GKCO etal, 1991 
Marone e/a/., 1999 
Deyerling e/a/., 1984 
Marone e/a/., 1999 
Haveriche^a/., 1989 
Haveriche^a/., 1989 
1997 
In vitro 
In vivo 
In vitro 
In vitro 
In vivo 
In vitro 
In vitro 
In vitro 
In vivo 
In vitro 
In vivo 
In vivo 
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Gontamicin derivative 
Tobramycin 
Cefoxitin 
Ciproflaxacin 
Polymixin B 
Mupirocin 
Norflaxacin 
Ceftazydime 
Tetracycline 
Nitroflirazone 
Cefotaxime 
Haverich e/<3/., 1992 
Neye/a/., 1990 
GxQco etal, 1991 
Kram etal, 1991; Thompson and 
Davis, 1997 
Tsourvakase/a/., 1995 
Kram e/a/., 1991 
Thompson and Davis, 1997 
Thompson and Davis, 1997 
Thompson and Davis, 1997 
Greco e/a/., 1991 
Woolverton et al, 2001; Kumar et 
al, 2004 
Thompson and Davis, 1997 
Zilch and lambiris, 1986; Van der 
Hame/fl/., 1992 
In vivo 
In vivo 
In vitro 
In vitro 
In vitro & In vivo 
In vitro 
In vitro 
In vitro 
In vitro 
In vitro 
In vivo 
In vitro 
In vivo 
1.1.3.1.2.2. Growth factor delivery 
Girowth factor delivery has been another arena in which fibrin-based delivery systems 
have proved their utility and these have been investigated for the sustained delivery of 
specifically exogenous growth factors that promote wound healing (Currie et al., 
2001). Local release of tissue specific growth factors, e.g., in an injury repair can be 
regulated by altering the interactions between the growth factor and the fibrin 
scaffold. The release profiles vary from few hours to several weeks. Control release of 
growth factor from fibrin often involves modification of interactions between the gel 
and the signalling protein. Some proteins such as basic fibroblast growth factor, 
comiective tissue growth factor, vascular endothelial growth factor and heparin bind 
reversibly but reasonably strongly to the fibrin clot (Odrljin et al, 1996; Sahni et al, 
1998; Sahni and Francis 2000; Yoshida and Munakata 2007). Heparin acts as a linker 
between fibrin and growth factors like nerve growth factor and neurotrophin-3 that do 
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net directly bind with the fibrin network (Lobb et al., \9'i6\ Taylor and Sakiyama-
Elbert, 2006). During attempts to accomplish highly sustained release of growth 
factors, phage display assay was performed to identify peptides with a high binding 
coefficient for nerve growth factor. These peptides were then linked to a 
transglutaminase substrate domain, which was covalently incorporated it into the 
polymerizing fibrin by the factor Xllla (Willerth et al., 2007). To coordinate the 
release of bone morphogenic protein-2 (BMP-2) with gel degradation, Schmoekel et 
al (2004) designed a fusion protein of BMP-2, containing a plasmin cleavage domain 
and a transglutaminase domain. Fibrin glue has also been investigated as a perfusion 
barrier to protect spinal canal and nerve root from bone ingrowth encouraged by the 
use of recombinant human BMP-2 to facilitate spinal disc fusion (Patel et al., 2006). 
Suategies such as these allow researchers to design release profiles of growth factors 
that aptly fit into specific requirements. 
1.1.3.1.2.3. Gene delivery 
Use of fibrin scaffolds for gene vector delivery is in its early stages but has potential 
to serve a usefiil system both for viral and non-viral vectors (Breen et al., 2009 a; b). 
Among the viral systems, adenovirus delivery system has been studied in remarkable 
details. Fibrin-based delivery of adenovirus results in enhanced ti'ansfection of the 
desired gene at the oesophagus (Teraishi et al, 2003), bone (Schek et al., 2004), 
vasculatures (Cooney et al, 2007) and dermal ulcers (Breen et al, 2009 a; b). Fibrin 
delivery of adenovirus AdGFP encoding keratinocyte growth factor (KGF) and 
marker gene green fluorescent protein (GFP) shows greater transfection as compared 
to injection of AdGFP alone (Escamez et al, 2008). Also, the method of delivery 
greatly influences the localization of the transgene, for example, bare adenoviral 
delivery showed transfected cells of mesenchymal origin, while the fibrin-based 
delivery of the adenovirus resulted in transfected epidermal cells. Fibrin based 
delivery of eNOS encoding adenovirus has been studied in diabetic wound healing 
(Breen et al, 2008) and results indicate significantly higher rates of wound 
epithelialization {via fibrin delivery of AdeNOS) as related to controls. It is assumed 
that fibrin molecules bind the adenovirus which is then release gradually by 
plasminolysis of the clot. Interestingly, cells attracted to the fibrin scaffold have 
greater exposure to the vector and hence greater transfection (Breen et al, 2009a). 
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Among the non-viral delivery systems plasmid delivery (Jozkowicz et al, 2003; 
Cliristman et al., 2005; Trentin et al, 2006) and liposome based vector delivery 
(Griannoni et al, 2003; Meyenburg et al, 2000) have received remarkable attention. 
While significant differences were not observed by Jozkowicz et al. (2003) utilizing 
fibrin-based delivery of vascular endothelial growth factor (VEiGF) plasmid as 
compared to that by the plasmid alone in a hind limb ischemia model, Christman et al. 
(2005) reported significantly enhanced vasculature and increased arteriole density via 
delivery of plasmid pleitrophin entrapped in fibrin clots. In a study on fibrin delivery 
of DNA/ polyethylenimines (PEI), a stable fibrin-DNA/PEI association was observed 
in vitro. Uncomplexed DNA did not show any transfection, complexed DNA bound to 
fibrin surface showed transient transfection while DNA complex inserted in the 
scaffold showed long term transfection (Saul et al., 2007). Another experiment 
resulted in significantly reduced necrotic tissue area, enhanced perfusion at 7 days and 
enhanced transfection of cells in the fibrin plasmid VEGF-A and lipofectamine 
group compared to fibrin plasmid VEGF-A and fibrin alone groups alone (Escamez et 
at., 2008). 
A tethering approach in gene therapy has also been developed. For example, the 
plasmid HIFl-a lacking oxygen-sensitive degradation domain (HIFlaAODD) was 
fastened to fibrin via a bi-peptide domain consisting of factor Xllla substrate 
sequence and a DNA-binding domain, in addition to a nuclear localization sequence. 
This novel approach resulted in proliferative formation of comparatively mature blood 
vessels in wounds as compared to the control fibrin (Trentin et al, 2006). 
Introducing whole cells as gene vectors has been another strategy in gene delivery via 
fibrin. Direct delivery of viral vectors has the inherent risk of toxicity or 
immunological issues. Pretransfection of cells before being offered to the target 
allows the host cells to witness the transgene product instead of being exposed to the 
naked viral vector (Breen et al, 2009 a; b). Cells are manipulated with a vector prior 
to their encapsulation within the fibrin scaffold and such manipulations yield better 
results. For example, preadipocytes transfected with VEGF and seeded in a fibrin 
scaffold, in chorioallantroic model resulted in greater number of vessels and vessel 
area than similarly delivered preadipocytes expressing GFP (Torio-Padron et al, 
2007). Delivery of adenovirus alone lacks reproducibility which is enhanced with 
fibrin delivery. Fibrin delivery of adenovirus encoding KGF compared to that of 
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fibroblasts transfected with KGF show that the cells expressing KGF delivered 
through fibrin offer the most reliable, reproducible and probably the safest method of 
ge;ne transfer (Escamez et al., 2008). 
1.1.3.1.2.4. Cell delivery 
Fibrin matrices have been examined for the delivery of living cells by several 
investigators. When used as a delivery system for cultured keratinocytes and 
fibroblasts, fibrin scaffolds offered remarkable advantage. Keratinocytes suspended in 
fibrin scaffolds were effective in reconstituting ftill thickness wounds in both mouse 
and human subjects (Horch et al. 1998; Gorodetsky et al., 1999; Horch et al. 2001). 
Human plasma derived fibrin as the scaffold for the development of a living bilayer 
human skin equivalent: fibrin-fibroblast and fibrin- keratinocyte (K-FF/FK SE) was 
pi"epared by Mazlyzam et al. (2007). Successful integration of the fibrin-based bilayer 
was achieved in a defective skinned mouse. Histological analysis suggested similar in 
vivo B-FF/FK SE properties as native human skin. Also, electron microscopy showed 
well-formed and continuous epidermal-dermal junction in the mice in vivo. 
Undifferentiated human preadipocytes using fibrin as carrier has been explored as a 
substitute to autologous tissue transplantation in cases of plastic surgery (Torio-
Padron et al., 2007). Fibrin glue as an injectable scaffold and v^ a^ll support were 
investigated in ischemic myocardium in rats occluded for 17 min and 
echocardiography performed 8 days after infarction. Improved cell survival and 
reduction in the infarct scar was evident suggesting its utility in myocardial cell 
tiansplantation (Christman et al., 2004a). 
Fibrin scaffolds have also been successfully used as cell delivery vehicle to reduce 
ischemia, improving their survival within ischemic tissues in the cardiovascular 
system (Nie et al, 2010). Different cell types, such as skeletal myoblasts (Christman 
et al, 2004b), cardiac myocytes (Birla et al, 2005), endothelial cells (ECs) 
(Chekanov et al, 2003), cardiac derived stem cells (Terrovitis et al, 2009), bone 
narrow-derived mononuclear cells (Zhang et al, 2008; Nakamuta et al, 2009), or 
mesenchymal stem cells (MSCs) (Martens et al, 2009) have been used in 
combination with fibrin matrices that lead to improvement in terms of infarct wall 
thickness, cardiac function, and infarct size when cells were injected in fibrin as 
compared with fibrin alone or cell injection alone. Fibrin scaffolds has been 
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extensively used as a cell implantation matrix to increase cell survival. A recent study 
on marrow-derived cardiac stem cells suggested that fibrin provides a suitable 
microenvironment for survival and proliferation of stem cells, protecting them from 
apoptosis and necrosis caused by anoxia, allowing them to differentiate (Barsotti et 
al. 2011). 
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F'ig.1.4. Schematic diagram of the common cells and molecules currently delivered 
via fibrin scaffolds (Breen et al., 2009b). 
1.1.3.1.3. Fibrin in cell differentiation and tissue engineering 
In addition to acting as a passive cell delivery matrix, fibrin binds specifically to 
many growth factors and clot components, such as fibronectin, hyaluronic acid and 
\'on Willebrand factor (Weisel, 2005). It is also known to have several integrin 
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binding sites (Cheresh et al, 1989; Altieri et al, 1990; Lishl:o et al., 2002; 
Cheraousov and Carey 2003). By modifying the chemical and mechanical properties 
of fibrin-based matrices, human mesenchymal stem cells can be induced to 
diJiferentiate into osteoblasts and mouse embryonic stem cells can be transformed into 
neural and astroglial lineages (Catelas et al., 2006; Willerth et al., 2006). Osteogenic 
differentiation requires very high concentrations of fibrinogen and Ca *, whereas 
neurogenic differentiation requires physiological fibrinogen and Ca^ "^  concentrations 
and preculturing of the embiyoid bodies in retinoic acid-containing media (Jamney et 
al, 2009; Breen et al, 2009b). 
Fibrin clots also serve as a scaffold for angiogenesis which makes then highly usefiil 
in cardiovascular tissue engineering. As in case of cartilage and nerve regeneration, 
the best results were achieved with a synthetic scaffold having desired mechanical 
properties combined with a biologically tuned fibrin gel (Mol et al, 2005; Sreerekha 
and Krishnan, 2006). Additional applications of fibrin include development of a 
moulding system to obtain tricuspid heart valve replacements from fibrin, fibroblasts 
and smooth muscle myocytes (Jockenhoevel et al, 2001 a; b). Eingineered valves 
wsre cultured in a pulsatile flow bioreactor, which resulted in less shrinkage and 
improved alignment of cells and the ECM components, strengthening the final valve 
(Flanagan et al, 2007). 
Table 1.3. Fibrin based matrices/scaffolds for drug and cell delivery for various 
tissue engineering applications. 
Polyiner(s) carrier/ TE Active Encapsulated cell References 
scaffold structure application biomolecule type 
Fibrin films 
Fibrin gel (tisseel ) 
combined with 
plotted PCL/TCP 
Not defined 
Bone 
FGF-2 Human MG-63 MIWQX etal, 
(Patterning) "preosteoblastic" 2006 
osteocarcoma cells 
rhBMP-2 Human osteoblasts Rai et al, 2005 
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Fibrin gel Bone 
Fibrin gel containing Vascularisa-
heparin conjugated tion 
nanospheres 
Fibrin gel 
Fibrin gel 
Ngl BMP-2 ._ Schmoekel et 
al, 2004 
Bfgf Human umbilical Jeon et al, 
vein endothelial 2006; 2007 
cells 
Vascularisa- VEGF variants Human umbilical Ehrbar et al, 
tion vein endothelial 2005 
cells 
SkinCardio TGF-pi, (insulin Human foreskin Neiderte/a/., 
and plasmin in the fibroblasts cell line 2002 
vascular culture medium) 
Fibrin gel and beads 
Fibrin gel 
F:ibrin gel 
Fibrin-collagen 
Fibrin gel 
gel 
Spinal cord 
mjury 
Perpheral 
nerve 
regeneration 
Interverteb-
ral disc 
Cartilage 
Cartilage 
Fibrin gel in a PGA 
non-woven gel 
Cartilage 
Porous fibrin gel Cartilage 
Fibrin glue (Tisseel) 
combined with 
plotted medical-
grade PCL 
Fibrin scaffold 
Osteochon-
dral 
Spinal cord 
injuiy 
NT-3 Chick dorsal root Taylor e/o/., 
ganglia cell culture 2004; 2006 
bFGF, VEGF, P- Chick dorsal root Lee et al, 2003 
NGF, NT-3 ganglia cell culture 
Human interverte- Gruber et al, 
2004 
bral disc cells 
Embryonic Perka et al, 
chondrogenic cells 2000a 
Bovine articular 
chondrocytes 
Pig chondrocytes 
Human articular 
chondrocytes 
Rabbit bone 
marrow-derived 
mesenchymal cells 
Eyrich et 
al,2007; 
Mouw et al, 
2005 
Ameer et al. 
2002 
Perka et al. 
2000b 
Shao et al, 
2006 
Murine embryonic Willerth et al, 
stem cells 2006 
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Fibrin tubes 
(autologous) 
Fibrin gel 
Fibrin gel in a 
based scaffold 
fibre-
Vascularisa-
tion 
Vascularisa-
tion 
Cardio-
vascular 
_. Outgrowth 
endothelial cells 
Rat aortic smooth 
muscle cells 
_ Human venous 
myofibroblasts 
Aper et al.. 
2007 
Rov/Qet ai. 
2007 
MoX etai, 
2005 
(Malafayae/a/.,2007) 
1.1.4. Stabilisation of the fibrin matrix 
Fibrinolysis in vivo is an efficient process and clots formed inside the body are 
dissolved/ eliminated. Plasmin plays an important role in the process and most of the 
blood clots are eliminated within few days. To extend the endurance of fibrin, 
antifibrinolytic agents are added to most fibrin-based formulations to delay 
fibrinolysis. These include aprotinin, epsilon-aminocaproic acid and CI-esterase 
inhibitor (Matras, 1985; Pipane/o/., 1992; Beduschfe/a/., 1999). 
Aprotinin is a serine protease inhibitor that acts specifically on trypsin, chymotrypsin, 
plasmin and kalliikrein (Mahdy and Webster, 2004). Its action on kalliikrein leads to 
the inhibition of the formation of factor Xlla of the coagulation cascade. Thus, both 
thi; intrinsic pathway of coagulation and fibrinolysis are inhibited. Additionally, its 
acfion on plasmin remarkably slows fibrinolysis (Mannucci, 1998). s-Aminocaproic 
acid or 6-aminohexanoic acid is an analogue of the aminoacid lysine. It is an effecfive 
inhibitor of enzymes like plasmin that recognize and bind to lysine (Alkjaersig et al, 
1958; Longstaff, 1994). Cl-esterase inhibitor is an inhibitor of the serpin superfamily. 
Its main funcfion is the inhibition of the complement system to prevent spontaneous 
activation (Davis, 2004; Cicardi et al, 2005) but it also inhibits proteases involved in 
the fibrinolytic, clotting, and kinin pathways. Cl-inhibitor is the most important 
physiological inhibitor of plasma kallikerin, factor XIa and factor Xlla (Visentin et 
a!., 1998). 
Gelation parameters such as concentration of fibrinogen, thrombin and ionic strength 
enormously influence gel appearance, mechanical properties and in vivo and in vitro 
stability of the fibrin gels (Willlerth et al., 2006; Cox et al., 2004; Deutsch et al., 
2009). Eyrich et al (2007) observed that optimal pH for preparing stable gels lies in 
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thf; range 6.8-9.0. Also, fibrin gels were more stable when the fibrin concentration in 
th(j preparation was at least 25 mg/ml and calcium concentration more than 20 mM. 
Thus, the behavior of fibrin based preparations are delicately dependent on a host of 
factors operating during its polymerization including fibrinogen concentration, rate of 
polymerization, activity of thrombin, charge interactions, pH, and temperature (Ho et 
al, 1995). 
Substances with different molecular weights e.g cytochrome C and (B-galactosidase 
having no binding affinity to fibrin are released promptly after clot formation. The 
addition of tranexamic acid did not affect the fast release of P-galactosidase and 
cytochrome C. Thus, substances without specifc affinity to fibrin were released from 
the fibrin gel by diffusion. Improvement in fibrin structure by addition of anti-
fibrinolytic agent did not affect the delivery rate of these substances. Fibrin-anchors 
slow the release of different substances having no natural affinity to fibrin (Morton et 
al, 2009). 
In bone tissue engineering, fibrin is always combined with inorganic materials, and 
these constructs exhibit superior mechanical strength to the preparation containing 
inorganic material alone. Le Nihouannen et al (2006) prepared novel composite 
scaffolds by combining calcium phosphate ceramics and fibrin glue and studied the 
association of the calcium phosphate granules with the glue at ultra-structural level. 
Mixing fibrin glue with granules (1:2) did not modify the microstructure of the clot in 
the composite. Thrombin however interacted with the bioceramic by inducing the 
nucleation of crystalline precipitate at the ceramic/fibrin glue interface. Combining 
the two could lead to new scaffolds with synergistic effects. Osathanon et al (2008) 
fabricated fibrin/calcium phosphate composite scaffolds with tightly controllable pore 
sizes, pore interconnection (50%), porosity (approximately 74%), and calcium 
phosphate deposition by sphere-templating and leaching fabrication methods. Cells 
seeded on mineralized fibrin scaffolds exhibited significantly higher alkaline 
phosphatase activity as well as osteoblast marker gene expression compared to fibrin 
scaffolds. Also, these composite scaffolds promoted bone formation in a mouse 
calvarial defect model and the bone formation was enhanced by addition of 
recombinant human bone morphogenetic protein-2 (rhBMP-2). 
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1.1.5. Fibrin based micro and nanoparticles 
Fibrin formulations in beaded form ranging from ~100-200|i have been prepared with 
a view to improve the delivery of entrapped substances (Gorodetsky et ai, 2004; 
Gorodetsky, 2008). In a typical study, concentrated fibrinogen treated with thrombin 
and was added to moderately heated oil (70-80 °C) and mixed vigorously (300-400 
rpm) for 6-8 hr to form gel droplets that continued to be crosslinked by endogenous 
factor XIII while losing their water content (Fig. 1.5). Dehydrothermal crosslinking 
reaction in the oil further stabilizes the dried fibrin matrix to form fibrin micro-beads 
(FMB), 10-180|xm in diameter with consistency of hard matrix. FMB loaded with 
cells could be incubated and cultured in bioreactors based on slowly rotating 
polypropylene tubes. 
The FMB has higher cell binding capacity as compared to the native fibrin gel, which 
are exploited for the isolation of mesenchymal stem cells (MSC) from different 
sources. Implanting such cells on FMB through the minimal invasive methods 
allowed better cell survival and integration in the target organs. The FMBs are 
biologically active and highly stable, inspite of the fact that they undergo undergo 
excessive exposure to organic solvents and ethanols rinsing. FMB also serve as a 
model for researches in tumor biology and cell behavior in suspension cultures 
(Gurevich et ah, 2002; Gorodetsky et al., 2004; Shimony et al, 2006). Rejinold et al. 
(2010) prepared fibrinogen nanoparticles have also been reported using ionic cross-
linking via CaClo through a two-step co-acervation process. 
A Fibrinogen 
Thrombin 
HMit to70-80^ 
Stirring &-8 hrs 
300-400 rorn 
Fig. 1.5. FMB fabrications in heated oil (Gorodetsky, 2008). 
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Praveen et al (2012) obtained fibrin nanoconstructs (FNCs) through a modified water-
in-oil emulsification-diffusion route without the use of any surfactants, resulting in a 
high yield synthesis of fibrin nanotubes (FNTs) and fibrin nanoparticles (FNPs). The 
fibrin nanostructures were investigated for the delivery of immunosuppressive drug, 
Tacrolimus, used widely to combat tissue rejection during allogenic transplantation. 
Drug encapsulation efficiency of 66% was achieved and a sustained in vitro release 
with the drug leaking completely over a one week. The in vivo dmg absorption rates 
analyzed in Sprague Dawley rats further confirmed the sustained release pattern of 
Tacrolimus suggesting the usefulness of the nanoparticles both for both oral and 
parenteral delivery routes. The submicron size of nanoparticles offers the advantage 
of a relatively higher intracellular uptake compared with microparticles (Pinto Reis et 
al, 2006; Rejinold et al, 2010). 
1.1.6. Affinity based fibrin systems 
Fibrin-based delivery systems for facilitating sustained and controlled release of 
substances have been developed using various fibrin anchors (Currie et al, 2001; 
Wong et al, 2003; Lee et al, 2007). Fibrin-anchors such as thrombin and fibronectin 
have a high natural binding affinity via specific binding moieties of fibrin (Liu et al, 
1979). For example, fibronectin binds to fibrin via affinity and is stabilized by Factor 
Xlll-crosslinking (Mosher and Johnson, 1983). DNA binds to fibrin owing to strong 
charged interactions (Morton et al, 2009). Appropriate chemical modification of 
fibrin support or pharmaceuticals can induce reversible or irreversible association 
between them (Fig. 1.6). 
Drug> 
Drug-
blnijjng' 
nil 
(FS-Anchor 
Drug- i 
binding? 
Fibrin Fibrin 
covalent binding affinity binding 
Fig. 1.6. Fibrin conjugates consist of a fibrin-anchor directly bound to a 
pharmaceutically active substance (left) or indirectly bound via a drug binding moiety 
(right). Moieties are either affinity bound or covalently bound (Morton et al, 2009). 
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Thrombin has a tight binding to fibrin with high binding capacity. Binding of proteins 
to thrombin by random chemical crosslinking reactions may modify the lysine 
residues within the fibrin binding exo-loop of thrombin and reduce the 
fibrin/fibrinogen binding activity. To avoid this, a modified form of the irreversible 
thrombin inhibitor D-phenylalanyl-L-propyl-L-arginine chloromethyl ketone 
(PPACK) was used to bind proteins to thrombin (Lyon et al, 1995). Conjugations of 
the biotynylated albumin to thrombin via PPACK lead to over 75% retention of the 
protein in the fibrin clot for over 4 days against an almost complete release of 
unconjugated albumin within a day. Also, the release of PPACK-coupled and 
uncoupled streptavidin without thrombin as a fibrin-anchor did not retard the release 
of the drug (Morton et al, 2009). Biotin-labeled fibronectin also leaked gradually 
from a fibrin clot over 14 days (Morton et al, 2009). 
Similarly, conjugation of an anti-TNF antibody to fibronectin achieved via l-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC) coupling technique and incorporation 
of TNF conjugates in fibrin clot facilitated the sustained release of the growth factor. 
Coupling of aprotinin to fibronectin and its assimilation into fibrin clots remarkably 
increased the strength of clots (compared to those without free aprotinin). In an 
extension of the study, plasmid-DNA encoding IL-10 gene was entrapped in fibrin 
matrix and the affinity of the DNA for fibrin permitted sustained release over an 
extended period (Morton et al, 2009). 
1,1.7. Improved release from fibrin matrices by pre-entrapmerit in liposomes 
Fibrin networks as discussed at length earlier offer remarkable advantage of mild 
polymerization conditions required and possibility of control of pore dimensions. The 
pore size of the least porous fibrin matrices is however, still large enough to facilitate 
ready diffusion of even macromolecules like proteins (Senderoff e/ al., 1991). One 
promising approach for improvement of retention of such molecules in gels is pre-
encapsulation in liposomes. Meyenburg et al (2000) encapsulated the model enzyme 
HRP in PC-octylglucoside liposomes which were further entrapped in fibrin matrix. 
Compared to soluble HRP entrapped directly in fibrin gels that was released with a 
half-life of 50 hr, the liposomized enzyme was retained in the matrix and could be 
released only by the plasminolysis of the fibrin network. It was also observed, in 
contrast to the earher observations, that phospholipids modify the mechanical and 
elasticity properties of fibrin (Gunther et al., 1995), entrapment of liposomes did not 
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affect the ultra-structure of the fibrin gels (Mayenburg et al., 2000). In fact the 
entrapment in fibrin matrix stabilized the entrapped liposomes since all the HRP 
released by proteolysis of the fibrin network was liposome associated. Support for 
applicability of the strategy to entrapment of small molecular weight water soluble 
drugs was provided by Wang et al (2009). The antithrombotic drug Tirofiban was 
loaded in stearylamine liposomes prior to entrapment in a composite fibrin-chitosan 
gel. Pore size of the composite was regulated by crosslinking with glutaraldehyde. 
The matrix containing the liposomized drug showed a dramatic decrease in the release 
of dnig as well as initial burst release. In an earlier study it was shown that liposomal 
surface charge may play an important role in determining both the burst release as 
well as sustained delivery of the entrapped drug for the composite fibrin-chitosan gels 
(Chung et al, 2006). The study was performed using Quinacrine, a fluorescent 
marker, as a model for small water soluble drug but the results was comparable with 
those obtained using Tirofiban. 
1.1.8. Erythrocyte mediated drug and vaccine delivery 
A broad spectrum of pharmacological and therapeutic targets based on slow drug 
release as well as targeted delivery has utilized erythrocytes as carriers. These serve as 
ideal carriers for antineoplastic agents, antimicrobial drug, vitamins, statins and 
steroids (Hamidi and Ta jerzadeh, 2003; Gothoskar, 2004). Erythrocytes are also 
potential vectors for the targeted delivery of peptides, modified oligonucleotides and 
genes (Magnani et al, 2002). Red blood cells (RBCs) have also been proposed as 
potential antigen delivery system. Several researchers have reported model protein 
antigens as BSA (Murray et al, 2006; Magnani et al, 1992), hog liver uricase, yeast 
hexokinase (Magnani et al, 1992), keyhole limpet haemocyanin (KLH), cholera toxin 
b subunit (CTB), bovine adenosine deaminase (ADA) (Murray et al, 2006) coupled 
to or encapsulated into autologous erytlirocytes to elicit an immunological response 
similar or even higher than that induced with the help of Freund's complete adjuvant 
(CFA) or Titer MaxGold™. The type of adjuvant used plays a critical role in 
governing the therapeutic efficacy of vaccine formulation. Vaccine adjuvants like 
CFA are however too toxic for routine clinical use. Many of them cause inflammatory 
reactions or granuloma fomiation. Alum adjuvants which are considered as less toxic 
are now known to induce IgE responses and a good degree of allergic reaction but 
they also elicit only weak humoral and cell mediated immunity (Murray et al, 2006). 
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Alternative approaches to increase the iiranunogenicity and decrease the toxicity 
include the use of antigen delivery systems as liposomes (Felnerova et ah, 2004), 
ISCOMs (Immunostimulatory complexes), poly-lactide-co-glycolide microsphers and 
virosomes (Daemen et al, 2005). 
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Materials and Methods 
2.0. MATERIALS AND METHODS 
2.1. Materials 
Blue-dextran, horse raddish peroxidase (HRP), amphotericin B (Amp B), 6-amino 
caproic acid, aprotinin, glutaraldehyde, egg phosphatidyl choline, cholesterol, 
Sephadex G-10, Sepharose 4B, ortho-phenyl diamine (OPD), trypsin, chymotrypsin, 
bicinchonic Acid (BCA) total protein determination kit, Complete Freund's Adjuvant 
(C'FA) and Incomplete Freund's Adjuvant (IFA) were purchased from Sigma 
Chemical Company, St. Louis, USA. Ethylene diamine tetra acetic acid (EDTA), 
CaCb and Tween 20 were obtained from SISCO Research Laboratory, USA. Triton-
X 100 was from Qualigens Fine Chemicals, Mumbai, India. o-Phenyl dianisidine 
dihydrochloride, Dinitro salisylic acid, HPLC water. Methanol and chloroform 
(HPLC grade) was purchased from HiMedia Laboratories Pvt. Ltd., Mumbai. Rabbit 
anti-mouse IgG Peroxidase Conjugate and Goat anti-rabbit IgG-HRP were purchased 
from Genei, India. Mouse Immunoglobulin Isotyping ELISA Kit, Monoclonal anti-
mouse CD4 , CD8 , CD80 and CD86 their isotypic control were purchased from BD 
Biosciences, USA. Other chemicals used in study were of analytical grade. 
2.1.1. Animals, collection of blood and isolation of plasma/serum 
Inbred female Balb/c mice (6-8 weeks old), weighing 25±2 g were obtained from the 
animal house facility of Central Drug Research Institute, Lucknow, India. Female 
Swiss albino mice (6-8 weeks old), weighing 25±2 g were procured from Laboratory 
Animal Resources, Indian Veterinary Research Institute, Barielly, India. Rabbits used 
in the study were out bred and purchased from a local animal supplier. All the animals 
v/ere provided with plenty of water and diet ad libitum (Hindustan Lever Ltd, India) 
throughout the investigation, unless mentioned otherwise. Bleeding, injection and 
sacrifice of animals were strictly performed following the mandates approved by the 
Institutional Animal Ethics Committee constituted as per the recommendations of 
(!^ omniittee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA), Government of India. 
Rabbit blood was collected from the ear vein with help of a syringe. Nine volumes of 
blood were mixed in tubes containing one volume of 2.7 % (w/v) EDTA in normal 
saline, mixed and centrifuged at 2400 x g for 10 min. The plasma obtained thus was 
(;ollected by aspiration and used immediately or stored at -20 °C till use. Mice were 
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bled through retro-orbital puncture with a glass capillary and blood collected in sterile 
Epjaendorf tubes. For collection of serum, blood was incubated at room temperature 
for one hr and subsequently kept at 4 °C for retraction of the clot. Finally, the tubes 
were centrifuged at 2400 x g for 10 min at 4 "C, serum collected by aspiration and 
stored if required at -20 °C. 
2.2. Methods 
2.2.1, Preparation of plasma beads 
Plasma beads (PB) were prepared by the procedure described by Ahmad et al (2011). 
Briefly, 250 y.1 of plasma was mixed with 50 (xl solution of the substance to be 
entrapped in 20mM phosphate buffered saline (PBS), pH 7.4 and CaCb was added to 
achieve a final concentration of 40 mM. In case of beads prepared in the presence of 
fibrinolytic inhibitors aprotinin and caproic acid, 20 ^1 solutions in 20mM PBS, pH 
7.4 were added to the plasma to attain a final concentration of 3000 KlU/ml and 10 
mg/ml respectively, before the addition of CaCb. Aliquots (3.0 |xl) of the mixture 
were transferred with the help of a multi-channel micropipette as droplets at regular 
distance over a glass slide covered with Parafilm and incubated at 37 "C for 40 
minutes in humid chamber to facilitate formation of the clot. The resulting beads 
were scraped from the Parafilm surface with sterile surgical blade, washed thrice in 
normal saline and finally washed and suspended in 0.15 M NaCl containing 20 mM 
PBS pH 7.4. The beads formed were of 2 mm diameter. 
Where indicated the plasma beads were treated with glutaraldehyde. For this purpose, 
30-35 beads were suspended in 1.0 ml PBS and glutaraldehyde solution was added to 
the required final concentration and incubated at 4 °C for 15 min to facilitate 
crosslinking. Crosslinking was stopped by adding 500 yd of 0.5 M glycine or 
methylamine, and the beads washed thrice with nonnal saline and finally in PBS. 
Beads were also prepared from plasma concentrated with the help of Sephadex G-10. 
Two milliliters of fresh plasma was mixed with 400 mg of the dry Sephadex beads, 
incubated for 30 min, and centrifuged at 10,000 x g for 10 min to separate the beads. 
The plasma obtained was remixed with addifional 100 rag of Sephadex, further 
incubated for 30 min and centrifuged. After a third cycle of concentration with 75 mg 
Sephadex, the plasma was used for the preparation of the beads. 
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Composite beads of plasma and calcium alginate were also prepared. A 2% (w/v) 
solution of sodium alginate was prepared by gentle stirring at room temperature for at 
least 1 hr. 25, 50, 75, 100 or 125 ^1 of the alginate solution was mixed in microfuge 
tubes with 50 i^l plasma and 50 |il solution of the substance to be esntrapped. Finally 
aj)propriate quantities of CaCh were added and the plasma-alginate beads were 
prepared as described above. Increasing the concentration of alginate resulted in rapid 
gfjUing and interfered with the formation of beads. 
Siiudies on the release of entrapped substances were usually perfcmned with 30-35 
plasma beads (necessitating the use of 0.1 ml plasma containing the entrapped 
pliarmaceutical and the required CaCl2). Beads were washed in normal saline, 
suspended in 1.5 ml of 20 mM PBS, pH 7.4 and incubated 25 °C. Released 
piroteins/drugs were quantitated in the PB-free medium. For calculation of extent of 
release, substances present in beads were taken as 100%. 
2,2.2. Preparation of multilamellar vesicles (MLVs) and large unilamellar 
vesicles (LUVs) 
The liposomes were prepared essentially by following the published procedures 
(Kirby and Gregoriadis, 1984; Hayward et al., 1985; Owais and Gupta, 2000). 
Briefly, egg PC (49 pmol) and cholesterol (21 i^mol) (24.7 mg egg PC and 5.36 mg 
cholesterol in a total of 30 mg) were dissolved in 10 ml of chloroform and methanol 
(9:1 v/v) and reduced to thin dry film under N2 atmosphere in a round bottom flask of 
a rotary evaporator. The film was then hydrated with aqueous solution of blue dextran 
and Amp B, resulting in the formation of 245± 20 fxl of MLVs. The multilamellar 
liposomes were centrifuged thrice at 20,000 x g in saline to remove the unentrapped 
material. For the preparation of LUVs ranging in size 140 + 50 nm (Owais and Gupta, 
2000; (Jwais et al.. 2001) and used for the entrapment of HRP, the film was hydrated 
in saline, followed by sonication in a bath type sonicator (Hwashin Technology Co., 
Korea) intermittently for 20 min at 4 °C, under N2 atmosphere. The liposomes thus 
formed were mixed with an equal volume of HRP (6-10 mg/ml). The mixture was 
Hash frozen and thawed (3 cycles) subsequently and passed through a Sepharose 4B 
column (Lundahl et al., 1999) (Bed dimensions 51 x 1.3 cm). Fractions containing 
liposomes were collected and lyophilized to a minimum volume for use. The amount 
of encapsulate (blue dextran/ Amp B/ HRP) was calculated by dissolving 20 ^l of the 
loaded liposomes in in 20 mM PBS, pH 7.4 contaimng 1% Triton X-100. Appropriate 
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volume of the MLVs/LUVs containing the required amount of encapsulate were 
added either in PBS or added to the plasma mixture for the preparation of beads. The 
substances released from the liposomes were assayed as described. 
2.2.3. Quantitation of the Amp B in the plasma beads 
2.2.3.1. Amp B quantitation 
Amp B and blue dextran and were quantitated using spectrophotometrically by 
measuring the absorption at 405 nm (McNamara et al, 1998) or 629 nm (Errington et 
ai, 1992), respectively. PB with entrapped Amp B/Amp B were suspended in 1.5 ml 
of 20 mM phosphate buffered saline and the release of the antibiotic in the PB free 
solution. The drug release was quantitated with the help of a standard curve. The total 
dmg retained was also calculated by dissolving 5 freshly prepared beads in 1 ml of 0.1 
N NaOH to measure the percentage of released Amp B. Release of blue dextran from 
the; various formulations was studied similarly by monitoring the absorbance at 629 
nm. 
In case of formulations that contained blue dextran/Amp B encapsulated in liposomes 
and fortlier entrapped in the PB, the supematants for various time-point was made 1 % 
(\\/v) triton X-100 and read spectrophotometrically at 629/405 nm respectively. 
2.2.3.2. HRP assay 
The HRP assay was performed following the method described by Wititsuwannakul 
et al. (1997). Three milliliters of assay mixture comprised of 100 \i\ of 17 mM H2O2, 
100 |iil of 25 mM o-dianisidine hydrochloride, 100 |al of the suspending buffer 
containing HRP and 2.7 ml of 0.2 M phosphate buffer, pH 6.0. The mixture was 
incubated for 15 min, at 37 "C in a water bath. The reaction was stopped by adding 
1.0 ml 6.0 N HCl and absorbance was monitored at 460 nm. 
2.2.4. HPLC analysis of Amp B 
For Amp B quantitation, the protocol followed was that described by Nilsson-Ehle et 
al (1977) as standardized in the laboratory. The HPLC system used was Dual X 
Absorbance Detector (Waters 2487) with a Binary HPLC Pump (Waters 1525). A 
CI 8 reversed phase column (250 mm x 4.6 mm) with the particle size 5 |um was used. 
The mobile phase comprised a mixture of 5mM EDTA and methanol (20: 80, v/v). 
Flow rate was kept at 1.0 ml/minute and absorbance of the Amp B was measured at 
405 nm. Separate calibration curves of Amp B were prepared after extracting the 
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add(;d drug from plasma, liver, kidney and spleen. The slope and intercept of the 
calibration lines were determined by linear regression using least squares method. 
The extractability of Amp B was determined by adding various measured amounts of 
the drug to the tissue homogenate and plasma and following the procedure of 
extraction discussed subsequently (Nilsson-Ehle et al, 1977). Extraction efficiencies 
obtained were above 95% in case of plasma and spleen extracts and above 85% in 
kidney and liver extracts which were consistent with earlier reports (Li Yanga et al, 
2007; Es)mda et al, 2008). 
2.2.4.1. Amp B analysis in plasma/ tissues 
To one hundred microliters plasma, 300 |il methanol was added. Weighed portions of 
liver, kidney and spleen were washed in PBS and traces of the buffer solution were 
reraoved by blotting with micro wipes. Specimens were then reweighed. One gram of 
liver tissue was homogenized using a Remi, Tpye RQT 127-A homogenizer and 
enough cold saline added to obtain volume 2.0 ml, which represents a tissue to liquid 
ratio of 1:1 (m/v). In case of kidney and spleen, the organs were weighed, crushed in 
sal ine and homogenized such that the final volume of the homogenate is 1.0 ml. 
Aliquots of the homogenate were taken and mixed with thrice the volume of methanol 
and subjected to 60 min incubation at room temperature. The samples were then 
centrifuged at 10,000 x g for 10 min, supernatant collected and filtered through a 
0.45p.m millipore filter. Aliquots (usually 20 \i\) of the resultant supematant were 
injected into the HPLC system for analysis. The resultant peaks were quanfified by 
comparison of amphotericin B peak at 405 nm with standards of known concentration 
eluted at the same retention time. 
2,2,5. Invertase encapsulation into erythrocytes 
Packed rabbit/mice erythrocytes were washed thrice by centrifugation at 500 x g for 
10 minutes in 154 mM NaCl, 10 mM Tris buffer (pH 7.4). They were dialysed at a 
hematocrit of 60% against 1.0 L of distilled water for 2 hrs. Invertase was added at the 
beginning of dialysis as denaturation was not a problem with the highly glycosylated 
enzyme (Reddy et al, 1988; Ziegler et al, 1988). Appropriate quantities NaCl was 
added to achieve a final concentrafion of 154 mM and the samples incubated at 37°C 
for 30 minutes to facilitate resealing. The resealed erythrocytes with loaded invertase 
were washed thoroughly (atleast thrice) to remove unentrapped material (Deloach and 
Ihler, ;977). 
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2.2.6. Entrapment of enzyme loaded erythrocytes into plasma beads 
En,zyme-loaded cells were subjected to glutaraldehyde treatment to provide 
stabilization and lower the rate of efflux of the entrapped enzyme. Aliquots of the 
enzyme loaded cells (5% hematocrit) were incubated with a varying concentration of 
glutaraldehyde (0.025%, 0.05%, 0.1 % and 0.25%) v/v) in PBS at room temperature 
for 15 minutes. After incubation the suspension was diluted with 0.5 M glycine, pH 
7.0 to stop crosslinking. The cells were then washed thrice with normal saline and 
finally washed and suspended in PBS. Alternatively, the glutaraldehyde treatment 
W£is also given to plasma beads containing invertase-loaded erythrocytes. 
2.2.7. In vitro release of invertase from erythrocytes and erythrocytes entrapped 
in plasma beads 
In vitro leakage of invertase was monitored from invertase loaded er)'throcyte or those 
treated with glutaraldehyde. Similarly, release kinetics was followed for enzyme 
loaded cells encapsulated into plasma beads or enzyme loaded erj'throcytes treated 
with glutaraldehyde. The cell suspension {5% hematocrit) in PBS was used for the 
study. Periodically supernatants (50|il volume) were withdrawn after centrifugation at 
2400 X g for 5 min from the triplicate preparations. Supernatant collected at different 
intervals was analyzed for enzyme assay. Total enzyme enh-apped was also 
d(5termined by comparing the enzyme in the supernatant with the total enzyme 
olDtained after hemolysis of the same volume of cells in distilled water. In the 
glutaraldehyde-treated samples, complete hemolysis was achieved by exposing the 
ci^ lls to I % triton (v/v) in distilled water. 
In some experiments, PB containing invertase entrapped erytlirocytes were also 
subjected to glutaraldehyde treatment at concentrations of 0.025%, 0.05%(, 0.1% and 
0.25% (v/v) as discussed in 2.2.1. Aliquots were collected from the supernatant 
periodically after gentle inversions of the 1.5 ml vial they were suspended into. Total 
enzyme content was calculated by subjecting the beads to complete degradation by 
i:ficubation with trypsin (20 \x% of trypsin for each aliquot) for 8-12 hr at 25° C and 
further lysing the entrapped erythrocytes in distilled water or 1% (v/v) triton in 
distilled water. 
40 
Materials and Methods 
2.2.8. Invertase assay 
The assay procedure described by Bemfeld (1955) was followed for the quantitation 
of invertase. The assay mixture contained in a total volume of 300 i^ l 150 ^1 of 0.2 M 
sodium acetate buffer pH 4.9, lOOpl of the suspending buffer (20 mM PBS, pH 7.4) 
containing invertase and 50 \il of 0.5 M sucrose. The samples were incubated for 10 
minutes at 37 °C and reaction stopped by addition of 200 |il of 0.5 M sodium 
phosphate (pH 7.0). The assay mixture was kept in boiling water bath for 5 minutes. 
After cooling, 1.0 ml of 1 % (w/v) di-nitrosalicylic acid reagent (DNS) was added and 
the tubes were kept at room temperature for 5 minutes followed by 5 minutes in water 
batii (100 °C). Three milliliter distilled water was added to the tubes and the samples 
were cooled and read at 540 nm. One unit of invertase is the amount that converts 1.0 
fimole of sucrose to glucose and fructose/minute at 37 °C. 
2.2.9. Immunization of rabbits and mice with PB-entrapped invertase 
formulations 
Three rabbits each with an average weight of 1.5 kg were taken in three separate 
groups for the in vivo study. Animals in the group I were subcutaneously administered 
invertase emulsified with CFA (CFA-Inv). In group II, erythrocytes entrapped 
invertase (EE-Inv) and in group III, invertase entrapped erythrocytes further 
entrapped into plasma beads (EE-Inv-PB) were administered intraperitoneally. The 
dose of the antigen administered in each group was 600 ^gs. A booster dose of 200 
jigs was given through the same routes on day 35 after the primary immunization. In 
case of the animals receiving the adjuvants however the booster dose was given with 
after emulsification with Freund's incomplete adjuvant (IFA). Sera were collected at 
regular intervals from all the groups and IgG levels measured by indirect ELISA. 
Inbred female Balb/c mice were used for the study. Five animals with an average 
\\'eight of 25|ig ± 2 were taken in twelve separate groups. Five groups were 
subcutaneously administered various invertase formulations. Group I administered 
free invertase (Sal-lnv), group II received invertase solubilized in in CFA (CFA-Inv), 
group 111 received erythrocyte entrapped invertase (EE-Inv), group IV was given 
erythrocyte encapsulated invertase further entrapped in PB( EE-Inv-PB) and group V 
received invertase encapsulated erythrocytes further entrapped in PB and crosslinked 
with 0 05% (w/v) glutaraldehyde (EE-Inv-PB-CL). 
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Animals that received the antigen intraperitoneally included those in the groups Sal-
Inv, BE-Inv, EE-Inv-CL, EE-Inv-PB and EE-Inv-PB-CL. Groups EE-Inv and EE-Inv-
CL also received the antigen intravenously. The animals received a priming dose of 
the Eippropriate preparation containing 60 |ig invertase and boosted with that with 
20^g of invertase on day 21. 
Sera were collected at regular intervals and indirect ELISA performed to quantitate 
antibody levels. 
2.2.10. Enzyme linked immunosorbant assay (ELISA) 
Antibody generation against invertase was monitored by ELISA (Murray et al, 2006). 
The plates were coated with antigen (1.0 fig of invertase /lOO fil of coating buffer, 50 
mM^  bicarbonate buffer, pH 9.4) in a microtitre plate and kept overnight at 4 °C. The 
plates were washed thrice in PBS containing 0.05% (v/v) Tween-20 (PBST), pH 7.0 
and blocked with 1% (w/v) BSA in PBS for 2 hr at room temperature. Plates were 
again washed three times with PBST and sera were serially diluted in the 1% BSA in 
PBST in the microtitre plate containing invertase and incubated at 37 °C. Second 
antibody diluted 1: 5000 in 1% BSA in PBST was then incubated for 40 min. Plates 
were washed six times with PBST and freshly prepared 100 \i\ substrate solution (10 
\i.\ of 30% H2O2 and 10 mg of o-phenyl diamine to 12 ml 0.1 M sodium citrate-citric 
acid buffer, pH 4.6) were added in each wells. One hundred microliters substrate 
solution was added to the wells after secondary antibody washings. The reaction was 
stopped by adding 50 j^ l of 1.0 M H2SO4 and absorbance was measured at 490 nm. 
2.2.IL Antibody isotype analysis 
Tiie isotypes were quantitated by procedure as described in the Mouse 
Immunoglobulin Isotyping ELISA Kit (BD Biosciences). Briefly, each isotype-
specific rat anti-mouse purified monoclonal antibody was diluted as mentioned (1:5) 
in coating buffer and 50 \i\ added to the wells of microtitre plates. The plates were 
incubated for 1 hr at 37"C or overnight at 4°C, washed thrice in 0.05% (v/v) Tween in 
PBS (PBST), blotted dry each time on a clean paper towel, and incubated with 200 \i\ 
of blocking buffer for 30 minutes at 25°C. Washing was done thrice in PBST, after 
v/hich 100 \i\ of appropriately diluted sera were placed in each well and incubated for 
1 hr at room temperature. Washing was performed thrice and 100 1^ of HRP-
conjugated rat anti-mouse IgG solution was pipetted to each well followed by 
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incubation at room temperature for 1 hr. The plates were washed six times with 
PBST and the wells soaked for 30 seconds to 1 min on each wash. One hundred \i\ of 
freshly prepared substrate solution was added to each well and plates incubated for 10 
minutes a1 room temperature. After addition of 50 [i\ of stop solution to each well the 
dev(;loped colour read at 450nm. 
2.2.12. Preparation of plasma microparticles (PMPs) 
The procedure described earlier for obtaining the fibrin micro/nano particles in the oil 
system with high speed stirring (Ho et alA995, Pinto Reis et al, 2006; Gorodetsky, 
2008; Praveen et al., 2012) with some modifications was followed. One millilitre of 
plasma was taken in a microfiige tube and mixed with 100 |.il of the pharmaceutical to 
be entrapped dissolved in PBS. Adequate CaCh was added to achieve a final 40 mM 
calcium concentration. The mixture was immediately transferred to a syringe with 
18G needle and dropped slowly into a beaker containing paraffin oil stirred at 8000 
rprn. The contents of the beaker were stirred for various durations (.30, 45, 60 or 75 
min) and temperatures (40 T , 45 °C and 50 "C). The microparticles formed were 
washed twice with diethyl ether and collected in a mixture of n-hexane and 
isopropanol (ratio 3:1). The particles were dried in an incubator to remove the organic 
solvents, washed and finally suspended in PBS. 
The particle size was measured by the instrument NANOPHOX Particle Size 
Analyser with Photon Correlation Spectroscopy (Sympatec, Germany) using 
WINDOX 5 software. 
2.2.13. In vitro release of substances from PMPs 
Release studies of PMPs containing Amp B (200|j.g of Amp B/ 7mg of PMPs) were 
performed as discussed for PB (2.3.3). Similarly invertase-loaded in the PMPs (250)ng 
invertase/ 7mg of PMPs) were analysed as discussed in 2.3.6. The supernatant in this 
case was however collected by centrifuging the PMPs at 10, 000 x g. The total drug or 
enzyme content was calculated by dissolving the PMPs (7mg) in a final of 0.1 N 
NaOHorI%TritonX-100. 
2.2.14. Proteolysis of PMPs and crosslinked PMPs in the presence of trypsin and 
chymotrypsin 
PMPs with or without treatment with glutaraldehyde (7 mg) were incubated with 
trypsin (20 |ig) and chymotrypsinin (20 \ig) in PBS in a total volume of 1.0 ml. The 
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samj)les were incubated at 25 °C and aliquots of the supernatant were withdrawn at 
various time intervals. Protein was estimated by BCA method. Control samples 
contained plasma particles or crosslinked plasma particles without any protease. 
Percent proteolysis was calculated by dissolving equal amount of the control particles 
inl%tritonX-100. 
2.2.15. Immunization of rabbits and mice with PMPs 
Separate groups containing three rabbits each with an average weight of 1.5 kg were 
used for the study. Animals in the group I were subcutaneously administered CFA-
Inv. In group II, PMPs loaded with Invertase (PMPs-Inv) and in group III, PMPs 
loaded with invertase cross-linked with 0.05% glutaraldehyde, (PMPs-Inv-CL) were 
administered intraperitoneally. Immunization schedule as well as dose of 
administration was same as discussed in 2.3.13. 
Inbred female Balb/c mice were used for immuization. Four groups of mice consisting 
of 8 animals in each group with an average weight of 25)ig ± 2 were used. The 
animals immunized were as follows: Invertase dissolved in saline, (Sal-Inv), CFA-
Inv, PMP-Inv and (PMP-Inv- CL). All groups with the exception of CFA-Inv were 
administered the antigen i.p. while CFA-Inv received the antigen subcutaneously. 
Immunization schedule as well as dose of administration was same as discussed in 
2.3.8. 
2.2.16. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE analysis was carried out as described by Laemmlli (1970) in a vertical 
mini-gel electrophoresis apparatus (ATTO, .lapan) using 10% (w/v) resolving gel and 
5% (w/v) acrylamide stacking gel. Electrophoresis was carried initially at 9 mA to 
facilitate the stacking of the sample and the current subsequently raised to 18 mA. 
Electrophoresis was performed until the tracking dye reached the bottom of the gel. 
The gels were then taken out from the plates and stained with 0.1%) (w/v) Coomassie 
Brilliant Blue R-250 (prepared in methanol, glacial acetic acid and water in 45:10:45 
ratio). The gels were destained with a solution containing ten parts each of methanol 
and glacial acetic acid and eighty parts of water. 
Equal volume of plasma as well as plasma obtained on concentration by Sephadex G-
10 matrix in each step as discussed in 2.3.1 were equally diluted and added to 5 x 
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sample loading buffer (150 mM Tris-HCl, 5% (w/v) SDS, 25% (v/v) glycerol, 12.5 
mM P-mercaptoethanol, 0.06% (w/v) bromophenol blue) and subjected to 
electrophoresis. 
PMI's were prepared at different time-points and temperatures (as discussed in section 
2.3.9). 2 mg of PMPs dissolved in 0.1 N NaOH and protein was estimated by BCA 
method. Further, same amount of PMPs were dissolved in 500 |il of 5 x sample 
loading buffer. Aliquots were taken and diluted 4 times in PBS and samples boiled 
and loaded to the wells and subjected to electrophoresis. 
2.3.17. Staining for T cell and co-stimulatory surface markers 
On day 5 post administration of the booster, three mice from each group were 
sacrificed by cervical dislocation. Spleens were aseptically removed from the mice, 
washed with PBS and then crushed with the rough end of the frosted end slides. The 
resulting suspensions were taken in the culture tubes and centrifliged at 4 °C at 200 x 
g for 8 min and supernatant was discarded. The pellet was then suspended in ACK 
lysis buffer (10-15 ml) for 10-15 min for the lysis of the RBCs. The splenocytes were 
washed with RPMl 1640 medium containing 10% fetal calf serum. Viable cells were 
counted by 0.1% Trj^an Blue dye exclusion method. 
Vs.rious surface markers present on the antigen presenting cells (APS) were studied. 
The splenocytes were harvested as described earlier for cell proliferation assay and 
1x10^ cells were taken into microfuge tubes containing 1.0 ml FACS buffer (PBS with 
1% BSA and 0.1% sodium azide) and washed twice with the same buffer and 
centrifuged at 204 x g for 10 min. To the cells was added the Fc block (2.4 G2), 
followed by 125 ng of FITC/PE tagged monoclonal antibodies (CD4, CDS, CD80, 
CD86 or anti- isotype control). The tubes were incubated at 4 "C for 30 min, the 
splenocytes washed twice with the FACS buffer to remove unbound antibodies and 
fixed with 1% (v/v) paraformaldehyde. The flow cytometry data was obtained using a 
fluorescence activated cell sorter and data analyzed using the express plus software 
(GUA\'A, USA). 
2.3.18. Statistical analysis 
All the data were analyzed by one-way analysis of variance (ANOVA) following 
Holm-Sidak or Tukey test method (All pairwise multiple comparison methods) and 
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Dunnett test (comparison vs control). Values of P < 0.05 were considered 
statistically significant. 
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3.0. RESULTS 
3.1. Preparation and characterization of plasma beads for sustained drug release 
3.1.1. Entrapment of macromolecules in the PB 
For the preparation of beaded form of plasma (PB) clot, blood collected in presence of 
the anticoagulant EDTA was centrifuged and plasma separated. The plasma was 
mixed with the components to be entrapped, CaCia was added to a final concentration 
of 40 niM and the mixture transferred rapidly as tiny droplets with the help of 
micropipette to a glass slide roofed with parafilm. The slides were incubated in a 
chamber lined with moist filter paper and cotton for a minimum of 40 min to facilitate 
bead formation (Ahmad et ah, 2011). For most studies the 3 1^ aliquots of plasma 
were transferred leading to the formation of beads with a diameter of 2 mm (Ahmad 
el ai. 2011). Where indicated, the beads were subjected to cross-linking with 
glutaraldehyde. In some experiments concentrated plasma or that mixed with sodium 
alginate was used. 
Studies on the release of entrapped therapeutics were usually performed with 100 PB, 
which necessitates the use of 250 i^ l of blood plasma containing the entrapped 
pharmaceutical and the required CaCh. The beads were washed in normal saline and 
suspended in 1.5 ml of normal saline containing 20 mM phosphate buffered saline 
(PBS), pH 7.4 and incubated at 25°C. 
PB entrapment of the macromolecules was efficient and both blue dextran and Horse 
Raddish Peroxidase (HRP) were effectively entrapped. As can be seen from the Table 
3.1, addition of 500 i^g of blue dextran to a final 250 ^\ of plasma mixture resulted in 
approximately 65 % entrapment of the polysaccharide in the beads. Further increase 
in the amount of added blue dextran decreased the entrapment yield, although amount 
of the entrapped polysaccharide continued to increase. Similar entrapment pattern 
suggesting decrease in entrapment yields with increase in the protein added was also 
observed during the entrapment of HRP (Table 3.1). 
3.1.2. Release of blue dextran from PB in vitro 
Blue dextran is a neutral high molecular mass (2,000 kDa) polysaccharide with 
covalently linked chlorotriazine dye. The polysaccharide was selected with a view to 
study the porosity of plasma beads for neutral and large molecules. On incubation in 
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vitw the initial rapid release of blue dextran from the beads was followed by a more 
gradual leakage. About 50% of the entrapped drug was released into the medium 
during the first 24 hr while near complete release was observed in 168 hr (Fig. 3.1.1). 
The rate of blue dextran release decreased markedly as a result of cross-linking of the 
PB with the bifunctional reagent glutaraldehyde. PB treatment with 0.008, 0.01 or 
0.35% (v/v) glutaraldehyde resulted in the release of 50 % of the entrapped 
polysaccharide in 64, 72 and 100 hr respectively. At the end of 168 hr of incubation 
also, the release of the polysaccharide from the cross-linked beads was low (93%, 
87%) or 77%) respectively for plasma beads cross-linked with 0.08. 0.01 and 0.05%) 
glutaraldehyde) as compared to that from uncrosslinked preparations. Leakiness of the 
plasma beads however remained unaffected on inclusion of calcium alginate in the 
plasma (Fig. 3.1.1). 
Release rates of blue dextran from PB decreased further when the polysaccharide was 
pre-encapsulated in multilamellar PC-cholesterol liposomes. Appropriate volumes of 
the ML,Vs loaded with blue dextran were added to attain their required amount in PB. 
Less than 40% of the liposomized blue dextran emerged in the medium in 168 hr (Fig. 
3.1.2). Glutaraldehyde treatment lead to a further significant decrease in the release 
v^ith the preparation treated with 0.05% glutaraldehyde, releasing only 29% of the 
entrapped drug in 168 hr. The multilamellar liposomes were stable and released only 
5 % entrapped blue dextran when suspended in PBS for 168 hr. 
3.1.3. In vitro release of HRP from the PB 
Release kinetics from the plasma beads was also investigated using a relatively small 
glycoenzyme, the HRP (44kDa). The entrapped glycoenzyme, as shown in Fig. 3.1.3, 
was released almost completely in about 72 hr. The release curve was biphasic with 
over half of the enzyme being released during the first 12 hr of incubation. As 
observed earlier with blue dextran, the release rate of HRP from the plasma beads 
decreased markedly as a result of cross-linking with glutaraldehyde. Treatment with 
0.01% and 0.05%) of the crosslinking reagent caused a lowering of about 83 and 71 %> 
of the release in 72 hr. 
Encapsulation of the HRP-loaded large unilamellar vesicles (LUVs) in the plasma 
beads caused a dramatic decrease in the release of the enzyme. As also evident from 
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the figure, only 21 % of the entrapped HRP was released in 72 hr of incubation and 
only marginal additional release resulted on extending the incubation to 168 hr. 
Thej'e are available reports of inhibitors of proteolysis restricting the release of 
substances entrapped in fibrin preparations (Yoshida et ai, 2000). Addition of 
caproic acid (10 mg/ml) and aprotinin (3000KIU/ml) to the plasma prior to bead 
preparation however did not markedly affect the release rate of HRP, which decreased 
only marginally in the presence of the inhibitors. 
3.1.4. Release of entrapped Amphotericin B from the PB 
Fig. 3.1,4 shows the in vitro release profile of the antifungal Amphotericin B (Amp B) 
from the PB prepared as described in methods. Release of the antifungal was 
surprisingly gradual and remarkably slow, with only about 36 % of the entrapped drug 
leaking out into the medium after 168 hr incubation. Crosslinking with glutaraldehyde 
resulted in additional marked decrease in the release rate. The drug release was only 
19 % in 168 hr from beads cross-linked with 0.05% glutaraldehyde. We envisage that 
the slow release of Amp B is related to its high affinity for plasma proteins, especially 
to human serum albumin and human ai-acid glycoprotein (Block et al, 1974; 
Bekersky et al., 2002; Hartsel et al., 2001) that are the constituents of plasma beads. 
Release profile of Amp B from plasma beads pre-encapsulated into multilamellar 
liposomes is shown in Fig. 3.1.5. Appropriate dilutions of the MLVs containing Amp 
B in PBS were made to obtain the required amount of the drug in the PB. Pre-
encapsulation of Amp B in the liposomes did not alter the release rates from PB 
significantly. Thirty three percent of the liposome entrapped Amp B was released in 
1 68 hr against 36% of the drug that leaked out when free Amp B was entrapped (Fig, 
3.1.4). Crosslinking of the beads containing liposome entrapped Arnp B (25|il MLVs 
containing 100)ig drug) however resulted in comparable decrease in the release of the 
I posoniized drug. 
Eixperiments with loading of Amp B in the liposomes showed maximum entrapment 
of 14.5 mg of the drug'ml of the MLVs beyond which a dramatic decrease in the 
entrapment efficiency of the drug was evident (Table 3.2). Equal volumes of MLVs 
(20|al) were suspended in PBS and release kinetics studied (Fig. 3.1.6), The Amp B 
entrapped liposomes were stable and only 14% leakage of the drug was observed 
from the MLVs in 168 hr, with most of the release occurring during first 24 hr. 
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Concentrations of drug loaded in the liposomes do not seem to affect significantly the 
release kinetics (Fig. 3.1.6). 
PB were also prepared from plasma concentrated with the help of Sephadex G-10. 
Two milliliters of fresh plasma was mixed with 400 mg of the matrix, incubated for 
30 min, and centrifijged at 10000 x g to separate the Sephadex beads. The plasma 
obtained was remixed with additional 100 mg of Sephadex, further incubated for 30 
min and centrifuged. After a third cycle of concentration with 75 mg Sephadex, the 
plasma was used for the preparation of the beads. Lane 3, 4 and 5 in Fig. 3.1.8 show 
the increase in concentration at each of the tliree steps mentioned. 
Fig. 3.1 9 shows the release profile of Amp B from normal PB as well as those 
prepared with concentrated plasma. The release of drug from glutaraldehyde cross-
linked samples in both the preparations was also compared. Only moderate lowering 
of the release rates resulted when the plasma was concentrated before preparation of 
the beads. Effects of glutaraldehyde treatment were also comparable in the 
experiments with the crosslinked preparations exhibiting lower release rates. 
Composite beads of calcium alginate were also equally leaky with veiy little alteration 
in the drug release kinetics. 
3.1.4.1. Amp B distribution in blood plasma after administration of the drug in 
PB-formulations 
Improvement in the drug pharmacokinetic behavior is the principal target of drug 
deliveiy systems. The present investigation encompasses a phamiacokinetic 
evaluation of the PB-based formulations in mice along with tissue distribution studies 
for systemic delivery of Amp B. In an in vivo study in the Balh/c mice, comparative 
tissue distribution was performed following intraperitoneal {i.p.) administration of 
Amp B Various formulations of Amp B were prepared as described under methods, 
injecteci, and the drug levels quantitated in blood as well as in the vital organs. The 
formulations used in the study include liposome encapsulated Amp B (Lip-Amp B), 
PB-entjapped Amp B (PB-Amp B), liposome encapsulated and PB-entrapped Amp B 
(PB-Lip-Amp B). Control animals received the drug in saline (Sal-Amp B). The drug 
administered in each case was 30mg/kg weight of the animal. 
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Mean plasma Amp B concentrations-versus-time curves after i.p administration of 
various formulations are shown in Fig. 3.1.10. The plasma concentration of Amp B 
was maximum of (2.43 |ig/ml) four hr after the administration of free drug, the level 
decreased rapidly and became undetectable after 72 hr. Plasma levels in case of 
animals receiving Lip-Amp B decreased more gradually from the initial 2.14 |ag/ml 
observed at 4 hr to non-detectable levels at the end of 144 hr. Animals receiving the 
drug entrapped directly in PB (PB-Amp B) or in PB after liposomal entrapment (PB-
Lip-amp B) exhibited maximum plasma drug concentrations after 24 hr, but the drug 
level declined gradually and almost 50 percent (658 and 703 ng/ml respectively) of 
maximum level of the drug remained in plasma after 144 hr. The observations suggest 
reraarkably slow and sustained release of the entrapped Amp B in the circulation from 
the PB formulations. No significant difference in plasma profiles of Amp B were 
however observed when the drug was administered in the plasma beads directly or 
after encapsulafion in the liposomes. 
3.1.4.2. Amp B profiles in liver 
Amp B analysis in the liver shows maximum concentration of the drug in the group 
receiving free Amp B at 24 hr with the level of drug reaching about 40)ug/g of the 
tissue (Fig. 3.1.11). The drug level however registered a rapid decline and reached 
21|iig/g and 9|ag/g at 48 and 72 hr respectively. In the animals of the Lip-Amp B 
group, maximum drug levels were also reached at 24 hr, but the levels were 
significantly lower compared to control group and the subsequent decrease was also 
more gradual. At the end of 144 hr the amount of drug retained in the livers of 
animals of the Lip-Amp B group was moderately higher than that of the control. In 
case of animals receiving PB-Amp B or PB-Lip-Amp B, the hepatic dmg level was 
quite low at 24 hr (5|ig/g and 4^g/g) but continued to increase gradually up to 144 hr. 
The level of the dnjg after 144 hr was 17|ig/g and 14|ug/g in PB-Amp B or PB-Lip-
Amp B groups respectively. 
3.L4.3. Amp B profiles in spleen 
The level of Amp B in the of spleens of mice receiving Amp B in saline was as high 
as 7l|iig;g at 24 hr after the administration of the drug (Fig. 3,1.12), decreased 
gradually and reached 27(ig g at the end of 144 hr. In the Lip-Amp B group, the drug 
levels were 43(ig/g at 24 hr and 19pg/g at 144 hr. On the other hand, in the groups of 
animals receiving PB-Amp B or PB-Lip-Amp B, the drug levels were low at 24 hr 
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(i.e. 15.6 and 16.7 ^g/g respectively) but gradually rose to 35 and 40 |ug/g 
respectively at 144 hr. 
3.1.4.4. Amp B profiles in kidney 
The distribution of Amp B levels in the kidneys of animals receiving various 
formulations of the drug was also studied and the pattern was comparable to that 
observed in the liver. As can be seen in Fig. 3.1.13, maximum drug levels (19.7fig/g) 
W(;re recorded in mice given free Amp-B or that after encapsulation in liposomes at 
24 hr. However, the levels decreased rapidly in case of control animals and fell to 
4.8|ig/g at the end of 144 hr. The maximum level of Amp B observed in mice of the 
Lip-AmpB group after 24 was low (12.8 /^ g/g) as compared to group. Kidney drug 
level in the group also decreased and became very low (4.75 |xg/g) at the end of 144 
hr. In animals administered Amp B directly entrapped in PB (PB-Amp B) or after 
encapsulation in liposomes (PB-lip-amp B), the detectable drug levels were 2.3^g/g 
and 2.").ig/g at 24 hr, followed by a subsequent gradual increase. The kidney level of 
the drug in PB-Amp B or PB-Lip-amp B was 10.7 (ag/g and 10.2 fxg/g respectively by 
144 hr 
From the above resuhs it is quite evident that amp B when administered in free form 
raipidly enters the circulation showing an early peak and decreases rapidly thereafter. 
In the group receiving Amp B encapsulated in liposomes also, the pattern was 
qualitatively similar with the dmg rapidly reaching a maximum and decreasing to low 
value but more gradually. Administration of the drug entrapped either directly or after 
pre-encapsulation in the PB remarkably altered the drug profiles with the level of the 
drug released increasing gradually and remaining at a much higher level in the tissues 
of the animals as compared to control groups. These studies show that plasma beads 
are quite effective in ensuring sustained release of the entrapped Amp B. In this study 
v/e however failed to observe any significant advantage of pre-encapsulation of the 
dj"ug in liposomes prior to entrapment in plasma beads. 
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Table 3.1. Entrapment of blue dextran and HRP in plasma beads. 
Addition Amount Amount entrapped Entrapment 
added (pg) Oig/IOOPB) (%) 
Blue 
dextran 
HRP 
500 
1000 
2000 
2500 
250 
500 
750 
1000 
323.5 ±18.4 
571.3 ±17.6 
997.5 ± 9.2 
931.9 ±14.2 
134 ±7.9 
249 ±6.8 
324.1 ±8.6 
339.3 ±4.7 
65 
57 
50 
37 
54 
48 
43 
34 
Each value represents the average ± SD of atleast three determinants. 
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Fig. 3.1.1. Release of blue dextran from PB in vitro. PB containing entrapped blue 
dextran (1000 fxg) was incubated in I'BS at 25°C and release kinetics of the drug was 
determined spectrophotometrically as described under Methods. Blue dextran 
entrapped in PB (D), blue dextran entrapped in PB treated with 0.008 %^ 
glutaraldehyde (•), 0.01 % glutaraldehyde (A) or 0.05 % glutaraldehyde (•). Blue 
dextran entrapped in beads prepared from plasma-alginate composite (0). Each value 
represents mean ± SD of four determinations. 
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Fig. 3.1.2. Release of blue dextran from polysaccharide entrapped PB and 
liposomes. PB containing liposomes encapsulated blue dextran (1000|ig) were 
incubated in PBS at 25 °C and release kinetics of the drug was determined 
spectrophotometrically as described under Methods, Blue dextran encapsulated in 
MLVs and further entrapped in PB (n), the dually entrapped blue dextran treated with 
0.008 % glutaraldehyde (•), 0.01 % glutaraldehyde (A) or 0.05 % glutaraldehyde (•). 
Release of blue dextran from MLVs alone was also investigated (0). Each value 
represents mean ± SD of four determinations. 
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Fig. 3.1.3, Release of HRP from PB. Plasma beads containing entrapped HRP 
(250pg) were incubated in PBS at 25 °C and release kinetics of the drug was 
determined spectrophotometrically as described under Methods. PB containing 
entrapped HRP (•), HRP and caproic acid (A) or HRP and aprotinin (•). HRP 
entrapped PB treated with 0.01 % glutaraldehyde (a) or 0.05 % glutaraldehyde (A). 
PB containing HRP pre-encapsulated in LUVs (o). Each value represents mean ± SD 
of four determinations. 
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Fig. 3.1.4. Release of Amp B from PB. Plasma beads containing entrapped Amp B 
(10()|ig) were incubated in phosphate buffered saUne (PBS) at 25°C and release 
kinetics of the drug was determined spectrophotometrically as described under 
Methods. PB containing entrapped Amp B (n), PB containing entrapped Amp B 
treated with 0.008 % glutaraldehyde (•), 0.01 % glutaraldehyde (A) or 
0.05?oglutaraldehyde (•). Each value represents the mean ± SD of four 
determinations. 
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Fig. 3.1.5. Release of Amp B from PB containing liposomes encapsulated Amp B. 
PB containing liposomes entrapped Amp B (I00|ig) were incubated in PBS at 25°C 
and release kinetics of the dmg was determined spectropiiotometricaliy as described 
under Methods. Amp B encapsulated in MLVs and further entrapped in PB (3). The 
dually entrapped Amp B treated with 0.008 % glutaraldehyde (•), 0.01 % 
glutaraldehyde (A) or 0.05 % glutaraldehyde (•). Each value represents mean ± SD 
of foui- determinations. 
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Fig. 3.L6. Release of Amp B from multilamellar liposomes. Liposomes containing 
entrapped Amp B were incubated in PBS at 25°C and release kinetics of the drug was 
determined spectrophotometrically as described under Methods. Appropriate volume 
(20^1) of MLVs containing 80 ^g (0), 140 ^g (A), 220 ^g (a) or 270 ng (o) of Amp B 
were used. Each value represents mean ± SD of four determinations. 
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Fig. 3.1.7. SEM Image of MLVs entrapped in fibrin meshwork. 
Table 3.2. Entrapment of Amp B in MLVs 
Amp B added 
(n»8) 
1.0 
2.0 
3.0 
4.0 
6.0 
Amp B entrapped 
rag/ml packed 
3.89 ± 0.27 
7.56 ± 0.21 
10.94 i 0.19 
14.47 i 0.47 
15.9 ± 0.34 
MLVs 
£ntrapmeiit 
{%) 
96 
94 
91 
90 
67 
Each value represents mean ± SD of four determinations. 
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Fig. 3.1.8. SDS-PAGE of rabbit plasma before and after concentration. Fresh 
plasma or that after concentration was subjected to electrophoresis. Lane 1 contains 
protein molecular weight markers and lane 2 contains rabbit plasma proteins. Lanes 3-
5 are loaded with plasma concentrated with varying amount of Sephadex GIO as 
described under Methods. Equal volume of plasma was equally diluted in each case. 
Amount of protein loaded (ng) (as estimated by BC A method) in lanes 2, 3, 4 and 5 
were 15, 21, 25 and 31 respectively. 
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Fig. 3.1.9. Release kinetics of Amp B from beads prepared using plasma, 
concentrated plasma and alginate-plasma mixtures. PB containing entrapped Amp 
B (100 ixg) was incubated in PBS at 25"C and release of the dnig was detemiined 
spectrophotoraetrically as described under Methods. The PB prepared from normal 
(•) and further treated with 0.01 % glutaraldehyde (A) or beads treated with 0.05 % 
glutaraldehyde (o). The PB prepared from concentrated plasma (•) and further treated 
with 0.01 % glutaraldehyde (A) or 0.05 % glutaraldeyde (•). PB prepared from 
plasma-alginate mixtures were also investigated (0). Each value represents mean + SD 
of four determinations. 
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Fig. 3.1.10. Amp B concentrations in the plasma of mice administered the 
antifungal formulations intraperitoneally. Animals received 30 mg/kg body weight 
of the drug dissolved in saline (Sal-Amp B) (a), encapsulated in liposomes (Lip-Amp 
B) (•), entrapped in plasma beads (PB-Amp B) (A ) or encapsulated in liposomes and 
further entrapped into plasma beads (PB-Lip-Amp B) (•). The animals were bled 
after \arious time intervals and plasma concentration of the antifungal determined by 
reverse phase HPLC as described. Each value represents the mean ± SD of four 
determinations. 
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Fig. 3.1.11. Amp B concentrations in the liver of mice administered the 
antifungal formulations intraperitoneally. The animals were sacrificed after 
various intervals of time and liver tissue concentration of the antifungal determined by 
HPLC as described. Each value represents the mean ± SD of four determinations. For 
details, please refer to the legend to Fig. 3.1.10. 
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Fig. 3.1.12. Amp B concentrations in spleen of mice administered tiie antifungal 
formulations intraperitoneally. The animals were sacrificed after various intei-vals 
of time and spleen tissue concentration of the antifungal determined by HPLC. Each 
value represents the mean ± SD of four determinations. The legends are discussed in 
Fie. 3.:. 10. 
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Fig. 3.1.13. Amp B concentrations in the kidney of mice administered the 
antifungal formulations intraperitoneally. The animals were sacrificed at various 
intervals and kidney tissue concentration of the antifungal determined by HPLC as 
described. Each value represents the mean ± SD of four determinations. For details 
p'ease refer to the legend to Fig. 3.1.10. 
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3.2. Antigen delivery through PB 
The observed slow release of the antifungal drug Amp B both in vitro and in vivo 
from the PB prompted us to investigate potential of PB as delivery vehicles of protein 
antigens for the generation of effective immune response in animal models. 
Considering the high porosity of the PB and rapid release of the high molecular 
weight molecule like blue dextran, it was considered essential to employ a strategy to 
restrict the ready exit of the antigen to facilitate its delivery over long duration. Yeast 
invertase that is highly immunogenic (Melnick et al., 1990; Romanos, 1995; 
Schreuder et al., 1996) was used as model antigen and erythrocyte entrapment was 
adopted as the strategy to further slowdown the release of invertase from the beads. 
The potential of erythrocyte entrapped antigen in inducing immunity is now 
recognized (Polvani et al., 1991; Chiarantini et al., 1997; Dominici et al., 2003). 
Erythrocyte entrapment has been shown to facilitate effective targeting of the 
associated antigen to the Antigen Presenting Cells (APCs) like dendritic cells and 
macrophages (Gautam et al., 1987; Murray et al., 2006). 
3.2.1. Loading of invertase in rabbit erythrocytes 
Knowledge of the optimum conditions for the entrapment of antigen in eiythrocyte is 
essential before they can be used as an antigen delivery system. With this aim, the 
effect of concentration of added invertase on enzyme loading in erythrocytes and on 
the entrapment efficiency was investigated. As can be seen in Fig. 3.2.1, there is a 
consistent increase in the amount of entrapped invertase with increase in 
concentration of the added enzyme up to 3320 U (=8 mg). Under the conditions the 
eiythrocyte entrapped 135 U (325|Lig) /O.l ml resealed cells. Increase in the 
cancenlralion of added enzyme resulted in no further increase in that entrapped. The 
entrapment efficiency decreased with increase in added enzyme but was compensated 
by the t)verall increase in the amount of entrapped enzyme (Fig. 3.2.1). The recovery 
of packed cells during the entrapment studies ranged between 83 and 92%. 
3.2.2. Stability of the invertase loaded erythrocytes 
Fig. 3.2.2 shows the in vitra release of invertase entrapped in eiythrocytes also after 
crosslnking with glutaraldehyde. Most of the enzyme encapsulated in uncrosslinked 
erythrocytes was released in the medium in 64 hr. A burst release that resulted in 
appro innately 20% leakage of the enzyme in the initial 2 hr was observed. A 
concentration dependent decrease in the release of the enzyme was observed when 
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glutaraldehyde treatment was given to the enzyme encapsulated erythrocytes. The 
0.025, 0.05, 0.1 and 0.25% glutaraldehyde-treated erythrocytes released 83, 64, 45 
and 18 % of the entrapped invertase respectively after 64 hr incubation. 
Glutaraldehyde treatment slowed the release of invertase effectively and those 
crosslinked with 0.25% dialdehyde showed a remarkable 80% decrease when 
compared with the uncrosslinked samples at the end of incubation. Also, there was a 
remarkable decrease in initial burst release with only about 2 % leakage of the 
enzyme in 2 hr. Glutaraldehyde treatment of invertase loaded cells thus resulted in 
remarkable increase in their stability and slowed down the release of enzyme. 
3.2.3. In vitro release of enzyme from invertase encapsulated erythrocytes further 
entrapped in PB 
The release of invertase from plasma beads containing invertase entrapped 
ejythrocytes is shown in Fig. 3.2.3 Only 50 %> of entrapped invertase leaked out from 
plasma beads into the medium in 64 hr. Plasma beads prepared from concentrated 
plasma were only moderately superior and released 43% of the erythrocyte entrapped 
enzyme in 64 hr. To further improve the sustained release , PB containing erythrocyte 
encapsulated invertase were treated with 0.025, 0.05, 0.1 and 0.25% glutaraldehyde 
(the enzyme encapsulated in erythrocytes alone were not cross-linked in this case). 
Release of enzyme from the beads was investigated. Crosslinking resulted in 
remarkable lowering of the leakage of invertase and as shown in Fig. 3.2.3, the release 
in 64 hr was 38, 31, 23 and 14% in case of 0.025, 0.05, 0.1 and 0.25% glutaraldehyde 
treatment respectively. 
3.2.4. Antibody response in rabbits after immunization with the invertase 
formulations 
Fig. 3 2.4 shovv's the antibody response in rabbits immunized with invertase 
emulsified with CFA (CFA-lnv), encapsulated in eiythrocytes (EE-lnv) or erythrocyte 
encapsulated invertase further entrapped into plasma beads (EE-lnv-PB) at 1:800 
dilutions of the sera. While the preparation with adjuvant was administered 
subcutaneously, others were injected intraperitonealy (Lp). All the immunized animals 
except the EE-lnv-PB group showed maximum levels of circulating IgG on day 20 
post immunization, but the levels decreased gradually by day 35. Interestingly, in case 
of animals administered EE-lnv-PB, the IgG titer increased up to day 28, decreased 
only moderately on day 35. The antibody level was significantly higher in animals 
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receiving EE-Inv-PB as compared those administered with EE-Inv (on day 35) but 
scimewhat lower when compared to CFA-Inv. The result suggested that the invertase 
loaded erythrocytes when further encapsulated into the plasma beads may be more 
el'fective in inducing antibody formation, possibly due to release of antigen gradually 
in inducing immunity in rabbits. 
3.2.5. Antibody response in immunized rabbits after a single booster dose 
Fiig. 3.2.5 shows that the administration of booster on day 35 resulted in a remarkable 
increase in the antibody titers in almost all the groups. The values shown are at 1:3200 
dilutions of the sera. While the rise was dramatic in the animals receiving invertase 
emulsified with IFA (IFA-Inv), marked increase was also observed in groups 
re;ceiving antigen entrapped in erythrocytes/plasma beads. As compared to the rabbits 
receivnig EE-Inv, those receiving EE-Inv-PB formulation exhibited significantly 
higher liter on day 8, day 15 and day 24 of booster administration. The results are 
significant in spite of the fact that IgG levels in the EE-Inv-PB and EE-Inv groups are 
lower as compared to those that received the adjuvants emulsified the soluble antigen. 
However considering the well-known toxicity of the Freund's adjuvant, obtaining 
reasonable IgG titers without adjuvant is encouraging, especially in case of the dual 
entrapment strategy. 
3,2.6. Antibody response in mice after immunization with invertase administered 
subcutaneously 
Fig. 3.2.6 shows the generation of specific antibodies (at 1:100 dilutions of the sera) 
in mice immunized subcutaneously with the various formulations of invertase. 
Immunogenicity of all the formulations in mice was remarkably lower than that 
obser\ed in rabbits. The formulations investigated included soluble invertase 
dissolved in 10 mM Tris-NaCl (Sal-Inv), invertase emulsified with CFA (CFA-Inv), 
encapsulated in erythrocytes (EE-lnv), erythrocyte encapsulated invertase further 
entrapped into plasma beads (EE-Inv-PB) and EE-Inv-PB treated with 0.05% 
glutaraidehyde (EE-lnv-PB-CL). Animals in all the groups received 60 |Lig of the 
antigen in the formulations. Sera were collected on day 10 and day 20 and antibody 
titers analyzed through indirect ELISA as discussed under Methods. Administration 
of invertase dissolved in PBS alone did not elicit any significant immune response 
either on day 10 and day 20 post immunization. Among the other groups studied, 
maximum antibody titer was observed in the CFA-Inv group on day 10 and the 
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antibody level increased remarkably on day 20. High levels of antibodies were also 
present in the groups EE-Inv and EE-Inv-PB with or without crosslinking. Among the 
non-adjuvant groups, maximum level of antibody was evident in EE-Inv at day 20 
post immunization. Unlike in the experiments with i.p. administered antigen 
formulation, antibody levels were relatively low in PB formulations. The booster 
dose-induced increase in the antibody level (in the non-adjuvant groups) was however 
more marked in EE-Inv-PB and EE-lnv-PB-CL (Fig. 3.2.7) and the overall order of 
antibody generation following the booster dose was IFA-Inv > EE-Inv-PB-CL > EE-
lav-PB > EE-Inv > Sal-Inv. However, the titers induced were not as remarkable as 
those obtained in rabbits after administration of boosters irrespective of the 
formulations administered. 
3.2.7. A comparison of antibody response in mice induced by Lp and Lv. 
administration of the invertase formulation 
Administration of the erythrocyte entrapped formulations either i.v. or i.p. did not 
significantly affect the induced antibody levels both on day 10 or day 20 (Fig. 3.2.8). 
Oosslinking however enhanced their ability to induce antibodies as evident from the 
titers obtained on day 20 compared to those observed at 10 days. Crosslinking of the 
invertase entrapped eryrthocytes was however moderately effective in increasing the 
antibody levels as compared to those not crosslinked. In this case too, the antibody 
levels of i.v and i.p. administered group were comparable. Compared to the 
uncrosslinked and crosslinked carrier erythrocytes administered i.p. those given the 
preparation after entrapment in PB showed relatively low antibody levels on day 10, 
but the levels increased remarkably on day 20. The effect was miore marked in the 
crosslinked preparations. The PB entrapped preparations could not be administered 
i.v. because of the particulate nature. 
The administration of a booster dose on day 20 dramatically increased the antibody 
liters in the mice receiving soluble invertase emulsified with IFA. Although the 
increase was less marked in animals receiving erythrocyte-entrapped antigen 
formulation delivered without the adjuvant, the antibody levels in these groups also 
registered significant increase as compared to those observed in animals receiving a 
single dose of the antigen (day 10 of booster administration). This was particularly 
true in case of mice receiving the PB-entrapped formulation. In all the groups the 
antibody levels registered a decrease on day 20. The antibody levels were highest in 
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groups of animals receiving crosslinked PB entrapped preparation followed by the 
uricrosslinked ones (Fig. 3.2.9). 
Route of primary immunization (Fig. 3.2.6 and 3.2.8) and booster (Fig. 3.2.7 and 
3.2.9) did not markedly affect the induction of specific immune response in case of 
enzyme encapsulated in erythrocytes was used as antigen. However, erythrocyte 
entrapped in PB formulations administered i.p. resulted in remarkably higher antibody 
tilers as compared those given subcutaneously. The study also suggests that while the 
erythrocyte/PB entrapped formulations were not as effective as those containing the 
adjuvant, they did induce reasonably high levels of antibodies that also remained 
longer in circulation for longer durations. 
3.2.8.1}.;Gl:IgG2a levels after primary immunization and post booster 
The relative contribution of Th2 and Thlin the induced immune response is measured 
by measuring the IgGl and IgG2a levels. The IgGl:IgG2a ratios were therefore 
measured 20 days after primary immunization and 10 days after a single booster 
administered subcutaneously (Fig. 3.2.10). This IgGl:IgG2a ratios ranged between 
0.95 to 1 in animals receiving CFA-Inv, EE-Inv, EE-Inv-PB and EE-Inv-PB-CL after 
pi-imary immunization indicating the induction of both Thl and Th2 type of immune 
response (Murray et al., 2006). The ratios increased significantly in animals receiving 
the booster. Higher IgGl .TgG2a ratios were observed in animals of the EE-Inv-PB-CL 
g:-oup (1.62) and EE-Inv-PB (1.53) as compared to EE-Inv (1.33) after 10 days post 
booster dose. This indicates a moderate shift towards Th2 phenotype after the 
administration of second dose. There was no change in the lgGlTgG2a ratios in the 
animals treated with the adjuvants. 
Compa'-able resuhs were also obtained when the route of administration was i.p. The 
IgGl: I gG2a ratio ranges from 1.0 to 1.1 in animals receiving primaiy dose of various 
formulations administered but the ratios increase after the administration of the 
booster (Fig. 3.2.11) Maximum increase was observed in case of EE-Inv-PB-CL 
group (Irom 0.98 after primaiy immunization to 1.78 after booster), followed by that 
which received EE-lnv-PB (1.04 to 1.66). The increase was relatively small in other 
groups of animals receiving either the antigen entrapped in uncrosslinked or 
crosslniked erythrocytes, irrespective of the route of administration. It is thus evident 
from the results that a shift towards Th2 response was seen in the animals 
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administered the crosslinked PB containing antigen-entrapped erythrocj^e, followed 
by those receiving the uncrosslinked preparations. 
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Fig. 3.2.1. Effect of added invertase on the enzyme entrapment in rabbit 
erythrocytes. To 600 ^1 of packed rabbit erythrocytes was added increasing 
concentration of invertase and entrapment was accomplished as described under 
methods. The hematocrit of the packed unloaded cells was 60 % in each case. The cell 
recovery ranged between 83 to 92 %. Each value represents tlie mean ± SD of four 
determinations. 
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Fig. 3.2.2. Release of invertase from the enzyme encapsulated erythrocytes. 
Rabbit erythrocytes were entrapped with invertase as described in the text. The 
eiythrocytes containing entrapped invertase (67.5U/50(il or 162.5|ag/50|il) were 
suspended in PBS and incubated at 25 T . Preparations investigated include invertase 
entrapped erythrocytes {zi) and those treated with 0.025 % (•), 0.05 % (A), 0.1 % (•) 
and 0 25 % glutaraldehyde (0). Each value represents the mean i SD of four 
determinations. 
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Fig. 3.2.3. Release of invertase from carrier erythrocytes entrapped in PB. Rabbit 
eiythrocytes were first loaded with invertase and further entrapped in PB as detailed 
in the text. PB containing invertase (67.5 U or 162.5)ag/100 PB) were suspended in 
PBS and incubated at 25 "C. The preparations investigated include erythrocyte 
entrapped invertase furthur entrapped in normal plasma beads (D), concentrated 
plasma beads (0) and plasma beads treated with 0.025 % (•), 0.05 % (•) 0.1 % (A) 
and 0,2.5 % gkitaraldehyde (•). Each value represents the mean i SD of four 
determinations. 
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Fig. 3.2.4. Antibody response in rabbit after immunization witi) various invertase 
formulations. Groups of rabbits were immunized with invertase preparation 
including free enzyme emulsified in complete Freund's adjuvant CFA (CFA-lnv); 
Invertase loaded into erythrocytes (EE-Inv) or invertase loaded erythrocytes 
entrapped into plasma beads (EE-lnv-PB).Totai sera IgG were measured in the sera of 
animals at the indicated intervals. All animals received 600 |ig of invertase as a single 
dose. Values represent the mean ± SD of four determinations at 1:800 dilutions of the 
sera. P value (all pairwise multiple comparison groups, Tukey test) among the various 
statistically significant groups on day 10 are (CFA-lnv vs EE-lnv, CFA-lnv vs EE-
Inv-PB <0.001; EE-lnv vs EE-lnv-PB <0.05), day 20 (EE-lnv vs EE-Inv-PB, CFA-
lnv vs EE-Inv-PB <0.00l), day 28 (CFA- Inv vs EE-lnv, CFA-lnv vs EE-Inv-PB < 
0.05) and day 35 (CFA-lnv vs EE-lnv, EE-lnv vs EE-lnv-PB <0.001; CFA-lnv vs EE-
lnv-PB < 0.05). 
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Fig. 3.2.5. Antibody response in rabbits immunized with various invertase 
formulations after a booster dose. Animals immunized as described in the legend to 
the Fig. 3.2.4 were administered 200 ^g of the respective antigen as booster and 
serum IgG levels were measured till 24 days. For details please refer to the legend to 
Fig. 3.2.4. The first group is invertase emulsified with IFA (IFA-Inv). Values indicate 
the mean ± SD of four determinants at 1:3200 dilutions of the sera. P values (all 
pairwise multiple comparison groups, Holm-Sidak test) among the various groups 
(IFA-inv vs EE-lnv, EE-lnv vs EE-Inv-PB and IFA-Inv vs EE-Inv-PB) on day 8 , day 
15 and day 24 post booster are <0.001. 
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Fig. 3.2.6. Antibody response in mice after subcutaneous immunization with 
invertase formulations. The response was monitored in the sera of the animal at day 
10 and day 20. Figure represents Invertase dissolved in PBS (Sal-lnv); emulsified 
with complete freund's adjuvant CFA (CFA-lnv); entrapped into erythrocytes (EE-
Inv); entrapped blood cells and further entrapped into plasma beads (EE-Inv-PB) or 
entrapped in blood cells, further entrapped into plasma beads treated with 0.05 % 
glutaraldehyde (EE-lnv-PB-CL). All the above preparations were administered 
subcutaneously. All animals received 60 ngs of invertase as a single dose. Values 
represent the mean ± SD of five determinations at I ;100 dilutions of the sera. P values 
among the various statistically significant groups are (all pairwise multiple 
comparison groups, Holm-Sidak test) on day 10 (EE-Inv vs EE-Inv-PB. EE-Inv vs 
EE-Inv-PB-CL, <0.001) and day 20 (EE-Inv vs EE-Inv-PB-CL, <0.001, EE-lnv vs 
EE-lnv-PB, <0.05). Sal-lnv and CFA-lnv group has statistically significant P-values 
compared to all groups both on day 10 and day 20 (<0.001) (comparison vs control, 
Dunnett test). 
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Fig. 3.2.7. Antibody response in mice after a second dose of invertase 
formulations. Animals immunized as described in the legend to the Fig. 3.2.6 were 
administered 20 ng of the respective antigen as booster and serum IgG levels were 
measured at day 10 and day 20. Values indicate the mean ± SD of five determinants, 
at 1:100 dilutions of the sera. All the preparations were administered subcutaneously. 
P values among the various statistically significant groups (all pairwise multiple 
comparison groups, Holm-Sidak test) on day 10 ( EE-Inv vs EE-Inv-PB, EE-Inv-PB 
vs EE-lnv-PB-CL < 0.05; EE-Inv vs EE-lnv-PB-CL, <0.001) and day 20 (EE-Inv vs 
EE-lnv-PB-CL, <0.001; EE-Inv vs EE-lnv-PB ; EE-Inv-PB vs EE-lnv-PB-CL <0.05). 
Sal-lnv and CFA-Inv group has statistically significant P-values compared to all 
groups both on day 10 and day 20 post booster (<0.001) (comparison vs control, 
Dunnett test). 
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Fig, 3.2.10. Mean IgGl: IgG2a isotype ratios in various groups in mice after 
primary immunization and after administration of a booster dose. Figure 
represents Invertase emulsified with complete freund's adjuvant CFA (CFA-lnv); 
entrapped into erythrocytes (EE-Inv); entrapped blood cells and further entrapped into 
plasma beads (EE-lnv-PB) or entrapped in blood cells, further entrapped into plasma 
beads treated with 0.05 % glutaraldehyde (EE-lnv-PB-CL). All the above 
preparations were administered subcutaneously. The values are the mean ± S.D. of 
five mice for each group. P value in the post booster group is statistically significant 
(EE-lnv vs EE-Inv-PB; EE-Inv vs EE-lnv-PB-CL < 0.05 (all pairwise multiple 
comparison group, Holm-Sidak test). Values are also statistically significant with 
CFA-lnv compared to all other groups (<0.001) in case of the post booster group. 
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Fig. 3.2.8. Antibody response in mice after ^v. and Lp. administration of 
invertase formulations. The response was monitored in the sera of the animal at day 
10 and day 20. The antigen preparations were administered either intravenously (i.v.) 
or intraperitoneally (i.p.). Please refer to the Fig. 3.2.6 for the details of abbreviations 
used. All animals received 60 ngs of invertase as a single dose. Each value represents 
the mean ±SD of five determinations at 1:100 dilutions of the sera. P values among 
the various statistically significant groups are on day 10 (EE-Inv-CL, IV vs EE-Inv-
PB, IP; EE-Inv-CL, IV vs EE-Inv-PB-CL, IP <0.05 (Tukey test)) and day 20 (EE-
Inv, IP vs EE-Inv-CL, IP; EE-Inv, IV vs EE-Inv-CL, IV; EE-Inv, IV vs EE-Inv-CL, 
IP; EE-Inv-PB, IP vs EE-Inv-PB-CL; EE-Inv-CL, IP vs EE-Inv-PB-CL, IP (< 0.05 
Holm-Sidak test)). Sal-lnv, IP group has statistically significant P-values compared to 
all groups both on day 10 and day 20 (<0.001) (Dunnett test). 
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Fig. 3.2.9. Antibody response in mice after a second dose of antigen formulations. 
Animals immunized as described in the legend to the Fig. 3.2.6 were administered 20 
|ig of the respective antigen as booster. The response was monitored in the sera of the 
animal at day 10 and day 20. The routes of administration were exactly same as 
discussed in Fig. 3.2.8 in each case. Each value represents the mean ± SD of five 
determinations, at 1:100 dilutions of the sera. P values among the various statistically 
significant groups on day 10 and day 20 post booster are (EE-Inv, IP vs EE-Inv, IP-
CL; EE-Inv, IV vs EE-Inv-CL, IV; EE -Inv-PB, IP vs EE-Inv-PB-CL, IP and <0.05 
(all pairwise multiple comparison test. Holm Sidak test). Sal-Inv, IP; EE-lnv-PB, IP 
and EE-lnv-PB-CL, IP group have statistically significant P-values compared to 
remaining groups both on day 10 and day 20 post booster (<0.00!) (Dunnett test). 
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Fig. 3.2.11. Mean IgGl: IgG2a isotype ratios in various groups in mice after 
primary immunization followed by a booster dose. The values are the mean ± S.D. 
of five mice for each group. EE-Inv were administered both i.p. and /.v.. and EE-lnv-
PB were administered i.p. alone. For details please refer to legend to Fig. 3.2.10. P 
values in the post booster group are statistically significant only in the EE-Inv and 
EE-Inv-PB groups, < 0.001 or EE-lnv-PB, IP and EE-Inv-PB-CL, IP (< 0.05) (all 
pairwise multiple comparison group, Tukey test). Values are also statistically 
significant with CFA-Inv compared to all other groups (<0.00I) in case of the post 
booster group. 
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3.3. Studies on Plasma microparticles 
3.3.1. Preparation of plasma microparticles 
Plasma microparticles (PMPs) were prepared using a set up comprising of a beaker 
containing paraffin oil kept in a larger water filled beaker and placed on a 
thermostatic hot plate. A high speed mechanical stirrer was employed to stir the oil 
(Fig. 3.3.1). Rabbit/mouse plasma mixed with invertase or Amp B and with or 
without CaCh was dropped into the mineral oil with the help of a syringe (2 ml sterile 
syringe with a 23G hi-tech needle) and stirred at 8, 000 rpm. The stirring was 
continued to facilitate formation of PMPs maintaining the required temperature (40-
50 T) . The PMPs formed were sedimented by centrifugation at 10,000 x g for 10 
rnin, v\'ashed twice with diethyl ether and thrice with a mixture of n-hexane and iso-
f)ropanol in a ratio of 3:1 to remove the oil phase (Ho et aL, 1995). 
Particle-size analysis (Fig. 3.3.2) suggested that the microparticles formed have a 
diameter in the range of 1.0 |im to 5.0 ftm, with majority of them lying in the range of 
2.0 -3.0 |xm. SDS-PAGE of the various PMP formulations suggest polypeptide 
composition comparable to that of plasma but increase in time of stirred heating 
resulted in increase in the bands in the region above 66 kDa (Fig. 3.3.3). PMPs 
prepared without added calcium showed fewer of the high molecular weight bands. 
The amount of entrapped invertase in the PMPs increased with the length of the 
stirred incubation but reached a plateau at 60 min (Fig. 3.3.4A). Entrapment yields of 
invertase were high with almost all the added enzyme being retained in the PMPs 
when the stirring was continued at 40 °C for 60 min or beyond (Fig. 3.3.4B). Enzyme 
entrapment in PMPs prepared without added calcium was very low. Most of 
experiments of the study were performed using the preparations obtained by stirred 
heating for 75 min in the presence of CaC^. 
PMPs containing invertase were prepared by varying the temperature during stirred 
incubation between 40 and 50 °C. No difference was however observed in the 
invertase entrapment efficiency (Fig. 3.3.5), hence 40 °C was chosen as the standard 
temperature for the preparation of PMPs. 
SDS-PAGE of PMPs incubated for 75 min at 40, 45 or 50 °C were also nearly 
identical with no major difference in the protein profiles suggesting lack of formation 
of additional crosslinking during the preparation incubated above 40 °C (Fig. 3.3.6). 
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3.3.2. Release of Invertase from PMPs 
Fig. 3.3.7 shows the in vitro release profile of invertase from PMPs prepared at 40 "C 
(as described in methods) and also after crosslinking with glutaraldehyde. As evident 
from the figure, approximately 26% of the entrapped invertase leaked into the 
medium from the PMPs in 72 hr. Crosslinking with 0.05% (v/v) glutaraldehyde 
resulted in further 50% decrease in the release of the enzyme (only 13%) of invertase 
l(;aked out in 72 hr). Increase in preparation temperature to 50°C however did not 
enhance the retention of the enzyme in the PMPs and the release kinetics remained 
comparable with those prepared at 40 °C. 
3.3.3. Release of Amp B from PMPs 
Fig. 3.5.8 shows the release profile of Amp B from PMPs loaded with the antifungal 
as well as those cross-linked with 0.5% glutaraldehyde. Release of the antifungal was 
ri;markably low with only about 14 % of the entrapped drug leaking out into the 
medium after an incubation time of 72 hr. Treatment with glutaraldehyde resulted in 
additional decrease in the release of the drug with only 6% of the entrapped Amp B 
leaking from the PMPs, that were given the 0.05%) glutaraldehyde treatment, in 72 hr. 
Amp B release kinetics remained unaffected when the preparation temperature of the 
PMPs was raised to 50 T . 
3.3.4. Proteolysis of the PMPs 
Proteolysis of the uncrosslinked PMPs and those treated with glutaraldehyde was 
undertaken with a view to study the possible in vivo stability (Fig. 3.3.9). Release of 
proteins from the PMPs incubated with tiypsin (20 |ig/ml) or chymotrypsin (20 
)jg/ml 1 was taken as a measure of proteolysis. Protein solubilization was monitored up 
to 72 br. The PMPs incubated without protease or those incubated with trypsin and 
chymoli"ypsin released 17, 24 and 31 percent respectively of the total proteins into the 
medium in 72 hr after an initial burst observed at 2 hr. Cross-linked PMPs, trypsin 
and chymotrypsin-treated crosslinked PMPs showed a released 10, 12 and 14 % of the 
total protein respecti\'ely under the conditions Glutaraldehyde crosslinking 
effectnely decreased susceptibility to proteolysis as evident from the release of 
protein inlo the medium. The results suggest that PMPs are signiJicantly stable to 
proteolysis by more than one enzyme. 
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3.3.5. Antibody response in rabbits against invertase entrapped PMPs 
Immunization potential of PMP-entrapped invertase was also investigated. Fig. 3.3.10 
shows the antibody response in rabbits after immunization with invertase emulsified 
with C'FA (CFA-Inv), PMP-entrapped invertase (PMP-Inv) and the PMP-Inv 
crosslinked with glutaraldehyde (PMP-Inv-CL). The CFA-Inv was administered 
subcutenously while the other preparations were injected intraperitonealy (i.p). All the 
animals receiving the antigen through various formulations showed increase in the 
level of anti-invertase IgG in sera till day 20 post immunizations. Highest titers were 
recorded in animals that received CFA-Inv followed by PMP-Inv and PMP-Inv-CL 
formulations. The titers however decreased gradually by day 35 in all the groups of 
animals with the exception of those that received the PMP-Inv-CL, In this group the 
\\lG titer increased till the day 28 and showed only a small decrease on day 35. The 
antibody titers were however comparable in the three groups by day 28. IgG levels 
were highest in animals receiving PMP-Inv-CL followed by CFA-Inv by day 35. 
Admmistration of the booster dose resuhed in enhancement of titers in animals the 
animals in the same order; PMP-Inv-CL> IFA-lnv = PMP-Inv (Fig. 3.3.11). 
3.3.6. Antibody response in mice against PMPs containing entrapped invertase 
The immunogenicity of PMPs was less marked in mice as compared to rabbits. 
Immunization studies in mice gave results similar to those observed in rabbits (Fig. 
3.3.12 and Fig. 3.3.13). Comparable increase in antibody titer were observed in mice 
both post primary immunization and administration of a booster dose in case of CFA-
Inv and PMP-Inv. As with rabbits, the increase in the antibody titers in case of the 
PMP-liiv-CL group was gradual and lower on the day 14 after immunization, but the 
levels increased beyond those of the adjuvant and uncrosslinked preparations on day 
35 of administration. Animals receiving PMP-lnv-CL also exhibited superior antibody 
titer alter receiving a booster dose as compared to those receiving incomplete 
adjuvant as well as the uncrosslinked preparations. Antibody levels in the uncross 
linked preparations both on day 10 and day 20 after the administration of the booster 
v/ere comparable with those receiving the antigen emulsified with the CFA-Inv. 
Invertase administered without adjuvant or entrapment (Sal-lnv) was weakly 
antigenic and resulted in poor antibody titers both after the first and the booster dose. 
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3.3.7. IgG2a/IgGl ratios in mice receiving PMP-entrapped invertase 
Mean IgG2a/IgGl isotype ratio in all the mice receiving invertase emulsifiedwith 
CFA or entrapped in crosslinked or uncrosslinked PMPs was approximately 1 (0.98 to 
1.04), 20 days after administration of the first dose (Fig. 3.3.14). However the ratio 
increased to 2.2 in PMPs and 2.7 in PMPs-Inv-CL after a booster, suggesting a shift 
of immune response towards Thl. The results suggest that PMP entrapment of 
invertase promoted the induction of cell-mediated immune (CMI) response. The shift 
towards Thl response was more marked in the groups receiving the cross-linked 
preparations. The booster dose did not however cause any noticeable shift in 
lgG2a/IgGl ratio in case of the adjuvant administered animals. 
3.3.8. Generation of CD4^ and CD8^ T lymphocyte 
Flow cytometric analysis was conducted to determine the population of CD4^ and 
CD8^ T-cells generated as a result of immunization by invertase delivered through the 
PMP formulations (Fig. 3.3.15 and Fig. 3.3.16). Splenocytes were isolated from the 
animals immunized with Sal-lnv (B), CFA-Inv (C), PMP-Inv (D) and PMP-Inv-CL 
(E) as described in methods. Immunization with cross-linked PMPs loaded with 
invertase results in up-regulation of both CD4" (21.07 %) and CD8^ (16.23%) 
populations, followed by non-crosslinked plasma particles (16.60 and 12.12 % 
respectively). Animals immunized with CFA emulsified antigen showed relatively 
lower expression of CD4^ (13.46%) and marked reduction in the generafion of CD8* 
(6.95 '>()) as compared to the other fonnulations. As expected, soluble invertase 
preparation induced minimum expression of CD4^ (3.2%) and CD8^ (3.35%) cell 
population. Three animals were sacrificed from each group on day 5 after 
administration of booster dose and data are expressed as mean percentage ± SD of 
respective cell populations (Fig. 3.3.17). 
3.3.9. Generation of CD80 and CD86 positive antigen presenting cells (APCs) 
Flow cytometric analysis was also carried out to evaluate the quantum of expression 
of CD8G & CD86 on the surface of splenocytes (antigen presenting cells, APCs) 
isolated from the animals immunized with Sal-lnv (B), CFA-lnv (C), PMP-lnv (D) 
and PMP-lnv-CL (E) formulations as described in methods. Three animals were 
sacrificed from each group on day 5 after administration of booster dose and 
splenocytes isolated as described earlier. The data shown in Fig. 3.3.18 and Fig. 
3.3.19 >uggests that the APCs isolated from animals immunized with cross-linked 
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plasma particles were also superior in expression of both CD80 (12.12%) and CD86 
(]2.36'!'o) on their surface as compared to other groups. APCs isoleited from animals 
immunized with uncrosslinked PMPs alone expressed comparable CD80 (10.52%) 
and CE>86 (11.47%) on their surface while animals immunized with CFA showed 
only 6.71% and 3.47% of CD80 and CD86 cells respectively. Expression of both 
CD80 (3.35%) and CD86 (3.36%) molecules were minimal in case of soluble 
ir vertase preparation, data are expressed as mean percentage ± SD of respective cell 
populations (Fig. 3.3.20). 
Results 
Fig. 3.3.1. Set-up used for the preparation of PMPs. 
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Fig. 3.3.2. Particle size of PMPs. Particle size were measured by NANOPHOX 
Particle Size Analyser with Photon Correlation Spectroscopy. 
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Fig. 3.3.3. SDS-PAGE of PMPs prepared with varying stirred incubation 
durations. Electrophoresis was performed using 10 % (w/v) acrylamide gels in Tris-
glycine buffer, pH 8.8 containing 1 % SDS and 1% P mercaptoethanol. Lane 1 
contained molecular weight markers, while lane 2 was loaded with PMPs prepared 
without added CaCh. PMPs prepared with plasma containing 32 mM CaCh and 
incubated respectively for 30, 45 and 60 min were loaded in Lanes 3, 4 and 5. The 
amount of protein loaded in each lane (2-5) is 30 ^g. 
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Fig. 3.3.4. Entrapment of Invertase in PMPs by varying incubation time at 40° C. 
PMPs were prepared as described in the text with or without added CaCb- Entrapment 
of Invertase (U/mg protein) [A] and percent entrapment (invertase added to invertase 
recovered) [B] are shown. Each value represents the mean ± SD of three 
determinations. 
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Fig. 3.3.5. Effect of temperature on entrapment of Invertase in PMPs. PMPs were 
prepared by stirred incubations carried out at various temperature and enzyme 
entrapment quantitated as described in the text. Each value represents the mean ±SD 
of three determinations. 
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Fig. 3.3.6. SDS-PAGE of PMPs prepared at various temperature. The PMPs were 
prepared as described earlier by incubation for 75 min at various temperatures (the 
sample in lane 2 was incubated for 60 min). Lane 1 contains molecular weight 
markers. Lanes 3, 4 and 5 contain PMPs prepared at 40, 45 and 50°C respectively. 
The amount of protein loaded in each lane (2-5) is 30 |xg. 
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Fig. 3.3.7. Release of invertase from PMPs. PMPs containing entrapped invertase 
(16 U or 36fj.g /mg protein) were incubated in 1.5 ml PBS at 25°C and the enzyme 
release was determined by assaying the activity described under Methods. PMPs 
investigated included those prepared at 40"C (0), prepared at 40" C in presence of 0.05 
% glutaraldehyde (•) or prepared at 50"C (A). Each value represents ± SD of four 
determinations. 
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Fig. 3.3.8. Release of Amp B from PMPs. PMPs containing entrapped Amp B (28.5 
|ig/mg protein) were incubated in PBS at 25°C and the drug release was determined 
spectrophotometrically as described under Methods. PMPs investigated include those 
prepared at 40°C (0), prepared at 40" C in presence of 0.05 % glutaraldehyde (•) or 
prepared at 50°C (A). Each value represents ± SD of four determinations. 
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Fig. 3.3.9. Proteolysis of PMPs //; vitro. Various preparations of PMPs (containing 7 
mg protein) were incubated with 20|ig/ml trypsin (A) or 20|ag/ml of chymotrypsin 
(B). Preparations investigated include protease treated (•) uncrosslinked and 
crosslinked PMPs (•) as well as uncrosslinked (a) and crosslinked (o) PMPs not 
exposed to the protease. All samples were incubated in phosphate buffered saline 
(PBS) at 25°C and solubilized protein release was quantitated by BCA as described 
under Methods. Each value represents mean ± SD of four determinations. 
95 
Results 
2.5 
E 
c 
« 
u 
c 
M 
JO 
JD 
< 
1.5 4 
1 J 
0.5 
CFA-lnv PMP-lnv PMP-lnv-CL 
Fig. 3.3.10. Antibody response in rabbit after immunization with PMPs 
containing entrapped invertase. Groups of rabbits were immunized with invertase 
preparation including the enzyme emulsified in complete Freund's adjuvant CFA 
(CFA-lnv), entrapped in uncrosslinked (PMP-lnv) and crosslinked PMPs (PMPs-Inv-
CL). Sera were collected and ELISA performed to quantitate total IgG content on day 
10, 20, 28 and 35 after the primary immunization. All animals received 600 jigs of 
invertase as a single dose. Values represent the mean ± SD of three determinations at 
1:800 dilutions of the sera. P value among the various statistically significant groups 
on day 20 (PMP-lnv vs PMP-lnv-CL <0.05; CFA-lnv vs PMP-Inv-CL < 0.001) and 
day 35 (PMP-lnv vs PMP-lnv-CL <0.001; CFA-lnv vs PMP-lnv-CL < 0.05), all 
pairwise multiple comparison (Holm-Sidak test). 
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Fig. 3.3.11. Antibody response in rabbits immunized with PMP-entrapped 
invertase and given a booster dose. Animals immunized as described in the legend 
to the Fig. 3.3.10 were additionally administered 20 ngs of the respective antigen and 
serum IgG levels measured on day 12 and day 24. Values indicate the mean ± SD of 
three determinants at 1: 3200 dilutions of the sera. P values among the statistically 
significant groups on day 12 post booster (IFA-lnv vs PMP-Inv-CL < 0.05; PMP-lnv 
vs PMP-lnv-CL, <0.001) and on day 24 post booster (IFA-lnv vs PMP-lnv-CL < 
0.05; PMP-lnv vs PMP-lnv-CL< 0.001), all pairwise multiple comparison (Holm-
Sidak test). 
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Fig. 3.3.12. Antibody response in mice after administration of PMP-entrapped 
invertase. Groups of mice were administered invertase dissolved in saline (Sal-Inv), 
emulsified with CFA (CFA-lnv), entrapped in uncrosslinked (PMP-lnv) or 
crosslinked PMPs (PMP-Inv-CL). All animals received 60 ngs of invertase as a single 
dose. Values represent the mean ± SD of five determinations at 1:100 dilutions of the 
sera. P values among the statistically significant groups on day 14 (CFA-lnv vs PMP-
Inv-CL and PMP-lnv vs PMP-Inv-CL < 0.05), and day 35 (CFA-lnv vs PMP-Inv-CL 
<0.05 and PMP-lnv vs PMP-Inv-CL < 0.001), all pairwise multiple comparison 
(Holm-Sidak test). P value with Sal-Inv and all other groups on day 14 and day 35 are 
statistically significant, < 0.001. 
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Fig. 3.3.13. Antibody response in the immunized after a single booster dose. Mice 
immunized as described in the legend to the Fig. 3.3.12 were administered 20 ngs of 
the respective antigen as booster n day 35 and serum IgG levels were measured on 
day 10 and day 20. Values indicate the mean ± SD of five determinants at 1:100 
dilutions of the sera. P values among the statistically significant groups on day 10 
post booster (IFA-lnv vs PMP-Inv-CL and PMP-lnv vs PMP-lnv-CL < 0.05), and 
day 10 post booster (IFA-lnv vs PMP-lnv-CL <0.05 and PMP-lnv vs PMP-lnv-CL < 
0.001), all pairwise multiple comparison (Holm-Sidak test). P value with Sal-Inv and 
ail other groups are statistically significant (< 0.001) both on day 10 and 20post 
booster. 
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Fig. 3,3.14. Mean IgG2a: IgGl isotype ratios in groups of mice immunized with 
invertase entrapped PMPs. Groups of mice were immunized witii invertase 
emulsified with CFA or entrapped in uncrosslinlced or crosslinl<ed PMPs. For details 
please refer to legend to Fig. 3.3.12. The values are the mean ± S.D. of five mice. P 
value in the post booster group is <0.05 (all pairwise multiple comparison group, 
Holm-Sidak test). 
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Fig. 3.3,15, FACS analysis of the surface marker CD4'^ on the splenic T 
lymphocyte population in mice immunized with Invertase formulations. The 
lymphocytes were subjected to FACS analysis as describe under Methods. The 
percentage of the surface marker CD4* present on the T cell population of the isotypic 
controls (A), Sal-Inv (B), CFA-lnv (C), PMP-lnv (D) and PMP-lnv-CL (E) are 
shown. For details please refer to legend to Fig. 3.3.14. Animals were sacrificed on 
day 5 after administration of the booster dose. 
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Fig. 3.3.16. FACS analysis of the surface marker CDS on the splenic T 
lymphocyte population in the mice immunized with invertase formulations. The 
percentage of the surface marker CD8' present on the T cell population of the isotypic 
controls (A), Sal-Inv (B); CFA-lnv (C); PMP-lnv (D) and PMP-lnv-CL (E) are 
shown. For details please refer to legend to Fig. 3.3.14. Animals were sacrificed on 
day 5 after administration of the booster dose. 
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Fig. 3.3.17. CD4* and CD8"^  cell populations in the mice immunized with PMP-
entrapped invertase. For details please refer to the legend to Fig. 3.3.14 The 
expression data are representative of three independent experiments, with values 
indicating mean ± SD (CD4^ cells, P values < 0.001) (CD8^ cells, P values: < 0.001). 
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Fig. 3.3.18. Up-regulation of co-stimulatory surface molecule CD80 on APCs in 
the groups of mice immunized with invertase formulations . The lymphocytes 
were subjected to FACS analysis as describe under methods. The percentage of the 
surface marker CD80 present on the T cell population of the isotypic controls (A), 
Sal-lnv (B); CFA-Inv (C); PMP-lnv (D) and PMP-lnv-CL (E) are shown. Animals 
were sacrificed on day 5 after administration of a booster dose. 
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Fig. 3.3.19. Up-regulation of co-stimulatory surface molecule CD86 on the APCs 
in groups of mice immunized with invertase formulations. The percentage of the 
surface marker CD86 present on the T cell population of the isotypic controls (A), 
Sal-lnv (B); CFA-Inv (C); PMP-lnv (D) and PMP-lnv-CL (E) are shown. Animals 
were sacrificed on day 5 after administration of a booster dose. 
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Fig. 3.3.20. CD80 and CD86 cell populations in the various immunized groups of 
mice. For details please refer to the legend to Fig. 3.3.14. The expression data are 
representative of three independent experiments, with values indicating mean ± SD 
(CD80 cells, P values < 0.05). 
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Blood clotting is an indispensible and intricate part of homeostasis that helps in 
preventing blood loss from a damaged blood vessel. Coagulation begins 
instantaneously after an injury to the blood vessel that has damaged the endothelial 
lining of the blood vessel. Exposure of the blood to the leaked proteins such as tissue 
factors initiate changes in blood platelets and plasma protein fibrinogen. Platelets 
immediately form a plug at the site of injury; this is called primary hemostasis. 
Secondary hemostasis occurs simultaneously; proteins in the blood plasma called 
coagulation factors respond in a complex cascade to form fibrin strands that 
strengthen the platelet plugs (Fig. 1.2.). Conversion of fibrinogen either in vivo or in 
vitro to fibrin is accompanied by the spontaneous formation of a three dimensional 
network resulting in clot formation. Polymerized fibrin has been and continues to be 
used as a sealant to prevent loss of blood for a variety of surgical applications 
(Jackson el ciL, 1996; Kjaergard and Fairbrother, 1996; Zhibo and Miaoba, 2009). 
More recent years have witnessed a remarkable interest in the use of fibrin matrices, 
additionally as remarkable, biocompatible, biodegradable systems for the sustained 
delivery of drugs, growth factors, gene vectors and even cells (Breen et ah, 2009b). 
Conversion of fibrinogen to fibrin necessitates proteolysis of the former by thrombin 
and stabilization of the resulting clot requires cross-linking of fibrin molecules by the 
transglutaminase (activated factor Xllla). Bovine thrombin and transglutaminase have 
been widely employed for the in vitro clotting of purified fibrinogen for sealant 
applications (Hartman et al., 1992; Martinowitz and Saltz, 1996). Immunological 
complications arising out of the use of bovine thrombin and factor Xllla during the 
preparation of the sealants prompted the use of recombinant human preparation 
(Nichols, 1994; Jackson, 2001). The risk of transmission of blood-born infection like 
AIDS and hepatitis are however a source of worry while using fibrinogen isolated 
from human blood. Some attempts of using fibrinogen from autologous blood have 
also been made (Epstein et al., 1986; Weis-Fogh, 1988; Veremeenko et al., 1991; 
Choi et al., 2006). 
Work described in the thesis was undertaken with the objective of developing a drug 
delivery system based on the ability of plasma separated from blood collected in 
presence of chelators to undergo clotting on addition of calcium chloride. The plasma 
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could be conveniently converted to beads of required dimensions designated as 
plasma beads (PBs) or plasma microparticles (PMPs). The procedure used by us for 
the preparation of plasma beads overcomes the tedious process of purification of 
fibrinogen from blood and use of additional enzyme while facilitating the use of 
autologous plasma. CaCh, the only externally added component could be easily 
sterilized and entire process of bead preparation realized with autologous plasma 
minimizing the risks of infection associated with fibrin clots (Redl et ai, 1983; Zilch 
and Lambiris, 1986). Thus, the procedure offers the advantage of the use of patient's 
own plasma to conveniently entrap various therapeutics for possible sustained 
delivery in his body (Ahmad et ai, 2011). The preparation protocol (Fig.4.1) is 
simple, inexpensive and time efficient. Also, large quantities of beads can be made 
with great ease in simple laboratory set up available in most hospitals. Also large 
number of beads can be prepared readily with multi-channel pipettes in less than one 
hour. 
Transfer / ^ 
Blood 
Ther^tutics 
\ Transfa 
Ca-" Enriched Plasma I / 
iqecnot. 
Fig.4.1. Diagrammatic representation of procedure for the preparation of plasma 
beads from blood with entrapped therapeutics and re-administration. 
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It is now recognized that fibrin matrices are highly porous, although porosity of 
matrices may vary depending upon the concentration of fibrin/thrombin used. It is 
estimated that pore size of cross-linked fibrin monomers is 1-10 i^rn that facilitates 
leakage also of macromolecules (Boyce et al, 1994; Woolverton et al, 2001). Also, 
the; stability of the fibrin matrix can be manipulated to some degree by regulating the 
pH., concentrations of calcium ions, fibrin and thrombin. Eyrich et al. (2007) reported 
the optimal pH for preparing stable gels in the range 6.8-9.0. Stable fibrin gels were 
reported at 25 mg/ml fibrin concentration and calcium concentration more than 20 
vcM. (Eyrich et al, 2007). Large increases in fibrin concentration however lead to a 
decrease in average bundle thickness while the fibrin gels prepared using low Ca^ * 
contained fibers with small bundle diameters and increase in total number of fiber 
bundles (Herbert et al, 1998). Rowe et al (2007) examined the effect of varying 
thirombin concentration on the morphology of fibers in 3-D fibrin constructs and 
found higher thrombin concentrations were less uniform. The plasma beads used in 
this study in view of the presence of relatively low concentration of fibrinogen are 
ejipected to be more porous. This also supported by the SDS-PAGE of the PB, as 
obtained in an earlier report from the laboratory (Ahmad et al, 2011). Most of the 
major plasma proteins of exhibit unaltered mobility indicating their physical 
entrapment in the PB rather than being covalently linked to other proteins during the 
clot formation. Both blue dextran and HRP with large and small molecular weights 
could be readily entrapped with high yields (Table 3.1). The beads readily released 
blue dextran (Fig.3.1.1) and HRP (Fig.3.1.3) suggesting their high porosity. The 
porosity of the PB could be remarkably decreased by treatment with bifunctional 
ci-osslinking reagents. Indeed crosslinking with glutaraldehyde resulted in remarkable 
dscrease in the release of blue dextran from the plasma beads; the time required for 
the release of half of the entrapped blue dextran increased to 100 hr in PB treated 
withO.05% glutaraldehyde from 24 hr in the uncrossHnked preparations (Fig.3.1.1). 
Other reports also suggest that porosity of the fibrin matrices can be decreased on 
crosslinking with glutaraldehyde (Ho et al, 1995; Chung et al, 2006) and other 
tdfiinctional reagents like l-ethyl-3- (1-3 dimethyl aminopropyl) carbodiamide (EDC) 
£.nd genipin (Sell et a/.,2008; Dare et al, 2009). Since blue dextran does not contain 
amino groups that can be crosslinked with the dialdehyde to the plasma proteins, the 
lowered rate of their release from the PB can be attributed to decrease in pore size of 
i:he protein network. The observed slow release of Amp B from the PB, as discussed 
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already may be attributed to the binding of the antifungal to the plasma proteins 
(Block et al, 1974; Hartsel et al., 2001; Bekersky et ai, 2002). Crosslinking of the 
Amp B-entrapped PB also decreased the release rates of the drug (Fig.3.1.4.), 
suggesting the effectiveness of introducing crosslinks in the PB containing clotted 
plasma. 
Eiual entrapment has also been a useful strategy in manipulating controlled release of 
pharmaceuticals from leaky/porous delivery systems. Encapsulatiion of substances 
into liposomes and their further entrapment into other biodegradable systems like 
chitosan and fibrin matrices decreases their release significantly (Meyenberg et al., 
2000; Chung et al., 2006). As reported earlier, cross-linked fibrin prepared using 
concentrated solutions of fibrinogen has pores with an upper limit of 10 |im and 
f icilitates the rapid release of entrapped blue-dextran, a 2000 kDa molecule with 
mean particle size of 300 nm (Deguchi et al., 2002). Pre-entrapment in multilamellar 
I.posomes (Hope et al., 1986; Owais and Gupta, 2000; Immordino etal., 2006) having 
a diameter mostly in the range of 1.5-3|im (Fig.3.1.7) provide a multi-fold reduction 
ia the release rate as shown in Fig.3.1.2. The PB containing blue dextran pre-
entrapped in MLVs released only about half of the polysaccharide as compared to 
those in which blue dextran was entrapped directly. Cross-linking v.'ith glutaraldehyde 
further reduced the release. The MLVs were prepared using PC and cholesterol and 
hence offered no groups for reaction with the aldehydic groups of glutarldehyde. 
Decrease in release of the liposome entrapped blue dextran is therefore the result of 
lowered pore size rather than covalent attachment of the vesicles to the PB proteins. 
The observation that the PB, also after glutarladehyde treatment were leaky to the 
vesicles, albeit at lowered rates provide further evidence of their highly porous nature. 
It has been shown in earlier studies that fibrin matrix prepared using concentrated 
solution of fibrin is completely impermeable to the liposomes which could be released 
only after proteolytic degradation of the matrix (Meyenberg et ai, 2000; Chung et al., 
2006) This suggests that the plasma beads are far more porous than the fibrin gels 
prepared with fibrinogen and thrombin in vitro. 
Other promising composite polymeric systems that provide better stability, enhanced 
perfonnance and facilitate sustained release of the entrapped therapeutics have also 
been described (Ameer et ai, 2002; Lee et al., 2007; Eyrich et al., 2007; Li et ai, 
2012; Mufamadi et al., 2011). Release time of doxorubicin in vitro has been reported 
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to be delayed remarkably from sodium alginate-fibrin comjjosite supports as 
compared to alginate alone (Kitazawa et al., 1997). Inclusion of sodium alginate in 
plasma beads in our studies however failed to produce any significant effect on the 
release kinetics of large molecule as blue dextran (Fig.3.1.1) and small molecule such 
as Amp B (Fig.3.1.9). This may be due to the inability of the system to incorporate the 
required amount of alginate essential for effectively reducing the porosity of the 
matrix as well as possible interference by the alginate in clot formation. 
Rapid release of HRP from the beads (Fig.3.1.3) may be accredited to its relatively 
lower molecular weight (44 kDa) and high water solubility. Addition of 
antifibrinolytic agents to the PB during preparation also failed to show any significant 
reduction in the release of the enzyme. Blood plasma is rich in various protease 
inhibitors e.g. ai-protease inhibitor, antithrombin III, Ci-inliibitor, a2-plasmin 
inhibitors and several others (Steinbuch et al., 1984; Kloczko et a!.., 1990; Goransson 
et al., 1998) which are likely entrapped during PB preparation and restrict the 
proteolysis of the plasma beads. The inclusion of additional anti-proteases aprotinin 
and caproic acid did not significantly alter the release kinetics of entrapped molecule 
in vitro (Fig.3.1.3). Significant decrease in HRP leakage was however observed when 
the beads were crosslinked with glutaraldehyde. Since HRP has several free amino 
groups (6 lysine residues) which are likely to be crosslinked to the PB proteins during 
treatment with glutaraldehyde (Lee et al., 2005). The decrease in the observed release 
rate of the enzyme is therefore the result both of covalent coupling of HRP to plasma 
proteins as well as the decrease in its pore size of the PB. Pre-encapsulafion of the 
enzyme in large LUVs (100-200 nm in diameter) (Hope et al, 1986; Owais and 
Gupta, 2000) prior to entrapment in plasma beads however decreased (about 80%) the 
release of HRP remarkably. The effect pre-entrapment in the liposomes was 
apparently more marked in case of HRP as compared to the release of blue dextran 
due to large differences in the dimensions and charge on the vesicles. 
Earlier studies on the release of antibiotics such as Ampicillin, Carbenicillin, 
Ceftazydime, Clindamycin, Gentamycin, Cefotaxim, Mezlocillin and Tobramycin 
from fibrin clots have revealed near complete release of the drugs by 96 hr (Greco et 
al, 1991). Release occurred faster in cases of Ampicillin (48 hr) and Clindamycin (72 
lir). Another study also suggests almost a complete release of the anfibiotics 
Gentamycin, Neomycin and Polymyxin E from the fibrin clots within 72 hr (Redl et 
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al, 1983). Studies with drugs such as Erythromycins, Tetracychns and PeniciUins 
suggested the water insolubility as the determining factor for long term release 
(Woolverton et al, 1995, 1999). Our earlier studies on the release of the antibiotic 
tetracycline and the anti-cancer drug Daunorubicin from the plasma beads substantiate 
the observation (Ahmad et al, 2011). Release of tetracycline was markedly low as 
compared to that of Daunorubicin with only 50 percent of the drug being released in 
20 hr against an approximately 80% release in case of the later. Most of the antibiotic 
v^as however released in about 100 hr. Tetracycline in addition to its lower solubility 
also binds to albumin at one high and six low affinity binding sites for the antibiotic 
on the protein (Alam et al, 2004). 
Amp B release from the PB revealed a surprisingly different kinetics profile, with 
]iot more than 25% of the entrapped drug leaking out of the PB in 100 hr (Fig.3.1.4) 
against almost a total leakage observed in case of most other drugs. The remarkable 
slow release of Amp B from the PBs may be due to its binding to plasma proteins 
(Bekersky et al, 2002), as also discussed earlier, and could be ven,' well exploited for 
:he treatment of various anti-fungal diseases. Sustained release of the drug from 
PBs in vivo also facilitates use of lower doses thereby reducing toxicity particularly to 
the erythrocytes (Forster et al, 1988; Legrand et al, 1992) and nephrotoxicity 
(Bekersky et al, 1999; Andes et al, 2006). 
Mutilamellar liposomes have two or more lipid bilayers surrounding an aqueous core. 
Two different environments in the carrier make them versatile c:arriers for a broad 
spectrum of hydrophobic, amphipathic and hydrophilic agents (Storm and Etten, 
1997) High entrapment efficiencies of Amp B in MLVs have been accomplished 
which may be attributed to the chemical nature of the drug (Manosroi et al., 2004; 
Patel et al, 2011). Amp B is an amphipathic drug containing several free hydroxyl 
groups and a long hydrocarbon polyene chain that facilitates its entrapment both in 
the aqueous hydrophilic compartments as well as intercalation the intermediate non-
polar lipid bilayers (Madden et al, 1990; Sharma and Sharma, 1997). In case of Amp 
B the encapsulation in the MLVs did not significantly decrease the release rate from 
the plasma beads as observed with blue dextran and HRP. This could be attributed to 
the high binding of the drug to matrix proteins that lowers the release rate remarkably. 
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F jngal infections pose a major difficulty in the management of imn:iunocompromised 
patients (Silva, 2010). In spite of the well-known toxicities and treatment letdowns, 
Amp B is the drug of choice for most of these infections (Schmitt, 1993; Li Yanga et 
a!., 2007). Uses of less toxic formulations have been envisioned to address the 
problem toxicity without compromising the drug dosage. Entrappmg Amp B into 
multi/unilamellar liposomes (Graybill et al., 1982; Midez et al., 1989; Gondal et al., 
1989) or binding it to other substances (Block et al., 1974; Haitsel et al., 2001; 
Bekersky et al., 2002) reduces its toxicity to host cells. Considerable research has 
been undertaken on the potential liposomized formulations of Amp B in the treatment 
of fungal infections. Injected liposomes in spite of their remarkable drug delivery 
potential (Midez et al., 1989; Chang et al., 2010) are easily trapped by the 
riJticuloendothelial system and are likely to be removed rapidly from circulation 
(Lasic, 1993;Gregoriadis, 1995;Lasic, 1998). 
The tissue distributions of the injected liposomized drug in vital organs suggested 
favorable pharmacokinetic behavior (Lee et al., 1994; Groll et al., 2000; Andes et al., 
2006; Chang et al., 2010). Taking into consideration the remarkably slow release 
t'Oth of free and liposomized Amp B from PB, the fate of the administered drug in 
\arious formulation were investigated in mice. Formulations of Amp B investigated 
include Amp B entrapped in- liposomes, PB and that preentrapped in MLVs prior to 
entrapment in PB. It was evident from the results that Amp B when administered in 
fi-ee form is rapidly taken up and cleared from the circulfation with little drug 
remaining in blood after 72 hr (Fig.3.1.10). In the group receiving Amp B 
encapsulated in liposomes, the drug reached peak after 4 hr after the injection and 
decreased more gradually reaching undetectable levels in 144 hr. The apparent 
circulating half-life in case of animals receiving free Amp B was less than 20 hr while 
it was about 68 hr in case of those administered the liposome encapsulated drug, 
(jondal et al (1989) observed similar longer retention of liposome encapsulated Amp 
B in circulation after i.v administration in mice. The relatively low blood levels of the 
(irug and longer retention in circulation obsei-ved in the study may be ascribed to the 
i;low release from PB and i.p administration and its consequent slow entry in the 
circulation. Administration of the drug entrapped either directly in the PBs or after its 
pre-encapsulation in liposomes revealed remarkably altered the drug profiles. The 
circulating dmg increased gradually reached maximum in 24 hr decreased very 
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giadually. At the end of 144 hr Amp B levels in the animals remained about 0.66 
\ig/m\ (drug entrapped either directly in the PBs) or 0.7 \ig/m\ (drug dually entrapped 
iri liposomes and PBs) against 1.5 ng/ml in 24 hrs. The drug directly entrapped in 
plasma beads or after pre-encapsulation in liposomes and plasma beads exhibited a ti/2 
of about 120 hr, indicating a far gradual clearance from the plasma. The comparable 
pharmacokinetic behavior of the drug in the groups of animals receiving Amp B 
entrapped directly or after liposomal encapsulation in PB is not surprising considering 
that in vitro release rate from the PB was also comparable. An earlier study from this 
laboratory has shown similar far gradual in vitro and in vivo release of PB entrapped 
Cefotaxime (Ahmad et al., 2011).The high apparent half-lives of the drug in the 
animals receiving the PB formulations, we believe, is due to the sustained release of 
the free and liposomized drug facilitating their retention in the plasma for longer 
durations. On the other hand, a rapid decline in the plasma concentration as in case of 
animals receiving free drug is indicative of a rapid absorption and distribution (of the 
drug) in organs such as spleen, kidney and liver as evident from tissue distribution 
studies. The presence of higher level of the drug in spleen and liver as compared to 
the kidneys may indicate its rapid uptake by the reticuloendothelial cell-rich organs 
(Juliano, 1982; Gondal etal 1989). 
Tissue distribution studies in mice suggest that the administered Amp B is taken up 
maximally by spleen followed by liver and kidney. Mice receiving free Amp B had 
I'emarkably high levels of the drug in all the three tissues compared to the animals 
receiving the liposomized drug at 24 hr after the injection. The level of the drug 
declined rapidly thereafter but significant quantities remained in the tissues even after 
144 hr. On the other hand the Amp B level in the tissues of animals continued to rise 
till 144 hr. This again suggests that the gradual release of the drug from the PBs 
continues in to the blood and there from in to the various tissues. Even the 
liposomized Amp B without entrapment in PB appears to be released gradually 
compared to the free drug, in to the circulation and in to the tissues studied. It was 
shown earlier that liposome encapsulation improved therapeutic index (Lopez-
Berestein et al, 1984; Taylor et al, 1982), lowered the toxicity and facilitated the use 
of higher Amp B (Storm and Etten, 1997; Schmitt, 1993) even when intravenously 
given to the mice (Gondal et al 1989). This study shows that plasma beads are 
effective in ensuring sustained release of the entrapped Amp B and possible reduction 
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the toxicity by restricting its rapid delivery in to circulation. Such sustained release 
a so ensures the possible presence of the drug in the organs in the required therapeutic 
range and in reducing the dosage frequency. Reports on the use of polymeric matrices 
like chitosan for the additional sustained release of liposome entrapped drugs (Chung 
et ai, 2006) and fibrin (Meyenburg et ai, 2000) and plasma beads (Ahmad et al. 
201], 2012) are also available. 
The sustained release of entrapped molecules from PBs encouraged us to investigate 
their efficacy in the slow release of antigen and induce antibody production in 
experimental animals. An ideal vaccine is one that can induce a strong and lasting 
immune response after a single dose without the need for booster doses and adjuvants 
(Caputo et al, 2008; Petrovsky and Aguilar, 2004). While administration of multiple 
booster doses is clinically challenging, immune adjuvants become indispensible if 
antigen in question is weakly immunogenic. Considering purified antigens and those 
generated by recombinant technology are usually poorly immunogenic, search for 
ideal adjuvants has been intense but has thus far met with only moderate success 
(Reed et al, 2009; Oyewumi et al. 2010). Also alums that have been in clinical use 
for decades as safe adjuvants have been reported to cause some untoward reactions 
and induce predominantly humoral immune response (Shijns et al., 2000). Efforts 
therefore continue to search both the immune potentiators and particulate and other 
vaccine delivery systems. Vaccine delivery systems are in fact currently considered as 
important as the immunogens themselves (Men et al. 1996). 
PBs \vere investigated as potential particulate antigen delivery systems with yeast 
invertase a high molecular weight enzyme (274 kDa) as the model antigen. In order 
to further slowdown the release of the protein from plasma beads, its encapsulation in 
erythrocytes, another biocompatible and promising drug delivery vehicle prior to 
entrapment in the PB was investigated. Entrapment in erythrocytes was originally 
envisioned as a strategy for drug and protein/enzyme delivery (Ihler et al, 1973; 
Sprandel, 1987; De Loach et al, 1980) and continues to be investigated for a variety 
of applications (Magnani, 2012; Lande et al, 2012). More recently carrier 
erythrocytes have been found to have potential in antigen/vaccine delivery (Hamidi et 
al, 2007a; Murray et al, 2006). 
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Si.Tiple procedures are available for the encapsulation of both small and large 
molecules in erythrocytes (Kumar et ai, 2012). High entrapment yields in 
erythrocytes (30-80%) are achievable for several drugs, enzymes, proteins and 
peptides which facilitate the use of small volume of the cells to deliver adequate 
quantity of therapeutics (Deloach and Ihler, 1977; Benatti et al., 1989; Talwar and 
Jain, 1992 a; Mishra et al., 1996; Tajerzadeh and Hamidi, 2000; Hamidi et al., 
2()07a). Molecular weight forms the key parameter on which efficiency of entrapment 
oi" various substances in erythrocytes depends, although surface charge, polarity and 
diffusion co-efficient may also make significant contribufion (Eichler, 1987; Bax et 
ai., 1996; 2000). Thus, drugs such as Adriamycin could be incorporated in 
eiythrocytes with entrapment as high as 80% (De Flora et al., 1986), ADA (33kDa) 
and CTB (12kDa) were entrapped with yields of 65%) and 60% respectively in mouse 
ei-ythrocytes (Murray et ai, 2006). Entrapment yield of 40-42% was accomplished in 
case of BSA, a 66kDa protein during entrapment in human erythrocytes (Hamidi et 
al., 2007b). 
/ipproximately 135 U (325|ig) invertase could be entrapped in rabbit erythrocytes per 
0.1 ml resealed cells with 30 % yields (Fig.3.2.1). The relatively low yields of 
entrapment accomplished may be related to the large molecular dimension of yeast 
invertase. Comparable entrapment was also observed in the mouse erythrocytes. The 
required quantity of antigen (600|ig for the priming and 200ug for the booster) was 
therefore present in 170 ^1 and 57^1 packed resealed cells. In an earlier study it was 
Sihown that in vitro release of entrapped substances from erythrocytes occurs 
gradually and majority of the encapsulated BSA was released between 48 hr to 96 hr 
from human erythrocytes (Hamidi et al, 2001; Hamidi et al., 2007a; Hamidi et al., 
2007b). In our experiments near complete release of invertase from the enzyme 
entrapped erythrocytes was evident in 64 hr (Fig.3.2.2). The rate of enzyme release 
was comparable with that of hemoglobin suggesting that release is not due to selective 
diffusion of the entrapped antigen out of the intact cells but to cell lysis (Hamidi and 
Tajerzadeh, 2003). Similar release kinetics has been reported for the polar drugs such 
as heparin (Eichler et al., 1987), Gentamicin (Eichler et al, 1986; 1987), Enalaprilat 
(Hamidi et al., 2001) suggesting that release occurs primarily due to hemolysis. 
Lipophilic drugs such as Phenytoin (Eicheler et ai, 1987), Primaquin (Talwar and 
Jain, 1992b), Methotrexate (Lewis and Alpar, 1984), Vitamin B12 (Eichler et al., 
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1985), and Dexamethasone (Eichler et al, 1987), the drug can diffuse readily out of 
the intact cells. The size and polarity of the entrapped molecule thus direct their 
release rate from the resealed erythrocytes (Eichler, 1987). 
Cross-linking of erythrocytes with agents like glutaraldehyde is known to reduce the 
re! ease rates of entrapped substances remarkably (Talwar and Jain, 1992a & 1992b; 
Mishra et al, 1996) primarily due to crosslinking of the membrane proteins (De 
Loach et al, 1977). The rate of release of invertase from the erythrocytes (Fig.3.2.2) 
decreased as the concentration of glutaraldehyde used for crosslinking was raised. The 
in vitro release of invertase from the resealed erythrocytes in the first 24 hr of study 
was 47%, 40%, 25.5%, 14.5% and 7.5% in case of uncrosslinked, 0.025%, 0.5 %, 
O.r/o and 0.25%) glutaraldehyde treated preparations respectively. Exposure of 
eiythrocytes with crosslinking agents like glutaraldehyde leads to remarkable 
resistance to hemolysis (Talwar and Jain, 1992a & 1992b). It is therefore likely that 
glutaraldeyde-treated erythrocytes restrict the release of the entrapped invertase due to 
their resilience to lysis. While it could not be ascertained if crosslinking also induces 
covalent linkages between the erythrocyte and other membrane proteins, invertase 
being highly glycosylated is known to be recalcitrant to treatment with 
glutaraldehyde. Encapsulation of the invertase loaded blood cells into plasma beads 
v\/as successful in further restricting the efflux of the enzyme into the medium, 
ensuring a highly controlled release (Fig. 3.2.3). Cross-linking of the PB with 
e;ntrapped invertase pre-encapsulated in the erythrocytes was more effective in 
decreasing the leakage of invertase, apparently both due to lowered pore size of the 
PB as well as lower hemolysis of the entrapped crosslinked erythrocytes. 
Antigen entrapped erythrocytes have been studied as potential candidates for 
eliciting immune responses (Chiarantini et al, 1997; Dominici et al, 2003; Murray et 
al, 2006). Interestingly, erythrocytes entrapped antigen induce immune responses of 
magnitudes similar to those produced by the potent Freund's complete adjuvant 
(CFA) (Dominici et al, 2003) or Titer MaxGold™ (Murray et al.. 2006) even after a 
single dose. Magnani et al (1992) studied several proteins- BSA; hog liver uricase 
and >east hexokinase coupled to autologous erythrocytes with a biotin-avidin-biotin 
bridge to immunize mice. The immunological response elicited was at least as high as 
that obtained using CFA. Effectiveness of erythrocytes coated with viral proteins in 
inducing immune response superior to that obtained by classical adjuvants has also 
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been documented (Magnani et al 1992; Chiarantini et al., 1997).This makes carrier 
er)'throcytes an attractive antigen delivery system since most of the effective 
adjuvants are too toxic for clinical use. Alum adjuvants are considered as less toxic 
but elicit only weak humoral and cell mediated immunity. They not only induce IgE 
responses but lead to allergic reactions (Gupta and Siber, 1995; Giudice et al., 2001). 
In the present study too, primary immunization (a single dose) with invertase-loaded 
rabbit erythrocytes (EE-Inv) in rabbits, elicited after 20 days, specific serum antibody 
titers comparable to those induced when the antigen emulsified with CFA-Inv was 
acministered (Fig.3.2.4). While the antibody titers in rabbits receiving erythrocyte 
entrapped antigen further entrapped in PB (EE-Inv-PB) were lower on the day 20, 
compared to other groups they registered a moderate increase on day 28 and as lower 
d(;crease on day 35; on day 35 the antibody titers were higher that the EE-Inv groups 
and only moderately lower than those of CFA-lnv, suggesting a sustained in vivo 
release of the antigen. After administration of the booster dose, the antibody titers 
rose remarkably in the sera of rabbits receiving various formulations on day 8. 
Maximum increase was however observed in the animals receiving adjuvants, 
followed the EE-lnv-PB group (Fig.3.2.5). The level of antibody generated in the EE-
Inv-PB group remained higher between day 8 and day 24 as compared to that in EE-
Inv administered rabbits. 
Experiments performed in mice also suggests the usefulness of erythrocyte associated 
invertase in inducing specific antibodies and significant titers were observed in EE-
Inv, EE-Inv-PB and EE-Inv-PB- CL groups, although these were lower than the CFA-
lnv group on day 10 and 20 after the first immunization. This indicates the 
(Effectiveness of erythrocyte associated antigen in increasing the immunogenicity is 
not species-specific, although in our study the generated antibody levels were not as 
high as those observed in rabbits. While the reasons for the observed differences are 
not clear these may be related to difference in nature of animal model and antigen 
used (Murray et al, 2006). Earlier studies also suggest that effectiveness of 
erythrocyte-linked antigen in inducing immunity in cats and mice (Chiarantini et al, 
1997; 1998). 
In contrast to the observations after primary immunization (Fig.3,2.6), comparatively 
higher antibody titers were evident in the EE-Inv-PB-CL group mice after the 
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sti-ategy to enhance the vaccine potential of the erj^hrocyte entrapped antigen. 
Eiythrocyte associated invertase induced enhanced antibody production irrespective 
ol'route of administration. In fact, PBs containing invertase loaded eiythrocytes cross-
linked withO.05% glutaraldehyde injected i.p. (compared to those administered 
siibcutaneously) in mice show significantly higher titers not only after primary 
immunization (Fig.3.2.6 and Fig.3.2.8) but also after a booster dose (Fig.3.2.7 and 
Fig. 3.2.9). Murray et al (2006) compared the antibody response to carrier erythrocyte 
entrapped BSA, cholera toxin subunit and adenosine deaminase administered i.v with 
tb.e same antigens administered subcutaneously emulsified with TiterMaxGold '. It 
was observed in case of BSA, adenosine deaminase and cholera toxin subunit that the 
antibody levels were comparable, the levels were higher with carrier erythrocyte 
entrapped keyhole limpet haemocyanin, an indication that natun^ of protein may 
influence the type of immune response. Dominici et al (2003) investigated the 
induction of immunity in mice of a biologically active recombinant HIV-1 Tat protein 
coupled to autologous erythrocytes via a biotin-avidin-biotin linkage. Animals 
rticeivmg the erythrocyte coupled antigen intra-peritoneally exhibited response that 
v^ as comparable with those receiving that emulsified in Freund's adjuvant. The 
erythrocyte coupled antigen was effective in inducing neutralizing antibodies and 
CTL response even at doses over 250 times lower than those required for induction 
of comparable effect with soluble antigen. 
Erythrocytes are naturally removed fi'om the circulation by macrophages some of 
Vk'hich are able to process and present antigens associated to MHC molecules to the 
immune cells (Kovacsovics-Bankowski et al., 1993). Magnani et al (2002) have 
shown that erythrocytes loaded with ubiquitin analogues and modified 
oligonucleotides delivered the same to macrophages in vitro. Interestingly, 
e;rythr()cytes administered i.p. enter and sun/ive in the circulation as well as those 
given by intravenous injections (DeLoach and Droleskey, 1986). 
(3ther advantage of erythrocyte entrapment/coupling of antigen is reduction in 
immunosuppression observed in case of some proteins. Native HIV-1 Tat protein 
liuppresses immune response when administered in mice together with a second 
anfigen (Cohen et al, 1999) but coupling to erythrocytes restricts the 
immunosuppressive action (Magnani et al, 1992; Dominici et al., 2003). Several 
studies also suggest that far smaller doses of antigen are required for immunization 
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while using carrier erythrocytes. Animals receiving the erytlirocyte coupled 
recombinant HIV-1 Tat protein intraperitoneally exhibited response that was 
comparable with those receiving that emulsified in Freund's adjuvant. The 
ePi^hrocyte coupled antigen was effective in inducing neutralizing antibodies and 
CTL response even at doses over 250 times lower than those required for induction 
of comparable effect with soluble antigen (Dominici et ai, 2003). Autologous 
erythrocyte encapsulated bacterial antigens elicit impressive immune response in mice 
afier multiple injections and produce specific neutralizing antibodies (Polvani et ai, 
1S'91). While antigens associated with erythrocytes both by entrapment and coupling 
to surfaces have been shown to be effective, the former may help to protect the 
antigen better in vivo also because the enzyme as discussed above does not leak out of 
the cells unless they undergo lysis. 
Our results do not indicate dramatic differences in the induced titers while employing 
different routes {s.c, i.v. and i.p.) of immunization using carrier erytlirocyte-entrapped 
antigen, Comparatively higher titers were however, observed when plasma beads 
containmg invertase encapsulated erythrocytes were injected i.p. as compared to 
those of the mice that received the antigen subcutaneously (Fig.3.2.6-Fig.3.2.9 ). 
The differentiation of naive T cells into Thl cells are characterized by the production 
of cell-mediated immunity by stimulating natural killer cells, macrophages and CD8^ 
cytotoxic T lymphocytes (Constant and Bottomly,1997; Moingeon, 2002; Broere, 
2011). Th2 responses are characterized by the production of B cell-dependent 
humoral immunity against an antigenic challenge. The subclass of immunoglobulin 
tiiggered offers an indirect indication of the relative involvement of Th2-type and 
Thl-type cytokines. It has been established that the production of IgGl and lgG2a are 
firimanly induced by Th2 and Thl responses, respectively, and thus the ratio of 
IgGl:lgG2a can indicate the T cell phenotype induced by immunization (Stevens et 
al., 1988; Moingeon, 2002; Murray et al., 2006). Administration of the primary dose 
of invertase in various formulations/routes resulted in IgGl :IgG2a ratios between 0.95 
and 1.1, indicating that both Thl and Th2 immune responses (Fig.3.2.10 and 
?ig.3.2.11). Booster doses however lead to a moderate increase in Th2 type response 
3y the invertase-encapsulated erythrocytes. The shift was more marked in groups of 
mice that received plasma beads containing invertase loaded eiytlirocytes, especially 
when crosslinked with glutaraldehyde indicating higher humoral responses. 
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Polarization of an antigen towards a Thl or Th2 response is thought to depend on a 
host of factors including antigen size, antigen dose, number of doses, route of 
administration, the type of antigen presenting cell and on the system used to deliver 
the antigen (Constant and Bottomly, 1997; Rothoeft et al, 2003). For example, 
several studies suggest that high doses of an antigen induce humoral (Th2) responses 
while low doses lead to cell-mediated (Thl) immunity (Parish & Liew, 1972; 
Brestcher et al., 1992; Bancroft et al., 1994; Sarzotti et al., 1996). Several studies 
however reported use of different doses of antigen to induce opposite dichotomy, with 
high versus low doses of antigen leading to humoral versus cell-mediated responses, 
respectively (Constant et al, 1995; Query et al, 1996; Wang et al., 1996; Rothoeft et 
al, 200.3). Hayglass et al (1986) reported the polymerization of ovalbumin to induce a 
predommant Thl-type response in mice compared to the mixed Thl/Th2 phenotype 
induced by raonomeric ovalbumin suggesting a size-dependent. Murray et al (2006) 
have suggested contribution both of antigen size and immunization route as a possible 
reason for the induction of strong humoral immunity in mice receiving erythrocyte 
coupled KLH. Dominici et al (2003) using HIV-1 Tat observed that both Thl and Th2 
type of immune responses were induced when the protein was administered Ip. after 
cciupling to autologous erythrocytes. Our experiments suggest only moderate shift 
towards Th2 after a booster dose when invertase was administered after erythrocyte 
entrapment irrespective of the route of administration although the shift was more 
marked in case of mice receiving the antigen i.p. after entrapment in PB followed by 
ciosslinking. Apparently nature of antigen may be the determining factor. When 
administered /.v. the erytlirocyte entrapped ADA and BSA showed a shift towards 
Th2 after primary immunization followed by secondary dose. Comparable shift was 
however not evident in case of CTB and KLH (Murray et al, 2006). Further studies 
involving a detailed molecular mechanisms contributing to Thl/Th2 shift after an 
antigen challenge essential to develop useful vaccine delivery system. 
Taking into consideration that PB-entrapped invertase appeared to favor induction of 
Thl type immune response, especially after booster, possibilities of augmenting the 
Th2 t)pe of response were envisaged. Several recent studies suggest that size of 
vaccine delivery vehicle may be crucial to the nature and magnitude of elicited 
immune response (Oyewumi et al, 2010). Attempts to investigate plasma 
micn)particles (PMPs) as vaccine delivery candidates were therefore undertaken. 
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Some other studies also suggest that dimensions of the vaccine dehvery particles may 
dictate Thl, Th2 or mixed immune response (Kanchan and Panda, 2007). The PBs 
used in the work described earlier are large and it can be anticipated that they release 
the entrapped antigen from the injected site by diffusion rather than, entering along 
with the antigen to the circulation. 
Microparticles and nanoparticles formulated from biodegradable polymers such as 
poly (L-lactide) (FLA), Poly (D, L-lactide-co-glycolide) PLGA, or poly (ethylene 
gly:ol) (PEG) with PLA and PLGA have been used to target the delivery of 
entrapped to antigen presenting cells thereby inducing cellular immunity to 
significant levels (Rajapaksa and David, 2010; Pawar et al, 2010; Zhao and Rodgers, 
2005; Okada, 1997). Chitosan particle-based microparticles and nanoparticles have 
also proved their potential as vaccine candidates (Pandey and Khuller, 2006; Mao et 
al. 1996; Ahire et al, 20007; Alpar et al, 2005). 
The nature of the PMPs prepared by the procedure described was analyzed by 
Particle-size analysis which indicated that majority of the particles lie in the range of 
diameter of 1.5 |am-3)im (Fig.3.3.2). SDS-PAGE revealed polypeptide composition 
similar to that of plasma but additional and bands greater than 66 kDa appeared 
suggesting the formation of covalent inter-protein links apparently by endogenous 
transglutaminase activated in presence of calcium (Fig.3.3.3). The optimum time and 
temperature for the preparation of PMPs as also indicated by the entrapment yields of 
invertase (Fig.3.3.4 and Fig.3.3.5) were 60 min and 40°C. 
Most fibrin matrices readily release the entrapped substance owing to the larger pore-
size of the fibrin meshwork (Itokazu et al, 1997). The in vitro experiments with the 
invertase and Amp B-entrapped PMPs indicated that these are far less leaky than the 
PBs described earlier. Invertase loaded PMPs released only 26% in of the entrapped 
e])zyme in 72 hr (Fig 3.3.7) and the release rate was markedly lowered on 
ci-osslinking. Similarly, only 14%, of the entrapped Amp B was released into the 
medium in 72 hr from the PMPs which could be reduced further by glutaraldehyde 
tieatment. The slow release of the entrapped invertase as compared to PBs may be 
tiie result of compact network of glutaminase crosslinked matrix due to loss of water 
during the preparation of the former (Gorodetsky, 2008). 
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the result of compact network of glutaminase crosslinked matrix due to loss of water 
during the preparation of the former (Gorodetsky, 2008). 
In vivo experiments were aimed at investigating the vaccine potential of invertase 
loaded microparticles both in rabbit and mice. The particles proved highly 
immunogenic and readily induced specific antibody production in the host. In rabbits, 
the uncrosslinked PMPs were almost as efficient as CFA in inducing high antibody 
titers on day 20 after immunization and even showed an enhanced titer, compared 
PMPs-lnv-CL group. Antibody levels rose in the PMP-Inv-CL group on day 28 and 
th(ise were highest among all the groups investigated on day 35 (Fig.3.3.10). Although 
booster doses resulted in about four fold increase in antibody levels these were still 
highest in the PMP-Inv-CL group while those in the IFA-Inv and PMP-Inv were 
comparable both on day 12 and 24 (Fig.3.3.11). A similar pattern was observed in 
case of mice with comparable titers in case of CFA/IFA and uncrosslinked PMPs both 
after a primary and a booster dose. Highest titers were obtained in the crosslinked 
PMPs in both the cases. However, in mice erythrocytes entrapped invertase failed to 
ir.duce as strong immune response as observed in case of rabbit erythrocytes, as also 
ooserved in case of PB-entrapped antigen. 
Isotype profile showed almost similar results in all cases following the prime dose. 
IgG2a: IgGl ratio was found to be around 1, suggestive of both humoral and cell-
mediated response (Moingeon, 2002). Isotype profiling after a booster dose was 
however suggestive of a more marked Thl type response (IgG2a>IgGI) in case of 
PMPs-lnv-CL followed by PMPs-Inv suggesting cellular immune response (Espuelas 
et ai. 2005). The equal contributions both of Thl and Th2 response (IgG2a ~ IgGl) 
^vere however evident suggesting the involvement both cellular and humoral immune 
responses in the animals that were immunized CFA emulsified antigen (Murray et al., 
2006). 
Considerable information is available on the dependence of the elicited immune 
response on the dimensions of the particulate antigen delivery systems. While some 
suggest, based on model antigens entrapped in particles of different sizes that larger 
dimensions of the particulate delivery by systems induce strong antibody response 
(Gutierro et al. 2002; Kanchan and Panda, 2007), while other studies found those with 
smaller particle size more effective in the regard (Katare et al., 2005; Oyewumi et al., 
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take up particles of 500 nm or less, while larger particles may be taken up via 
endiDcytosis leading to the inducement of CD4 and CDS cells and preferential Thl 
type of immune response (Mottaram et al, 2006). Shaip et al (2009) observed a rather 
higher limit (> 10 um) for efficient uptake by the DC. Also it was shovra that particles 
with relatively larger dimensions were dependent upon DC for transport to the lymph 
nodes while smaller ones diffuse directly (Manolova et al, 2008). Horisawa et al 
(2002) and Kanchan and Panda (2007) also suggested that large particles (micron 
sized particles) preferentially attach to the macrophage surfaces and serve as an 
effective depot system for continuous antigen release thereby acting as better immune 
adjuvants as compared to the submicron size particles. 
The greater CD4^ and CDS"*^  cells in animals immunized with the antigen bearing 
cress-linked plasma particles evidently supports their ability to inducing the 
proliferation T cell populations. The sustained accessibility of antigen facilitates 
greater interaction with APCs, expediting their processing and presentation in host 
body. The antigens presented on the surface of APCs activate CD4" and CD8"^  cells 
and lead to their maximum proliferation and differentiation. Marked elevation in the 
CD4^ and CD8^ cells is an evidence of T cell proliferation in the animals 
administered uncrosslinked PMPs or those after crosslinking. The gradual release of 
invertase from or entry of the PMPs themselves in the circulation may contribute 
towards enhanced interactions of the APCs with the antigen and consequent uptake, 
processing and presentation. The APC with antigen on their surface in turn may 
stimulate the CD4^ and CD8* cells to differentiate and proliferate (Owais and Gupta, 
2000; Ahmad e?fl/., 2012). 
Higher expression of CD80 and CD86 shows the superior antigen presentation to the 
macrophages and expansion of Th cell population (Agrewala et al., 1996). Several 
studies suggest that biodegradable microparticles of size <10 ul facilitate extended 
aatigen presentation to the APCs (Horisawa et al., 2002; Audran et al, 2003; and 
Flanchan and Panda, 2007; Balasse et al. 2008; Oyewumi et al, 2010) and it is likely 
tiat PMPs used in the study may act accordingly. As discussed in results, APCs 
obtained from animals immunized with PMPs-Inv-CL were superior in expression of 
c;o-stmiulatory CD80 and CD86 on their surface as compared to other groups. In case 
of animals of the group PMPs-Inv, the expression was only slightly lower suggesting 
(efficient T-cell proliferation in this case as well. 
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co-stimulatory CD80 and CD86 on thieir surface as compared to other groups. In case 
of animals of tlie group PMPs-Inv, the expression was only slightly lower suggesting 
efficient T-cell proliferation in this case as well. 
In this study we propose that the PMPs (formed from autologous plasma without the 
use of any external agent save CaC^has excellent potential in the sustained release of 
the therapeutics. Also, they form strong candidates for eliciting immune response in 
the host system. The immune response generated may be similar to potent adjuvants 
as (^ FA as in case of humoral immunity or highly superior as in case of cell-mediated 
immunity. The plasma microparticles (fibrin based systems) as discussed earlier are 
biocompatible, biodegradable, non-toxic, easy to handle, often easily injectable to 
targets, available in bulk as autologous plasma and thus are safer systems for drug/ 
vaccine delivery. Also their biodegradability (Fig.3.3.9) and porosity can be regulated 
by treatment with crosslinking agents. Thus, the PMPs provide us vvith an excellent 
alternative to toxic adjuvants without compromising the therapeutic efficiency. They 
seem to effective antibody generators, and have shown great deal of cell-mediated 
response in case of the antigen invertase used. It is very well known that the 
generation of different type of responses depends on a variety of factors which 
include the type of antigen, the dose and the route of immunization. Extensive in vitro 
and in vivo studies therefore are needed be performed for a large number of 
pharmaceuticals and antigens so that the type and quality of the response generated 
can be known and even manipulated if necessary. The clinical applications of these 
micro-particles can subsequently be undertaken. It may also be worthwhile to 
prepare plasma particles of nano dimensions and investigate their antigen 
carrier/delivery potential. 
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